[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Supplementary Material : A multiplex bead-based immunoassay and data analysis pipeline for 12 markers of fever severity in dried blood spots",
    "section": "",
    "text": "A multiplex bead-based immunoassay and data analysis pipeline for 12 markers of fever severity in dried blood spots\n\n\nSupplementary information\nTegwen Marlais1, Rebecca L. Handley1, Mayfong Mayxay2, Elizabeth Ashley2, Quique Bassat3, FIEBRE Laos site colleagues, FIEBRE biomarker colleagues, Chris Drakeley1, Heidi Hopkins1, David Mabey1, Chrissy h. Roberts1\n1 Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK\n2 ….. Lao PDR\n3 ISGlobal…\n\n\nOverview\nThis HTML book provides extended supplementary information for [insert final paper title and ref here].\nIt is intended that this resource should provide you with sufficient information to fully reproduce the assay presented in the paper. It also provides information on how to perform quality assurance experiments and to evaluate performance parameters such as the coefficient of variation. We also provide some analysis protocols which will support you to import, process and perform a quality controlled analysis of data from this or any multiplexed immuno-bead assay created on the MagPix platform.\nWe provide a static copy of these documents as a supplement to the paper. A living version (which may be updated in the future) is available on https://chrissyhroberts.github.io/Mos-Def/"
  },
  {
    "objectID": "Marker_List.html#markers-included-in-the-assay",
    "href": "Marker_List.html#markers-included-in-the-assay",
    "title": "1  List of Markers",
    "section": "1.1 Markers included in the assay",
    "text": "1.1 Markers included in the assay\n\n1.1.1 Angiopoietin-1 (Ang-1)\nConstitutively expressed by pericytes and smooth muscle cells, also stored in platelets (Brouwers et al. 2013). Ang-1 is an agonist binding the TIE2 receptor. It promotes endothelial cell survival and maintains vascular quiescence. Activates or inhibits angiogenesis, depending on the context. Ang-1 mediates blood vessel maturation/stability (Leligdowicz et al. 2018).\n\n\n1.1.2 Angiopoietin-2 (Ang-2)\nExpressed by endothelial cells. Ang-2 binds to TIE2 in competition with Ang-1 but is an antagonist. Increased Ang-2 levels lead to increased vascular leakage, resulting from destabilised vascular endothelium, remodelling, and leakiness (Kim et al. 2016). Ang/Tie2 dysregulation is thought to be “pathogen agnostic” (Leligdowicz et al. 2018).\n\n\n1.1.3 Azurocidin 1 (Azu)\nReleased early in infection from granules in polymorphonuclear leukocytes. Azu acts as a chemo-attractant to several leukocyte types, provokes cytokine secretion, and induces capillary leakage. Azu is directly cytotoxic to certain Gram-negative bacteria (Fisher and Linder 2017).\n\n\n1.1.4 Chitinase 3-like 1 (CHI3L1)\nProduced by many cell types, including immune, epithelial and others. Overexpressed in infectious and non-infectious inflammatory conditions, including sepsis and cancer. Crucial role in protecting against pathogens, antigen- and oxidant-induced injury responses, inflammation, and tissue repair and remodelling. Regulates a range of essential biological processes (Zhao et al. 2020).\n\n\n1.1.5 Interleukin 6 (IL-6)\nProduced by immune and other cell types during chronic and acute inflammation. Triggers actue phase proteins in the liver. Can be pro- and anti-inflammatory. Stimulates B cells to produce antibodies. Links innate to acquired immune response by promoting differentiation of CD4+ T cells. Pyrogenic and pro-coagulative. Tanaka 2014 https://doi.org/10.1101%2Fcshperspect.a016295 & Kang 2021 https://doi.org/10.1038%2Fs12276-021-00649-0\n\n\n1.1.6 Interleukin 8 (IL-8)\nProduced by many cell types including monocytes, lymphocytes, granulocytes, fibroblasts, endothelial cells, epithelial cells, hepatocytes, mesangial cells and chondrocytes and is released only under inflammatory conditions. Platelets store IL-8 in their granules and rapidly release IL-8 in inflammation (Matsushima, Yang, and Oppenheim 2022).\n\n\n1.1.7 Interleukin 10 (IL-10)\nA key anti-inflammatory mediator. Regulator of cellular immune response. Produced by various cell types and detected by macrophages and a range of other cell types. Limits antigen presentation and anti-microbial mechanisms such as nitric oxide production. Saraiva 2020 https://doi.org/10.1084/jem.20190418\n\n\n1.1.8 Interferon gamma inducible protein 10 (IP-10)\nA chemokine released from various immune cells in response to IFNg and other cytokines. Activates and recruits lymphocytes. Elevated in viral and HIV infection, particularly acute HIV [Lei et al. (2019)](Hayney et al. 2017). Associated with disease progression.\n\n\n1.1.9 Myxovirus resistance protein A (MxA)\nCytoplasmic GTPase with activity against Influenza A a range of other viruses. Inhibits viral gene transcription by binding to the viral nucleoprotein. MxA is activated by type I and type III interferons. Haller 2020\n\n\n1.1.10 Soluble Tumor necrosis factor receptor 1 (sTNFR1)\nIncreased levels of soluble TNFR1 are competitive inhibitors for circulating TNF, thereby reducing signalling through TNFR1 (an endogenous pyrogen) that can promote cell death, tissue damage and subsequent inflammation. NEED REFS.\n\n\n1.1.11 Soluble Triggering receptor expressed on myeloid cells (sTREM-1)\nSoluble form of TREM‐1 shed from the membrane of activated phagocytes in response to bacterial and fungal infections. NEED REFS.\n\n\n1.1.12 TNF-related apoptosis-inducing ligand (TRAIL)\nElevated in viral infections and possibly downregulated in bacterial infections. Viruses may stimulate TRAIL expression in host or immune cells, may also sensitize host cells to TRAIL-mediated induction of apoptosis. NEED REFS."
  },
  {
    "objectID": "Marker_List.html#markers-which-were-screened-but-which-failed-assay-quality-tests",
    "href": "Marker_List.html#markers-which-were-screened-but-which-failed-assay-quality-tests",
    "title": "1  List of Markers",
    "section": "1.2 Markers which were screened, but which failed assay quality tests",
    "text": "1.2 Markers which were screened, but which failed assay quality tests\n\n1.2.1 Procalcitonin (PCT)\nProduced in the thyroid, but also in all parenchymal tissues during bacterial infection. PCT is secreted in response to bacterial endotoxins, lipopolysaccharides, and inflammatory cytokines. It is inhibited by IFN-gamma during the response to viral infections (Davies 2015- linked below)\nThe PCT assay was screened out of our multiplex due to difficulty in finding a working pair of antibodies that did not cross-react with other antigens in the multiplex, particularly azurocidin.\nhttps://jcp.bmj.com/content/68/9/675\n\n\n1.2.2 C-Reactive Protein (CRP)\nCRP is a component of the innate immune response. It is produced by hepatocytes, … and activates Complement, as well as IL-6 secretion… READ tHIS REVIEW FOR MORE… (Sproston 2018, linked below)\nhttps://www.frontiersin.org/articles/10.3389/fimmu.2018.00754/full\nThe CRP assay was dropped from the multiplex because a reliable standard curve could not be obtained and, crucially, because of the need for much higher sample dilution than the other markers."
  },
  {
    "objectID": "Marker_List.html#sflt-1",
    "href": "Marker_List.html#sflt-1",
    "title": "1  List of Markers",
    "section": "1.3 sFlt-1",
    "text": "1.3 sFlt-1\nadd some info here - also reason why screened out\n\n\n\n\nBrouwers, Judith, Rintis Noviyanti, Rob Fijnheer, Philip G. de Groot, Leily Trianty, Siti Mudaliana, Mark Roest, Din Syafruddin, Andre van der Ven, and Quirijn de Mast. 2013. “Platelet Activation Determines Angiopoietin-1 and VEGF Levels in Malaria: Implications for Their Use as Biomarkers.” Edited by Ana Paula Arez. PLoS ONE 8 (6): e64850. https://doi.org/10.1371/journal.pone.0064850.\n\n\nFisher, J., and A. Linder. 2017. “Heparin-Binding Protein: A Key Player in the Pathophysiology of Organ Dysfunction in Sepsis.” Journal of Internal Medicine 281 (6): 562–74. https://doi.org/10.1111/joim.12604.\n\n\nHayney, Mary S., Kelsey M. Henriquez, Jodi H. Barnet, Tola Ewers, Heather M. Champion, Sean Flannery, and Bruce Barrett. 2017. “Serum IFN-γ-Induced Protein 10 (IP-10) as a Biomarker for Severity of Acute Respiratory Infection in Healthy Adults.” Journal of Clinical Virology 90 (May): 32–37. https://doi.org/10.1016/j.jcv.2017.03.003.\n\n\nKim, Minah, Breanna Allen, Emilia A. Korhonen, Maximilian Nitschké, Hee Won Yang, Peter Baluk, Pipsa Saharinen, et al. 2016. “Opposing Actions of Angiopoietin-2 on Tie2 Signaling and FOXO1 Activation.” Journal of Clinical Investigation 126 (9): 3511–25. https://doi.org/10.1172/jci84871.\n\n\nLei, Jie, Xiaowan Yin, Hong Shang, and Yongjun Jiang. 2019. “IP-10 Is Highly Involved in HIV Infection.” Cytokine 115 (March): 97–103. https://doi.org/10.1016/j.cyto.2018.11.018.\n\n\nLeligdowicz, Aleksandra, Melissa Richard-Greenblatt, Julie Wright, Valerie M. Crowley, and Kevin C. Kain. 2018. “Endothelial Activation: The Ang/Tie Axis in Sepsis.” Frontiers in Immunology 9 (April). https://doi.org/10.3389/fimmu.2018.00838.\n\n\nMatsushima, Kouji, De Yang, and Joost J. Oppenheim. 2022. “Interleukin-8: An Evolving Chemokine.” Cytokine 153 (May): 155828. https://doi.org/10.1016/j.cyto.2022.155828.\n\n\nZhao, Ting, Zhongping Su, Yingchang Li, Xiaoren Zhang, and Qiang You. 2020. “Chitinase-3 Like-Protein-1 Function and Its Role in Diseases.” Signal Transduction and Targeted Therapy 5 (1). https://doi.org/10.1038/s41392-020-00303-7."
  },
  {
    "objectID": "Buffers_and_Reagents.html#buffers-for-general-assay-procedures",
    "href": "Buffers_and_Reagents.html#buffers-for-general-assay-procedures",
    "title": "2  Buffers & Reagents",
    "section": "2.1 Buffers for general assay procedures",
    "text": "2.1 Buffers for general assay procedures\n\n2.1.1 Deionised water (dH2O)\nFilter 50 mL of deionised water through a 0.2 µm filter into a sterile container.\n\n\n2.1.2 PBS\n1 tablet (Sigma; P4417) per 200 mL deionised water.\nFilter through 0.2 µm filter into one or more sterile containers.\n\n\n2.1.3 PBST (wash buffer)\nPBS + 0.5 mL/L (0.05% v/v) Tween 20\nMake fresh every week.\n\n\n2.1.4 PBS-TBN (blocking/storage/assay buffer)\nPBST + 10 mg/mL BSA + 0.5 mg/mL sodium azide\nPer 100 mL PBST, add:\n\n1 g BSA\n500 µL of 10% (100 mg/mL) sodium azide solution in deionised water\n\n*CAUTION* - use appropriate PPE and safety measures when handling solid and liquids with sodium azide.\n\n\nFilter through 0.2 µm filter and store in a fridge until use."
  },
  {
    "objectID": "Buffers_and_Reagents.html#buffers-for-bead-coupling",
    "href": "Buffers_and_Reagents.html#buffers-for-bead-coupling",
    "title": "2  Buffers & Reagents",
    "section": "2.2 Buffers for bead coupling",
    "text": "2.2 Buffers for bead coupling\n\n2.2.1 Activation buffer\n0.1 M sodium phosphate monobasic, pH 6.2\n\n1.19 g NaH2PO4 (Sigma, S8282)\n100 mL dH2O\nAdjust pH to 6.2 with 5 or 10 M NaOH. Filter through 0.2 µm filter and store in the fridge until use.\n\n\n\n2.2.2 Coupling buffer\n50 mM MES, pH 5.0\n\n0.976 g MES (Sigma, M3671)\n100 mL dH2O\nAdjust pH to 5 with 5 or 10 M NaOH. Filter through 0.2 µm filter and store in the fridge until use."
  },
  {
    "objectID": "Buffers_and_Reagents.html#reagents",
    "href": "Buffers_and_Reagents.html#reagents",
    "title": "2  Buffers & Reagents",
    "section": "2.3 Reagents",
    "text": "2.3 Reagents\nThe following equipment and reagents are needed\n\n\n\n\n\n\n\n\n\nManufacturer\nPart No.\nPack size\nPRODUCT DESCRIPTION\n\n\n\n\nSigma\nP4417-100TAB\n100 tablets\nPBS tablets\n\n\nRoche\n11697498001\n20 tabs\nProtease inhibitor (for DBS samples)\n\n\nSigma\nA4503-100G\n100 g\nBSA\n\n\nSigma\n11851335\n5 g\nEDC\n\n\nSigma\n10391314\n500 mg\nNHS\n\n\nSigma\nM3671\n50 g\nMES\n\n\nSigma\nS8282\n500 g\nSodium phosphate monobasic\n\n\nSigma\nP1379-100ML\n100 ml\nTween 20\n\n\nSigma\nS5881-500G\n500 g\nNaOH (sodium hydroxide)"
  },
  {
    "objectID": "Capture_Antibody_Prep.html#capture-antibodies",
    "href": "Capture_Antibody_Prep.html#capture-antibodies",
    "title": "3  Capture Antibody Preparation",
    "section": "3.1 Capture Antibodies",
    "text": "3.1 Capture Antibodies\n\n\n\n\n\n\n\n\n\n\nManufacturer\nPart No.\nPack size\nPRODUCT DESCRIPTION\nComponent\n\n\n\n\nbio-techne\nH00054210-M04\n100 µg\nTREM1 Antibody (2E2)\nCapture\n\n\nbio-techne\nMAB206-100\n100 µg\nHuman/Primate IL-6 MAb (Clone 6708)\nCapture\n\n\nbio-techne\nMAB2172-100\n100 µg\nHuman IL-10 MAb (Clone 127107)\nCapture\n\n\nbio-techne\nMAB225-100\n100 µg\nHuman TNF RI/TNFRSF1A MAb (Clone 16803)\nCapture\n\n\nbio-techne\nMAB25991-100\n100 µg\nHuman/Primate Chitinase 3-like 1 MAb (Clone 384327)\nCapture\n\n\nbio-techne\nMAB266-100\n100 µg\nHuman CXCL10/IP-10/CRG-2 MAb (Clone 33036)\nCapture\n\n\nbio-techne\nMAB375-100\n100 µg\nHuman TRAIL/TNFSF10 MAb (Clone 75411)\nCapture\n\n\nbio-techne\nMAB9231-100\n100 µg\nHuman Angiopoietin-1 MAb (Clone 171733)\nCapture\n\n\nbio-techne\nNB110-85467\n100 µg\nAngiopoietin-2 Antibody (MM0020-1F29)\nCapture\n\n\nbio-techne\nNBP2-12045\n100 µg\nAzurocidin/CAP37/HBP Antibody (MM0099-7F31)\nCapture\n\n\nThermo\nM801\n500 µg\nAnti IL-8 (clone 3IL8-H10)\nCapture\n\n\nThermo\nMA5-24914\n100 µg\nAnti MxA\nCapture"
  },
  {
    "objectID": "Capture_Antibody_Prep.html#equipment-consumables",
    "href": "Capture_Antibody_Prep.html#equipment-consumables",
    "title": "3  Capture Antibody Preparation",
    "section": "3.2 Equipment & Consumables",
    "text": "3.2 Equipment & Consumables\n\n\n\n\n\n\n\n\nItem\nSupplier\nCatalogue Number\n\n\n\n\nPipettes and tips for 100-200 µL\nAny suitable\n\n\n\n0.2 µm syringe filter or bottle filter unit\nAny suitable\n\n\n\nSyringe, 50 mL, sterile\nAny suitable\n\n\n\n50 mL tube, sterile\nAny suitable\n\n\n\nProtein low-bind microtubes\nEppendorf\n0030108116\n\n\nLabels or permanent marker pen\nAny suitable\n\n\n\nPhosphate buffered saline (PBS)\nSigma\nP4417"
  },
  {
    "objectID": "Capture_Antibody_Prep.html#protocol",
    "href": "Capture_Antibody_Prep.html#protocol",
    "title": "3  Capture Antibody Preparation",
    "section": "3.3 Protocol",
    "text": "3.3 Protocol\n\nMake up PBS as per the Buffers and Reagents protocol.\nSet out and label 10 microtubes per capture antibody.\nRemove antibodies from freezer storage.\nAdd 100 µL of the PBS to each lyophilised antibody (anti IL-8 and anti MxA are already liquid at 1 mg/ml so do not need any liquid adding).\nAllow to rehydrate for a few minutes, vortex gently then spin liquid down briefly.\nAliquot all antibodies into 10 µL volumes, or 50 ul volumes for IL-8.\nStore at -20°C or below.\n\nAll capture antibodies are now at the same stock concentration of 1 mg/mL."
  },
  {
    "objectID": "Bead_Coupling.html#assay-specific-reagents",
    "href": "Bead_Coupling.html#assay-specific-reagents",
    "title": "4  Bead Coupling",
    "section": "4.1 Assay-specific reagents",
    "text": "4.1 Assay-specific reagents\nTable 1. Assay-specific reagents needed for bead coupling.\n\n\n\n\n\n\n\n\n\n\n\nMarker\nComponent\nCatalogue #\nSupplier\nBead region\nµg antibody/million beads\n\n\n\n\nAng-1\nBeads\nMC10018-01\nLuminex\n18\n5\n\n\nAng-2\nBeads\nMC10015-01\nLuminex\n15\n5\n\n\nAzu\nBeads\nMC10027-01\nLuminex\n27\n7\n\n\nCHI3L1\nBeads\nMC10030-01\nLuminex\n30\n4.5\n\n\nIL-6\nBeads\nMC10021-01\nLuminex\n21\n5\n\n\nIL-8\nBeads\nMC10022-01\nLuminex\n22\n5\n\n\nIL-10\nBeads\nMC10026-01\nLuminex\n26\n4\n\n\nIP-10\nBeads\nMC10029-01\nLuminex\n29\n5\n\n\nMxA\nBeads\nMC10028-01\nLuminex\n28\n6\n\n\nsTNFR1\nBeads\nMC10020-01\nLuminex\n20\n6\n\n\nsTREM-1\nBeads\nMC10014-01\nLuminex\n14\n6\n\n\nTRAIL\nBeads\nMC10025-01\nLuminex\n25\n6\n\n\nAng-1\nCapture antibody\nMAB9231\nBio-techne\n18\n5\n\n\nAng-2\nCapture antibody\nNB110-85467\nBio-techne\n15\n5\n\n\nAzu\nCapture antibody\nNBP2-12045\nBio-techne\n27\n7\n\n\nCHI3L1\nCapture antibody\nMAB25991\nBio-techne\n30\n4.5\n\n\nIL-6\nCapture antibody\nMAB206\nBio-techne\n21\n5\n\n\nIL-8\nCapture antibody\nM801\nThermo\n22\n5\n\n\nIL-10\nCapture antibody\nMAB2172\nBio-techne\n26\n4\n\n\nIP-10\nCapture antibody\nMAB266\nBio-techne\n29\n5\n\n\nMxA\nCapture antibody\nMA5-24914\nBio-techne\n28\n6\n\n\nsTNFR1\nCapture antibody\nMAB225\nBio-techne\n20\n6\n\n\nsTREM-1\nCapture antibody\nH00054210-M04\nBio-techne\n14\n6\n\n\nTRAIL\nCapture antibody\nMAB375\nBio-techne\n25\n6"
  },
  {
    "objectID": "Bead_Coupling.html#other-consumables-reagents-and-equipment-needed.",
    "href": "Bead_Coupling.html#other-consumables-reagents-and-equipment-needed.",
    "title": "4  Bead Coupling",
    "section": "4.2 Other consumables, reagents and equipment needed.",
    "text": "4.2 Other consumables, reagents and equipment needed.\nTable 2. Other materials needed for bead coupling.\n\n\n\n\n\n\n\n\nItem\nSupplier\nCatalogue number\n\n\n\n\nSodium phosphate monobasic (NaH2PO4)\nSigma\nS8282\n\n\nSodium hydroxide (NaOH)\nSigma\nS5881\n\n\nPhosphate buffered saline (PBS)\nSigma\nP4417\n\n\nSulfo-NHS\nThermo\n24510\n\n\nEDC\nThermo\n22980\n\n\nProtein low-bind microtubes, 1 per coupling\nEppendorf\n0030108116 or 0030108132\n\n\nPipettes and tips for 10 µL, 200 µL, 1 mL\nAny suitable\n\n\n\n0.2 µm syringe filters\nAny suitable\n\n\n\nSyringe, 50 mL, sterile\nAny suitable\n\n\n\n50 mL tube, sterile\nAny suitable\n\n\n\nMagnetic tube rack\nInvitrogen\n12321D\n\n\nEnd-over-end rotating mixer\nAny suitable\n\n\n\nFine balance\nAny suitable\n\n\n\npH meter\nAny suitable\n\n\n\nSonicating waterbath\nVWR\n142-6044"
  },
  {
    "objectID": "Bead_Coupling.html#preparation",
    "href": "Bead_Coupling.html#preparation",
    "title": "4  Bead Coupling",
    "section": "4.3 Preparation",
    "text": "4.3 Preparation\nThis protocol uses EDC [1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride)]. EDC absorbs moisture from the air. It is helpful to aliquot it into 50 mg, single-use, amounts in screw cap tubes on receipt and to store these in individual ziplock bags with desiccant, at -20° C.\nFor quality assurance processes, we recommend keeping note of the lot numbers and expiry dates of both beads and capture antibodies. The diagnostic performance of beads changes with time, see bead validity information elsewhere in this paper for individual bead validity, however all beads are useable for 3 months."
  },
  {
    "objectID": "Bead_Coupling.html#protocol-a---coupling-beads-for-8-plates",
    "href": "Bead_Coupling.html#protocol-a---coupling-beads-for-8-plates",
    "title": "4  Bead Coupling",
    "section": "4.4 Protocol A - Coupling beads for 8 plates",
    "text": "4.4 Protocol A - Coupling beads for 8 plates\n⌚ Timing: 2 hours, then 2 hours incubation, 1h45m to finish. Total approx. 5h45m.\nThis protocol takes place at ambient temperature. All incubations are at ambient temperature.\nTip: Protect beads from light with a foil cover when they are not being manipulated such as during incubations.\n\nPrepare the General Buffers and Buffers for Bead Coupling, as detailed in the Buffers and Reagents file.\nRetrieve capture antibodies: consult Table 3 below for the required number of aliquots of each capture antibody (prepared as detailed in Capture Antibody Prep), and place these in the fridge to thaw.\nLabel microtubes (Eppendorf, protein lo-bind) one for each coupling, with at least antigen name and bead region.\nVortex and sonicate the bead stocks for ~60 seconds of each. Vortex some more immediately before pipetting.\nTransfer 120 µL of bead stock (1.5 x 106 beads for 8 full plates) into each respective tube.\nPut tubes in magnet rack for 60 s.\nRemove supernatant without disturbing beads.\nWash beads: Remove tubes from magnet rack. Add 100 µL dH2O. Vortex & sonicate for ~20 s of each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nActivate beads: Remove tube from magnet rack. Add 80 µL Activation buffer. Vortex & sonicate, ~20 s each.\nIn two separate tubes, make up 50 mg/mL sulfo-NHS and 50 mg/mL EDC in Activation buffer. 25 mg in 500 µL is sufficient for 12 bead couplings. These should always be made fresh during the protocol immediately before use, and not stored.\nAdd 10 µL of the sulfo-NHS solution to the beads. Vortex.\nAdd 10 µL of the EDC solution to the beads. Vortex.\nIncubate 10 mins @ room temp. Vortex. Incubate for further 10 mins.\nDuring the incubation, set up new 1.5 ml tubes for antibody dilution in MES buffer, one tube per bead region.\nDispense 400 µL MES to each tube.\nRemove the MES volume indicated for each antibody in Table 3, column 5 (so that when antibody is added, the volume is restored to 400 uL in each case).\nAdd in the required volume of each antibody (Table 3, column 5):\n\nTable 3. Capture antibody for 1.5 x 106 beads, for 8 plates.\n\n\n\n\n\n\n\n\n\n\n\nAntibody on bead\n\n\nAb catalogue number (bio-techne unless stated)\n\n\nAntibody amount (µg) per million beads\n\n\nNumber of 10 ul aliquots of capture Ab needed\n\n\nVolume of capture antibody needed for 1.5e6 beads (µL)\n\n\n\n\n\nAng-1\nMAB9231\n5\n1\n7.5\n\n\nAng-2\nNB110-85467\n5\n1\n7.5\n\n\nAzu\nNBP2-12045\n7\n2\n10.5\n\n\nCHI3L1\nMAB25991\n4.5\n1\n6.8\n\n\nIL-6\nMAB206\n5\n1\n7.5\n\n\nIL-8\nM801 (Thermo)\n5\n1\n7.5\n\n\nIL-10\nMAB2172\n4\n1\n6.0\n\n\nIP-10\nMAB266\n5\n1\n7.5\n\n\nMxA\nMA5-24914 (Thermo)\n6\n1\n9.0\n\n\nsTNF-R1\nMAB225\n6\n1\n9.0\n\n\nsTREM1\nH00054210-M04\n6\n1\n9.0\n\n\nTRAIL\nMAB375\n6\n1\n9.0\n\n\n\n\nSet these antibody tubes aside and continue with the beads.\nBead tube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nMES wash 1: Remove tube from magnet rack. Add 250 µL MES buffer. Vortex & sonicate for ~ 20 s each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nMES wash 2: Remove tube from magnet rack. Add 250 µL MES buffer. Vortex & sonicate for ~ 20 s each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nAdd 100 µL MES buffer to each bead tube.\nTransfer all 400 µL of each antibody dilution into the respective bead tubes and vortex. (So that the antibody amount is eventually diluted in 0.5 mL of MES by the time it is incubated with the beads, as per Luminex scale-up table).\nIncubate 2 hours on rotating mixer at room temp. Record start time ______________\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nRemove tube from magnet rack. Add 500 µL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nPBS-TBN wash 1: Remove tube from magnet rack. Add 1 mL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nPBS-TBN wash 2: Remove tube from magnet rack. Add 1 mL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nRemove tube from magnet rack. Resuspend coupled beads in 200 µL PBS-TBN. Vortex. This is 1.66x the original volume (120 µL) to give a theoretical count of 7.5 x 106 beads/mL.\nEnsure newly coupled bead tubes are fully labelled with at least: assay, bead region, date.\nStore the coupled beads at +4°C and protect from light."
  },
  {
    "objectID": "Bead_Coupling.html#protocol-b---coupling-beads-for-52-plates",
    "href": "Bead_Coupling.html#protocol-b---coupling-beads-for-52-plates",
    "title": "4  Bead Coupling",
    "section": "4.5 Protocol B - Coupling beads for 52 plates",
    "text": "4.5 Protocol B - Coupling beads for 52 plates\n⌚ Timing: 2 hours, then 2 hours incubation, 1h45m to finish. Total approx. 5h45m.\nThe protocol takes place at ambient temperature. All incubations are at ambient temperature.\n\nPrepare the General Buffers and Buffers for Bead Coupling, as detailed in the Buffers and Reagents file.\nRetrieve capture antibodies: consult Table 2 below for the required number of aliquots of each capture antibody (prepared as detailed in Capture Antibody Prep), and place these in the fridge to thaw.\nLabel microtubes (Eppendorf, protein lo-bind) one for each coupling, with at least antigen name and bead region.\nVortex and sonicate the bead stocks for ~60 seconds of each. Vortex some more immediately before pipetting.\nTransfer 500 µL of bead stock (6.25 x 106 beads for ~52 full plates) into each respective tube.\nPut tube in magnet rack for 60 s.\nRemove supernatant without disturbing beads.\nWash beads: Remove tubes from magnet rack. Add 100 µL dH2O. Vortex & sonicate for ~20 s of each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nActivate beads: Remove tube from magnet rack. Add 80 µL Activation buffer. Vortex & sonicate, ~20 s each.\nIn two separate tubes, make up 50 mg/mL sulfo-NHS and 50 mg/mL EDC in Activation buffer. 25 mg in 500 µL is sufficient for 12 bead couplings. These should always be made fresh during the protocol immediately before use, and not stored.\nAdd 10 µL of the sulfo-NHS solution to the beads. Vortex.\nAdd 10 µL of the EDC solution to the beads. Vortex.\nIncubate 10 mins @ room temp. Vortex. Incubate for further 10 mins.\nDuring the incubation, set up new 1.5 mL tubes for antibody dilution in MES buffer, one tube per bead region.\nDispense 400 µL MES to each tube.\nRemove the MES volume indicated for each antibody in Table 4, column 5 (so that when antibody is added, the volume is restored to 400 uL in each case).\nAdd in the required volume of each antibody (Table 4, column 5):\nTable 4. Capture antibody for 6.25 x 106 beads, for approx. 52 plates.\n\n\n\n\n\n\n\n\n\n\n\n\nAntibody on bead\n\n\nAb catalogue number (bio-techne unless stated)\n\n\nAntibody amount per million beads\n\n\nNumber of 10 ul aliquots of capture Ab needed\n\n\nVolume of capture antibody needed for 1.5e6 beads (µL)\n\n\n\n\n\nAng-1\nMAB9231\n5\n4\n31.3\n\n\nAng-2\nNB110-85467\n5\n4\n31.3\n\n\nAzu\nNBP2-12045\n7\n5\n43.8\n\n\nCH3L1\nMAB25991\n4.5\n3\n28.1\n\n\nIL-6\nMAB206\n5\n4\n31.3\n\n\nIL-8\nM801 (Thermo)\n5\n4 (1 if 50 ul aliquot)\n31.3\n\n\nIL-10\nMAB2172\n4\n3\n25.0\n\n\nIP-10\nMAB266\n5\n4\n31.3\n\n\nMxA\nMA5-24914 (Thermo)\n6\n4\n37.5\n\n\nsTNF-R1\nMAB225\n6\n4\n37.5\n\n\nsTREM1\nH00054210-M04\n6\n4\n37.5\n\n\nTRAIL\nMAB375\n6\n4\n37.5\n\n\n\n\nSet these antibody tubes aside and continue with the beads.\nBead tube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nMES wash 1: Remove tube from magnet rack. Add 500 µL MES buffer. Vortex & sonicate for ~ 20 s each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nMES wash 2: Remove tube from magnet rack. Add 500 µL MES buffer. Vortex & sonicate for ~ 20 s each.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nAdd 100 µL MES buffer to beads.\nTransfer all 400 µL of each antibody dilution into the respective bead tubes and vortex. (So that the antibody amount is eventually diluted in 0.5 mL of MES by the time it is incubated with the beads, as per Luminex scale-up table).\nIncubate 2 hours on rotating mixer at room temp. Record start time ______________\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nRemove tube from magnet rack. Add 500 µL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nPBS-TBN wash 1: Remove tube from magnet rack. Add 1 mL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nPBS-TBN wash 2: Remove tube from magnet rack. Add 1 mL PBS-TBN. Vortex & sonicate for ~20 s.\nTube into magnet rack, 60 s.\nRemove supernatant without disturbing beads.\nRemove tube from magnet rack. Resuspend coupled beads in 830 µL PBS-TBN. Vortex. This is 1.66x the original volume (500 µL) to give a theoretical count of 7.5 x 106 beads/mL.\nEnsure newly coupled bead tubes are fully labelled with at least: assay, bead region, date.\nStore the coupled beads at +4°C and protect from light."
  },
  {
    "objectID": "Coupling_Confirmation.html#overview",
    "href": "Coupling_Confirmation.html#overview",
    "title": "5  Coupling Confirmation",
    "section": "5.1 Overview",
    "text": "5.1 Overview\nThis protocol can be used to confirm that antibodies have been correctly conjugated to beads. It works by using anti-species antibodies. Anti mouse-biotin is diluted in a series and reacted with the newly coupled beads which are coupled to mouse and rat antibodies."
  },
  {
    "objectID": "Coupling_Confirmation.html#reagents-consumables-equipment",
    "href": "Coupling_Confirmation.html#reagents-consumables-equipment",
    "title": "5  Coupling Confirmation",
    "section": "5.2 Reagents, consumables & equipment",
    "text": "5.2 Reagents, consumables & equipment\n\n\n\nItem\nManufacturer\nCatalogue number\n\n\n\n\nAnti mouse-biotin antibody\nBio-techne\nBAF018\n\n\nPhosphate buffered saline (PBS)\nSee buffers & reagents section\n\n\n\nPBS-TBN\nSee buffers & reagents section\n\n\n\nStreptavidin-R-Phycoerythrin (SA-PE, 1 mg/mL)\nThermo\nS806\n\n\nAntibody-coupled beads\nSee bead coupling section\n\n\n\nProtein low-bind microtubes 1.5 or 2 mL\nEppendorf\n\n\n\nBlack 96-well plate\nBio-Rad\n\n\n\nPipettes and tips for 1-200 µL\nany suitable\n\n\n\n0.2 um syringe filters\nany suitable\n\n\n\nSyringe, 50 mL\nany suitable\n\n\n\nSterile 50 mL tube\nany suitable\n\n\n\nMagPix machine\nLuminex"
  },
  {
    "objectID": "Coupling_Confirmation.html#protocol",
    "href": "Coupling_Confirmation.html#protocol",
    "title": "5  Coupling Confirmation",
    "section": "5.3 Protocol",
    "text": "5.3 Protocol\n⌚ Timing: about 3 hours.\n\nOn first use of the anti mouse-biotin, rehydrate it to be 0.2 mg/mL and aliquot into small volumes for freezer storage to minimise freeze-thaw cycles.\nThaw an aliquot of anti mouse-biotin, 3 µL is required for running two columns on a plate.\nAdd 900 µL of PBS-TBN to a tube for diluting the beads.\nGet the newly coupled beads, vortex then sonicate for 20 s of each.\nAdd 2.4 µL of each newly-coupled bead to the 900 uL and vortex mix. (To give a theoretical 20,000 beads/mL, or 1000 beads/well, assuming 7.5x106 beads/mL stock).\nLabel 7 tubes (1-7) for the anti mouse-biotin dilutions, corresponding to concentrations: 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031 µg/mL.\nDispense PBS-TBN diluent into each tube in the volumes indicated in the bottom row of Figure 1.\nSerially dilute anti mouse-biotin in PBS-TBN by adding 3 µL of the 0.2 mg/mL stock into Tube 1 (297 µL PBS-TBN) and transferring 150 µL of this into 150 µL PBS-TBN sequentially until Tube 7, vortex mixing between pipetting (Figure 1).\n\n\n\n\nFigure 1. Dilution series of anti mouse biotin.\n\n\n\nDispense 50 µL/well of the diluted beads into two columns of a black plate as per plate layout below.\nWash beads once: Put plate on magnet, wait 60 s, invert plate on magnet to empty the liquid. Add 100 µL/well PBST, removing from the magnet when adding wash buffer. Replace plate on magnet for 60 s and remove liquid as before, dabbing gently on tissue before adding the next reagent.\nAdd 50 µL/well of the anti mouse-biotin dilutions (1-7) in duplicate, and 50 µL PBS-TBN as the blank, as per plate layout:\n\n\n\n\n\n1\n2\n\n\n\n\nA\n2.00 µg/mL\n2.00 µg/mL\n\n\nB\n1.00 µg/mL\n1.00 µg/mL\n\n\nC\n0.50 µg/mL\n0.50 µg/mL\n\n\nD\n0.25 µg/mL\n0.25 µg/mL\n\n\nE\n0.125 µg/mL\n0.125 µg/mL\n\n\nF\n0.063 µg/mL\n0.063 µg/mL\n\n\nG\n0.031 µg/mL\n0.031 µg/mL\n\n\nH\nBlank 0 µg/mL\nBlank 0 µg/mL\n\n\n\n\nCover and incubate on shaker for 45 mins at ambient temperature.\nDuring the incubation, dilute SA-PE to 3 µg/mL by adding 2.7 µL of SA-PE to 900 µL PBS-TBN. Store this in the fridge until use.\nWash plate 3 times as before with 100 uL/well PBST.\nAdd 50 µL/well of diluted SA-PE to the plate.\nCover & incubate on shaker for 45 mins.\nWash plate 3 times as before with 100 µL/well PBST.\nAdd 100 µL PBS-TBN to each well and read on MagPix the same day using the 12-plex protocol."
  },
  {
    "objectID": "Coupling_Confirmation.html#analysis-interpretation-of-results",
    "href": "Coupling_Confirmation.html#analysis-interpretation-of-results",
    "title": "5  Coupling Confirmation",
    "section": "5.4 Analysis & interpretation of results",
    "text": "5.4 Analysis & interpretation of results\nWe performed a series of coupling confirmations. The MagPix output file is provided in data/coupling_confirmation/Bead_Coupling_Data.csv\nFor this analysis, we use only the median fluorescence data and only need to include the rows of the mfi data which relate to the experiments where a biotinylated, anti-mouse antibody was directed against the assay specific, antibody-coupled microbeads.\nThe basic steps include\n\nLoading the csv file, renaming problematic columns\nRemoving headers from the MagPix output file\nFiltering the data to include only MFI data\nFiltering the MFI data to include only the relevant lines of data\nPivoting the data in to a tidy format\nCharting the data\n\n\n\n\n\n\nThe chart above confirms that these microbeads (a) have successfully coupled to the assay specific mouse and rat antibodies and (b) that the MFI response varies in response to serial dilution of the biotinylated anti-mouse secondary antibody.\n\nggplot(df,aes(as.numeric(dilution),as.numeric(mfi)))+\n  geom_smooth(method = \"loess\",formula = \"y~x\")+\n  geom_point()+\n  facet_wrap(.~marker,scales = \"fixed\")+\n  xlab(\"Dilution Series\")+\n  ylab(\"mfi\")+\n  ggtitle(\"Absolute mfi [fixed y axis] of antibody conjugated microbeads\")\n\n\n\n\nWhen charted on a fixed y axis, it becomes clearer that some markers (i.e. CHI3L1 and MxA) have a much lower MFI across the full range of dilutions. This could be explained by lower avidity or affinity between the primary and secondary antibodies. This is likely the case for the CHI3L1 antibody which is from rat and exhibits low reactivity with the anti mouse-biotin. Low signal could also indicate steric effects, or experimental issues and failure to couple efficiently which may indicate that the beads are not useable.\nNote that whilst both MxA and CHI3L1 both had lower MFI values than other markers, they still exhibited a dose-response curve that seems appropriate for experimental use. Assays such as MxA and CHI3L1 which both had low dose:response ratios with the anti mouse coupling confirmation are potentially usable because the response with the specific antigen standards may differ and would determine their true utility in the assay.\nWe would reject a bead-set where there was either (a) no, or unexpectedly low fluorescence response or (b) no dose-response, in the coupling confirmation."
  },
  {
    "objectID": "Detection_Antibody_Prep.html#detection-antibodies",
    "href": "Detection_Antibody_Prep.html#detection-antibodies",
    "title": "6  Detection Antibody Prep",
    "section": "6.1 Detection Antibodies",
    "text": "6.1 Detection Antibodies\n\n\n\n\n\n\n\n\n\n\nManufacturer\nPart No.\nPack size\nPRODUCT DESCRIPTION\nComponent\n\n\n\n\nbio-techne\n370-0010\n3\nLightning-Link (R) Rapid Type A Biotin Antibody Labeling Kit\nDetection\n\n\nbio-techne\nAF2200\n100 ug\nHuman Azurocidin/CAP37/HBP Affinity Purified Polyclonal Ab\nDetection\n\n\nbio-techne\nAF7946\n100 ug\nHuman MxA/Mx1 Affinity Purified Polyclonal Ab\nDetection\n\n\nbio-techne\nBAF1278\n50 ug\nHuman TREM-1 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF206\n50 ug\nHuman/Primate IL-6 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF208\n50 ug\nHuman IL-8/CXCL8 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF217\n100 ug\nHuman IL-10 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF225\n50 ug\nHuman TNF RI/TNFRSF1A Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF2599\n50 ug\nHuman/Primate Chitinase 3-like 1 Biotinylated Aff Pur PAb\nDetection\n\n\nbio-techne\nBAF266\n50 ug\nHuman CXCL10/IP-10 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF375\n50 ug\nHuman/Primate TRAIL/TNFSF10 Biotinylated Aff Pur PAb\nDetection\n\n\nbio-techne\nBAF623\n50 ug\nHuman Angiopoietin-2 Biotinylated Affinity Purified PAb\nDetection\n\n\nbio-techne\nBAF923\n50 ug\nHuman Angiopoietin-1 Biotinylated Affinity Purified PAb\nDetection\n\n\nThermo\nS866\n1 mg\nSA-PE\nDetection"
  },
  {
    "objectID": "Detection_Antibody_Prep.html#reagents-and-materials",
    "href": "Detection_Antibody_Prep.html#reagents-and-materials",
    "title": "6  Detection Antibody Prep",
    "section": "6.2 Reagents and materials",
    "text": "6.2 Reagents and materials\n\n\n\n\n\n\n\n\nComponent\nSupplier\nCatalogue Number\n\n\n\n\nLightning Link (LL) biotin Type A kit\nbio-techne\n370-0010\n\n\nAnti Azu\nbio-techne\nAF2200\n\n\nAnti MxA\nbio-techne\nAF7946\n\n\nPBS (0.2 um filtered)\nSigma\nP4417"
  },
  {
    "objectID": "Detection_Antibody_Prep.html#protocol",
    "href": "Detection_Antibody_Prep.html#protocol",
    "title": "6  Detection Antibody Prep",
    "section": "6.3 Protocol",
    "text": "6.3 Protocol\n1. From LL-biotin kits, thaw LL-Modifier and LL-Quencher reagents and retrieve as many biotin vials as needed, one for each antibody to be conjugated.\n2. Label the LL glass vials with ‘Azu’ or ‘MxA’, date, ‘0.833 µg/mL’.\n3. Vortex and briefly spin down the LL-Modifier and LL-Quencher tubes.\n4. Rehydrate Anti Azu (AF2200) and Anti MxA (AF7946) each with 100 µL of filter sterilized PBS to give 1 mg/mL.\n5. Add 10 µL of LL-Modifier from the LL kit to each of the antibody aliquots and mix by pipetting up and down gently.\n6. Transfer all 110 µL to the respective glass vial and ensure that the lyophilised biotin is rehydrated by gently pipetting up and down once or twice.\n7. Incubate at least 15 mins at room temp. Can be left even overnight if more convenient.\n8. Add 10 µL of LL-Quencher to each glass vial and pipette gently to mix.\n9. Leave for 5 mins before use.\n10. Store the biotinylated antibodies in the fridge. Expiry is 18 months from conjugation date."
  },
  {
    "objectID": "antigens.html#protocol",
    "href": "antigens.html#protocol",
    "title": "7  Antigens",
    "section": "7.1 Protocol",
    "text": "7.1 Protocol\n⌚ Timing: 2-3 hours, but can be split into shorter periods if needed (see Tip 2).\nThis protocol takes place at ambient temperature. All incubations are at ambient temperature.\nTip: Keep the proteins as cold as possible, for as long as possible, to avoid degradation. Work with tubes on ice or in chilled racks. Likewise, thaw proteins that are in solution on ice.\nTip 2: If time is limited, prepare a smaller number of proteins at one time, completing the full process of rehydration, aliquotting and storage for these, and return another time to complete the next batch.\n\nPrepare filter-sterlised PBS as per Buffers and Reagents protocol.\nLabel protein lo-bind tubes with antigen name, catalogue number, concentration, volume and expiry date. The approximate number of tubes needed for each antigen is shown in column 6 in Table 1 below.\nRehydrate lyophylised antigens using the volumes of PBS listed in column 2 of Table 1.\nNOTE: MxA comes in solution and does not need rehydrating. See manufacturer’s data sheet for concentration.\nLeave vials to sit for 60 seconds to rehydrate, then vortex gently, spin down.\nAliquot into the volumes and number of tubes indicated in columns 5 and 6 of Table 1.\nStore aliquots at -70 or below immediately.\n\nTable 1. Recombinant antigen stock aliquotting.\n\n\n\n\n\n\n\n\n\n\n\n\nAntigen\n\n\nPBS to add to vial to make stock (ul)\n\n\nStock concentration (ug/ml)\n\n\nVolume needed each time (ul)\n\n\nAliquot size (ul)\n\n\nNumber of aliquots\n\n\n\nAng1\n250\n100\n6\n27\n9\n\n\nAng2\n250\n100\n12\n20\n9\n\n\nAzu\n250\n200\n12\n26\n9\n\n\nCHI3L1\n250\n200\n6\n27\n9\n\n\nIL-6\n100\n100\n4\n10\n9\n\n\nIL-8\n100\n100\n4\n10\n9\n\n\nIL-10\n100\n100\n4\n10\n9\n\n\nIP-10\n100\n100\n4\n10\n9\n\n\nMxA\nnone (already liquid)\nSee data sheet\nDepends on stock conc.\n13\n4\n\n\nsTNFR1\n250\n100\n4\n10\n9\n\n\nTREM1\n500\n100\n4\n54\n9\n\n\nTRAIL\n100\n100\n4\n10\n9"
  },
  {
    "objectID": "antibody_pairs.html#overview",
    "href": "antibody_pairs.html#overview",
    "title": "8  Antibody pair screening",
    "section": "8.1 Overview",
    "text": "8.1 Overview\nThe following tables provide information on how capture and detection antibodies are paired in the assay. A relatively large number of pairs were tested and we continued to screen pairs until we identified a pair for each marker which met the following quality criteria.\nADD CRITERIA HERE\n\nAND HERE"
  },
  {
    "objectID": "antibody_pairs.html#antibody-pairs-screened-and-selected-for-the-final-assay",
    "href": "antibody_pairs.html#antibody-pairs-screened-and-selected-for-the-final-assay",
    "title": "8  Antibody pair screening",
    "section": "8.2 Antibody pairs screened and selected for the final assay",
    "text": "8.2 Antibody pairs screened and selected for the final assay\nTable 1. Antibody combinations and recombinant antigens screened and reason for failure, or if passed screening and included in final multiplex. Reagents and catalogue numbers are from bio-techne unless specified otherwise. Product codes beginning AF relate to antigen affinity purified polyclonal antibodies and BAF to biotinylated versions of the same. MAB are monoclonal antibodies and BAM are biotinylated monoclonal antibodies. Clone numbers are given for monoclonal antibodies. Reagents and markers in bold were included in the final 12-plex.\n\n\n\n\n\n\n\n\n\n\nMarker\nCapture antibody\nRecombinant antigen\nDetection antibody\nIncluded in final assay (Pass), or Reason for failure\n\n\n\n\nAng-1\nMAB9231 (clone 171733)\n923-AN\nBAF923\nPass\n\n\nAng-2\nMAB098 (clone 85816)\n623-AN\nBAM0981 (clone 85834)\nCross-reaction with Ang-1\n\n\n\nMAB0983 (clone 180102)\n623-AN\nBAM0981 (clone 85834)\nWidespread cross-reactivity in multiplex\n\n\n\nNB110-85467 (clone MM0020-1F29)\n623-AN\nBAF623\nPass\n\n\nAzu\nMAB2200 (clone 246322)\n2200-SE\nAF2200*\nPoor sensitivity\n\n\n\nNBP2-12045\n2200-SE\nAF2200*\nPass\n\n\nCHI3L1\nMAB25991\n2599-CH\nBAF2599\nPass\n\n\nCRP\nMAB17071 (clone 232007)\n1707-CR\nBAM17072 (clone 232024)\nCross-reactivity with Azu antigen\n\n\n\nMAB17071 (clone 232007)\n1707-CR\nMA1-10323 (Thermo, clone C7)\nAssay removed from multiplex due to sample dilution needed and unreliable standard curve.\n\n\nIL-6\nMAB206 (clone 6708)\n206-IL\nBAF206\nPass\n\n\nIL-8\nMAB208 (clone 6217)\n208-IL\nBAF208\nPoor sensitivity\n\n\n\nM801 (Thermo, clone 3IL8-H10)\n208-IL\nBAF208\nPass\n\n\nIL-10\nMAB2172 (clone 127107)\n1064-IL\nBAF217\nPass\n\n\nIP-10\nMAB266 (clone 33036)\n266-IP\nBAF266\nPass\n\n\nMxA\nAF7946\nTP307418 (OriGene)\nAF7946*\nCross-reactivity with other antigens (ELISA screen)\n\n\n\nMA5-24914 (Thermo, clone OTI2G12)\nNBP2-51838\nAF7946*\nLower signal than OriGene antigen\n\n\n\nMA5-24914 (Thermo, clone OTI2G12)\nTP307418 (OriGene)\nAF7946*\nPass\n\n\nPCT\nMAB83501 (clone 944002)\n9607-PN\nMAB8350* (clone 919510)\nGeneral cross-reactivity in multiplex\n\n\n\nMAB83502 (clone 95123)\n9607-PN\nMAB8350* (clone 919510)\nGeneral cross-reactivity in multiplex\n\n\n\nMAB8350 (clone 919510)\n9607-PN\nMAB83502* (clone 95123)\nNo signal (ELISA screen)\n\n\n\nAF8350\n9607-PN\nAF8350*\nGeneral cross-reactivity in multiplex. This assay was dropped due to high cross-reactivity or poor performance of all screened antibody combinations.\n\n\nsFlt-1\nMAB321 (clone 49560)\n321-FL\nBAF321\nNo signal (multiplex)\n\n\n\nNBP2-34619 (clone FLT1/659)\n321-FL\nMAB321* (clone 49560)\nPoor sensitivity (ELISA screen)\n\n\n\nAF321\n321-FL\nBAF321\nPoor sensitivity (ELISA screen)\n\n\n\nAF321\n321-FL\nMAB321* (clone 49560)\nOk in singleplex (ELISA screen). Very low sensitivity in multiplex\n\n\n\nAF321\nRP-75748 (Thermo)\nMAB321* (clone 49560)\nNo signal (multiplex). This assay was dropped due to difficulty in finding a working antibody pair and recombinant antigen standard.\n\n\nsTNF-R1\nMAB625 (clone 16805)\n636-R1\nBAF225\nPoor sensitivity\n\n\n\nMAB6251 (clone 925224)\n636-R1\nBAF225\nNo signal\n\n\n\nMAB225 (clone 16803)\n636-R1\nBAF225\nPass\n\n\nsTREM-1\nAF1278\n1278-TR\nBAF1278\nHigh background\n\n\n\nMAB1278 (clone 193015)\n1278-TR\nBAF1278\nPoor sensitivity and cross- reaction with MxA antigen\n\n\n\nH00054210-M01 (clone 2E2)\n1278-TR\nBAF1278\nPass\n\n\nTRAIL\nMAB3751 (clone 124723)\n375-TL\nBAF375\nPoor sensitivity\n\n\n\nMAB375 (clone 75411)\n375-TL\nBAF375\nPass\n\n\n\n*These detection antibodies were biotinylated using a Lightning Link kit."
  },
  {
    "objectID": "Cross_Reactivity.html#intro",
    "href": "Cross_Reactivity.html#intro",
    "title": "9  Cross-reactivity Testing",
    "section": "9.1 Intro",
    "text": "9.1 Intro\nCross-reactivity would occur if an analyte triggered a measurable response in an assay other than that which was intended, for instance if an assay based on detection antibodies intended to be specific for MxA were reactive to purified sTNFR1 antigen. Cross-reactive antibody pairs cannot be trusted to provide specific and accurate estimates of analyte concentration.\nTo establish whether any assays were cross-reactive, we tested each assay against a standard curve of purified antigens for both its target analyte (which should be reactive) and all other analytes. Note that this approach cannot rule out assay cross-reactivity to analytes in the blood (or other sample) that were not directly tested here.\nThe data presented here include 13 antigens; those on the final 12-plex list of markers, plus C-Reactive Protein (CRP), which was part of our initial screening process."
  },
  {
    "objectID": "Cross_Reactivity.html#protocol",
    "href": "Cross_Reactivity.html#protocol",
    "title": "9  Cross-reactivity Testing",
    "section": "9.2 Protocol",
    "text": "9.2 Protocol\nThe protocol is initiated by making 13X stocks of the pure recombinant protein standards (13X because it was done as a 13-plex). Equal volumes of the 13X analytes were then mixed to achieve a multi-analyte pool in which each of the 13 analytes were at 1X concentrations. Separately, each 13X antigen was diluted 1 in 13 to achieve a 1X concentration standard curve of that antigen alone. This was so that each standard curve, either multi- or single-plex, originated from the same dilutions series, thus minimising variability.\nThe cross-reactivity assessment can be conducted for any level of multiplex (N-plex) by generating initial protiein standards at N times the 1X concentrations. This cross-reactivity assessment should be repeated if any changes are made to the antibodies or antigens in the assay i.e. if an additional assay were to be added to the multiplex, or a specific antibody or recombinant antigen replaced with another.\n\n9.2.1 Preparation needed prior to running the Cross-Reactivity protocol\n\nPrepare buffers for general assay procedures as per the Buffers and Reagents protocol.\nPrepare recombinant protein antigen stock aliquots as per the Antigens protocol.\nPrepare coupled beads as per the Bead_Coupling and Coupling_Confirmation protocols.\nPrepare biotin detection antibodies as per the Detection_Antibody_Prep protocol.\n\n\n\n9.2.2 Prepare analytes\n⌚ Timing: 1-2 hours set-up, 2 hr + 1 hr + 45 min incubations. Total approx. 6h.\nAll incubations are at ambient temperature.\nTip: Handle recombinant proteins on ice at all times to minimise degradation.\nNOTE: All 13 antibody-coupled beads and all 13 biotin-conjugated detection antibodies are present in all assays.\n\nGet coupled beads from fridge, bring to ambient temperature, vortex and sonicate for 30 sec of each.\nPut aliquots of the recombinant protein stocks on ice to thaw.\nIn a protein lo-bind 96-well plate, prepare 4-fold analyte dilutions of each antigen separately (i.e. one column per antigen) in PBS-TBN at 13X the final required concentration. Label the plate to know which order the antigens are in. Some analytes may need an initial pre-dilution in a separate tube.\ne.g. make 100 ul of dilution 1 in row 1, then serially transfer 25 ul into subsequent wells with 75 ul of PBS-TBN, pipetting up and down to mix well between transfers. The Standards Calculator Excel document can also be adjusted for the number of analytes in the multiplex and for the final volume needed.\nIn a second lo-bind plate- for the multiplex standards (‘13-plex’), combine equal volumes (e.g. 10 ul) of each of the 13X analyte stocks. i.e. 10 ul of each standard 1 will be transferred into well A1 to make 130 ul total, 10 ul of each standard 2 into well A2, etc. Again mixing well by pipetting up and down carefully several times.\nInto subsequent columns of the second lo-bind plate, add 120 ul of PBS-TBN and transfer 10 ul of each 13X standard to achieve 1X standards of each antigen, pipetting up and down to mix well.\n9.2.3 Prepare beads\n\nPrepare beads for a total of 208 wells, plus additional surplus, in Plates 1,2,3. The aim is to get 20,000 beads/ml [ie 1000 beads/well] based on stock of 7.5x106 beads/ml:\nAdd 11.044 ml of PBS-TBN to a Universal (20 ml capacity tube) i.e. 11,440 ul final wanted volume - (30.5 ul of 13 bead regions = 396.5 ul total bead volume) = 11,043.5 ul. Total final volume after addition of beads, will be 11.44 ml which allows 10% surplus volume.\nVortex bead stocks again as you add 30.5 ul of each bead to the tube.\nGet black mylar plates (“assay plates”) and label with date etc.\nAdd 50 ul of diluted beads to all 96 wells of 2 plates, plus columns 01 and 02 of a third plate.\nWash beads once: put plates on magent for 60 sec, discard liquid, remove form magent to add 100 ul PBST, replace on magent for 60 sec, discard liquid, dab gently on tissue to remove excess liquid. Cover plates until addition of antigens to prevent drying.\nTransfer the multiplex and single-plex standards to the assay plates into duplicate wells of 30 ul each, as per the plate layouts below.\nCover and incubate the plates on a shaker at ~200 rpm for 2 hours.\n\n\nTables. Plate layouts for cross-reactivity assessment assay. Each well will contain all capture antibodies (beads) and all detection antibodies, but either all antigens (13-plex) or each antigen alone (where named).\n\n\n\nPlate 1\n13-plex\nCHI3L1\nIL-8\nsTNFR1\nIL-6\nAng-2\n\n\n\n\nColumns\n01-02\n03-04\n05-06\n07-08\n09-10\n11-12\n\n\nRow A\n\n\n\n\n\n\n\n\nRow B\n\n\n\n\n\n\n\n\nRow C\n\n\n\n\n\n\n\n\nRow D\n\n\n\n\n\n\n\n\nRow E\n\n\n\n\n\n\n\n\nRow F\n\n\n\n\n\n\n\n\nRow G\n\n\n\n\n\n\n\n\nRow H\n\n\n\n\n\n\n\n\n\n\n\n\nPlate 2\nAng-1\nAzu\nMxA\nTRAIL\nIL-10\nIP-10\n\n\n\n\nColumns\n01-02\n03-04\n05-06\n07-08\n09-10\n11-12\n\n\nRow A\n\n\n\n\n\n\n\n\nRow B\n\n\n\n\n\n\n\n\nRow C\n\n\n\n\n\n\n\n\nRow D\n\n\n\n\n\n\n\n\nRow E\n\n\n\n\n\n\n\n\nRow F\n\n\n\n\n\n\n\n\nRow G\n\n\n\n\n\n\n\n\nRow H\n\n\n\n\n\n\n\n\n\n\n\n\nPlate 3\nsTREM1\nEMPTY\nEMPTY\nEMPTY\nEMPTY\nEMPTY\n\n\n\n\nColumns\n01-02\n03-04\n05-06\n07-08\n09-10\n11-12\n\n\nRow A\n\n\n\n\n\n\n\n\nRow B\n\n\n\n\n\n\n\n\nRow C\n\n\n\n\n\n\n\n\nRow D\n\n\n\n\n\n\n\n\nRow E\n\n\n\n\n\n\n\n\nRow F\n\n\n\n\n\n\n\n\nRow G\n\n\n\n\n\n\n\n\nRow H\n\n\n\n\n\n\n\n\n\n12. During the incubation, prepare biotin detection antibodies for 3 plates. The excess can be stored frozen for future use.\n\nWash the plates 3 times with PBST as before.\nAdd 30 ul per well of detection antibodies to all wells.\nCover and inclubate, shaking, for 1 hour.\nDuring incubation, prepare SA-PE at 3 ug/ml for a total of 6.9 ml in PBS-TBN.\nWash plates 3 times with PBST as before.\nAdd 30 ul per well of the diluted SA-PE to all wells.\nWash plates 3 times with PBST as before.\nAdd 100 ul PBS-TBN to each well, cover and refrigerate overnight.\nRead plates on Mag-Pix first thing the next day.\n\nExample data analysis using real data is given below."
  },
  {
    "objectID": "Cross_Reactivity.html#results-analysis",
    "href": "Cross_Reactivity.html#results-analysis",
    "title": "9  Cross-reactivity Testing",
    "section": "9.3 Results & Analysis",
    "text": "9.3 Results & Analysis\nThe raw data are in long format in the file data/crossreactivity_data/crossreactivity_data_long.csv\nEach line represents a well of the Luminex plate in which there was…\n\nAn analyte at one of 8 concentrations\nDetection antibodies for one of the 13 individual assays\n\n\n9.3.1 Load libraries\n\n\n9.3.2 Read in the data from the crossreactivity experiments.\n\n\n\n\n\nLocation\nanalyte\nmfi\nplate\nassay\nwell\nrow\nrep\nstandard\n\n\n\n\n1(1,A1)\nAng.1\n6665.5\n1\n13plex\n1\nA\n1\n1\n\n\n2(1,B1)\nAng.1\n2104.0\n1\n13plex\n2\nB\n1\n2\n\n\n3(1,C1)\nAng.1\n489.5\n1\n13plex\n3\nC\n1\n3\n\n\n4(1,D1)\nAng.1\n168.0\n1\n13plex\n4\nD\n1\n4\n\n\n5(1,E1)\nAng.1\n83.0\n1\n13plex\n5\nE\n1\n5\n\n\n6(1,F1)\nAng.1\n78.5\n1\n13plex\n6\nF\n1\n6\n\n\n7(1,G1)\nAng.1\n75.0\n1\n13plex\n7\nG\n1\n7\n\n\n8(1,H1)\nAng.1\n71.5\n1\n13plex\n8\nH\n1\n8\n\n\n9(1,A2)\nAng.1\n7102.0\n1\n13plex\n9\nA\n2\n1\n\n\n10(1,B2)\nAng.1\n2283.0\n1\n13plex\n10\nB\n2\n2\n\n\n11(1,C2)\nAng.1\n487.0\n1\n13plex\n11\nC\n2\n3\n\n\n12(1,D2)\nAng.1\n156.5\n1\n13plex\n12\nD\n2\n4\n\n\n13(1,E2)\nAng.1\n87.0\n1\n13plex\n13\nE\n2\n5\n\n\n14(1,F2)\nAng.1\n72.0\n1\n13plex\n14\nF\n2\n6\n\n\n15(1,G2)\nAng.1\n75.0\n1\n13plex\n15\nG\n2\n7\n\n\n16(1,H2)\nAng.1\n68.0\n1\n13plex\n16\nH\n2\n8\n\n\n17(1,A3)\nAng.1\n80.0\n1\nCHI3L1\n17\nA\n1\n1\n\n\n18(1,B3)\nAng.1\n75.0\n1\nCHI3L1\n18\nB\n1\n2\n\n\n19(1,C3)\nAng.1\n71.0\n1\nCHI3L1\n19\nC\n1\n3\n\n\n20(1,D3)\nAng.1\n74.0\n1\nCHI3L1\n20\nD\n1\n4\n\n\n21(1,E3)\nAng.1\n75.0\n1\nCHI3L1\n21\nE\n1\n5\n\n\n22(1,F3)\nAng.1\n70.0\n1\nCHI3L1\n22\nF\n1\n6\n\n\n23(1,G3)\nAng.1\n70.0\n1\nCHI3L1\n23\nG\n1\n7\n\n\n24(1,H3)\nAng.1\n69.0\n1\nCHI3L1\n24\nH\n1\n8\n\n\n25(1,A4)\nAng.1\n74.0\n1\nCHI3L1\n25\nA\n2\n1\n\n\n26(1,B4)\nAng.1\n70.0\n1\nCHI3L1\n26\nB\n2\n2\n\n\n27(1,C4)\nAng.1\n71.5\n1\nCHI3L1\n27\nC\n2\n3\n\n\n28(1,D4)\nAng.1\n68.0\n1\nCHI3L1\n28\nD\n2\n4\n\n\n29(1,E4)\nAng.1\n69.0\n1\nCHI3L1\n29\nE\n2\n5\n\n\n30(1,F4)\nAng.1\n78.5\n1\nCHI3L1\n30\nF\n2\n6\n\n\n31(1,G4)\nAng.1\n70.0\n1\nCHI3L1\n31\nG\n2\n7\n\n\n32(1,H4)\nAng.1\n72.0\n1\nCHI3L1\n32\nH\n2\n8\n\n\n33(1,A5)\nAng.1\n69.0\n1\nIL.8\n33\nA\n1\n1\n\n\n34(1,B5)\nAng.1\n65.0\n1\nIL.8\n34\nB\n1\n2\n\n\n35(1,C5)\nAng.1\n64.0\n1\nIL.8\n35\nC\n1\n3\n\n\n36(1,D5)\nAng.1\n66.0\n1\nIL.8\n36\nD\n1\n4\n\n\n37(1,E5)\nAng.1\n66.5\n1\nIL.8\n37\nE\n1\n5\n\n\n38(1,F5)\nAng.1\n65.0\n1\nIL.8\n38\nF\n1\n6\n\n\n39(1,G5)\nAng.1\n63.5\n1\nIL.8\n39\nG\n1\n7\n\n\n40(1,H5)\nAng.1\n76.0\n1\nIL.8\n40\nH\n1\n8\n\n\n41(1,A6)\nAng.1\n61.0\n1\nIL.8\n41\nA\n2\n1\n\n\n42(1,B6)\nAng.1\n75.0\n1\nIL.8\n42\nB\n2\n2\n\n\n43(1,C6)\nAng.1\n71.0\n1\nIL.8\n43\nC\n2\n3\n\n\n44(1,D6)\nAng.1\n70.0\n1\nIL.8\n44\nD\n2\n4\n\n\n45(1,E6)\nAng.1\n66.0\n1\nIL.8\n45\nE\n2\n5\n\n\n46(1,F6)\nAng.1\n71.0\n1\nIL.8\n46\nF\n2\n6\n\n\n47(1,G6)\nAng.1\n77.0\n1\nIL.8\n47\nG\n2\n7\n\n\n48(1,H6)\nAng.1\n70.0\n1\nIL.8\n48\nH\n2\n8\n\n\n49(1,A7)\nAng.1\n69.0\n1\nsTNFR.1\n49\nA\n1\n1\n\n\n50(1,B7)\nAng.1\n68.0\n1\nsTNFR.1\n50\nB\n1\n2\n\n\n\n\n\n\n\n9.3.3 Create counterfactuals and bind to data\nThe counterfactuals are used in the charts below to show the response curves when the assay is tested against its own analyte. These are shown as grey bars in the charts.\n\ncounterfactuals = filter(mfi_allplates,assay==analyte) %&gt;% \n  select(\n    assay,\n    standard,\n    rep,\n    mfi\n  ) %&gt;% \n  rename(mfi.cf = mfi)\n\nmfi_allplates &lt;- left_join(mfi_allplates,counterfactuals)\n\n\n\n9.3.4 Show results for individual analytes against all assays\nEach experiment was repeated and charts below show the results of experiments 1 & 2.\nDefine a function to plot each analyte.\n\nassay.plot&lt;-function(showanalyte){\nggplot(filter(mfi_allplates,analyte==showanalyte,assay!=\"13plex\"))+\n  geom_bar(stat = \"identity\",aes(standard,mfi.cf),fill=\"grey\",alpha=0.5)+\n  geom_bar(stat = \"identity\",aes(standard,mfi),fill=\"black\")+\n  \n  facet_grid(analyte~assay) +\n  xlab(\"Assay & Standard being tested\") +\n  ylab(\"Analyte Response (MFI)\")\n}\n\n\n9.3.4.1 Ang-1\n\nassay.plot(showanalyte = \"Ang.1\")\n\n\n\n\n\n\n9.3.4.2 Ang-2\n\nassay.plot(showanalyte = \"Ang.2\")\n\n\n\n\n\n\n9.3.4.3 Azu\n\nassay.plot(showanalyte = \"Azu\")\n\n\n\n\n\n\n9.3.4.4 CHI3L1\n\nassay.plot(showanalyte = \"CHI3L1\")\n\n\n\n\n\n\n9.3.4.5 CRP\n\nassay.plot(showanalyte = \"CRP\")\n\n\n\n\n\n\n9.3.4.6 IL-10\n\nassay.plot(showanalyte = \"IL.10\")\n\n\n\n\n\n\n9.3.4.7 IL-6\n\nassay.plot(showanalyte = \"IL.6\")\n\n\n\n\n\n\n9.3.4.8 IL-8\n\nassay.plot(showanalyte = \"IL.8\")\n\n\n\n\n\n\n9.3.4.9 IP-10\n\nassay.plot(showanalyte = \"IP.10\")\n\n\n\n\n\n\n9.3.4.10 MxA\n\nassay.plot(showanalyte = \"MxA\")\n\n\n\n\n\n\n9.3.4.11 sTNF-R1\n\nassay.plot(showanalyte = \"sTNFR.1\")\n\n\n\n\n\n\n9.3.4.12 sTREM-1\n\nassay.plot(showanalyte = \"sTREM.1\")\n\n\n\n\n\n\n9.3.4.13 TRAIL\n\nassay.plot(showanalyte = \"TRAIL\")\n\n\n\n\n\n\n9.3.4.14 Show 13-plex results\n\nlibrary(ggplot2)\nlibrary(dplyr)\nlibrary(readr)\n\n# Load the data\nmfi_allplates = read_csv(\"data/crossreactivity_data/crossreactivity_data_long.csv\", show_col_types = FALSE)\n\n# Create the plot with rotated facet labels and reduced y-axis ticks\nggplot(filter(mfi_allplates, assay != \"13plex\")) +\n  geom_bar(stat = \"identity\", aes(standard, mfi), fill = \"black\") +\n  facet_grid(analyte ~ assay,scales = \"free_y\") +\n  xlab(\"Assay & Standard being tested\") +\n  ylab(\"Analyte Response (MFI)\") +\n  theme(\n    strip.text.x = element_text(angle = 90, hjust = 0),\n    strip.text.y = element_text(angle = 0)\n  )"
  },
  {
    "objectID": "Standards_Prep.html#overview",
    "href": "Standards_Prep.html#overview",
    "title": "10  Standard curves",
    "section": "10.1 Overview",
    "text": "10.1 Overview\nThis protocol will support you to create a set of standard curves against which experimental fluorescence measurements from clinical specimens will be calibrated, normalised, and converted in to analyte concentration estimates. The standards are made as a multiplexed pool of the recombinant antigens for the various bead-conjugated sandwich assays (see bead coupling and antibody pairs) in the test. This pool is diluted several times, and the dilution series (along with an antigen free ‘buffer blank’ are included on every plate that is run on the MagPix device. This allows the user to normalise fluorescence signal variation between plates, and to establish a dose-response curve for each antigen on each plate. The dose-response curve is later used to convert the fluorescence signals from the multiplexed testing of clinical specimens in to estimates of the concentration of each analyte (see Analysis)."
  },
  {
    "objectID": "Standards_Prep.html#protocol",
    "href": "Standards_Prep.html#protocol",
    "title": "10  Standard curves",
    "section": "10.2 Protocol",
    "text": "10.2 Protocol\n\nPrepare PBS-TBN as per the Buffers and Reagents protocol.\nPrepare antigen stocks as per the Antigens protocol.\nYou will aim to create a multiplexed top-standard by mixing volumes of the recombinant antigen stocks together and then making up the residual volume with PBS-TBN buffer. A worked example is provided below.\nLINK TO EXCEL CALCULATOR AS WELL/INSTEAD OF THE CALCS BELOW.\n\n\n10.2.1 Calculations\n\ntarget_volume_ml is the total volume (mL) of standards to be created\nStock_g_ml is a list of the concentrations (g/mL) of the stock antigens\nTarget_g_ml is a list of the desired concentrations (g/mL) of the antigens in the multiplexed top-standard\ndilution_factor is a list of the factors required to dilute each antigen to the Target_g_ml activity. It is calculated as \\[dilution\\_factor = \\frac{Stock\\_g\\_ml}{Target\\_g\\_ml}\\]\nvolume_stock_ml is a list of the volumes of each stock antigen solution which will contribute to the target_volume_ml. It is calculated as \\[volume\\_stock\\_ml = \\frac{target\\_volume\\_ml}{dilution\\_factor}\\]\n\n\n### Composition of top standard from docx\n\n\nformulation_standards = \n  tibble(\n  Assay = c(\"IL-8\",\"IL-10\",\"sTREM1\",\"Ang-2\",\"Ang-1\",\"sTNFR1\",\"IL-6\",\"TRAIL\",\"AZU\",\"MXA\",\"IP10\",\"CHI3L1\"),\n  \n  Stock_g_ml = c(100e-6,100e-6,100e-6,100e-6,100e-6,25e-6,100e-6,100e-6,200e-6,220e-6,100e-6,200e-6),\n  \n  Target_g_ml = c(2.5e-9,4e-9,10e-9,100e-9,50e-9,2.5e-9,10e-9,10e-9,200e-9,300e-9,10e-9,100e-9),\n  \n  dilution_factor = Stock_g_ml/Target_g_ml,\n  \n  target_volume_ml = 1,\n  \n  volume_stock_ml = format(target_volume_ml/dilution_factor,scientific=T,digits=3)\n        ) %&gt;% \n  \n  \n  mutate(dilution_factor = format(dilution_factor,scientific=F,digits=1))\n\n\nkable(select(formulation_standards,-target_volume_ml),digits=10)\n\n\n\n\nAssay\nStock_g_ml\nTarget_g_ml\ndilution_factor\nvolume_stock_ml\n\n\n\n\nIL-8\n1.0e-04\n2.5e-09\n40000\n2.50e-05\n\n\nIL-10\n1.0e-04\n4.0e-09\n25000\n4.00e-05\n\n\nsTREM1\n1.0e-04\n1.0e-08\n10000\n1.00e-04\n\n\nAng-2\n1.0e-04\n1.0e-07\n1000\n1.00e-03\n\n\nAng-1\n1.0e-04\n5.0e-08\n2000\n5.00e-04\n\n\nsTNFR1\n2.5e-05\n2.5e-09\n10000\n1.00e-04\n\n\nIL-6\n1.0e-04\n1.0e-08\n10000\n1.00e-04\n\n\nTRAIL\n1.0e-04\n1.0e-08\n10000\n1.00e-04\n\n\nAZU\n2.0e-04\n2.0e-07\n1000\n1.00e-03\n\n\nMXA\n2.2e-04\n3.0e-07\n733\n1.36e-03\n\n\nIP10\n1.0e-04\n1.0e-08\n10000\n1.00e-04\n\n\nCHI3L1\n2.0e-04\n1.0e-07\n2000\n5.00e-04\n\n\n\n\n\nAfter mixing the appropriate volumes (volume_stock_ml) of antigen stocks together in a single tube, the remaining volume of the target_volume_ml is made up with PBS-TBN buffer (see buffers & reagents).\nThe required volume (mL) of PBS-TBN `volume_is calculated as \\[volume\\_PBS\\_TBN = target\\_volume\\_ml - (\\sum_{i=1}^{n} volume\\_stock\\_ml_i)\\]\n\nvolume_PBS_TBN = formulation_standards$target_volume_ml[1]-sum(as.numeric(formulation_standards$volume_stock_ml),na.rm=T)\n\nmessage(str_c(format(volume_PBS_TBN,scientific = T), \" mL\"))\n\n9.95075e-01 mL\n\n\nThe final step is to carry out a serial dilution of the top-standard, using 1:4 v/v dilutions in PBS-TBN buffer. We used six serial dilutions (creating seven standards including the top-standard) and an 8th “buffer blank” which contained only PBS-TBN buffer (no antigen). During analysis the buffer blank specimen was used to calculate background fluorescence."
  },
  {
    "objectID": "Standards_Prep.html#recommendations",
    "href": "Standards_Prep.html#recommendations",
    "title": "10  Standard curves",
    "section": "10.3 Recommendations",
    "text": "10.3 Recommendations\n\nLabel all vials with with expiry date (as per data sheet, but rule of thumb 3 months)\nTest new standards side-by-side with older formulations, to assess conformity and uniformity\nAliquot standard curves into single-plate volumes (70 µL) and store at -70° C\nAliquots should be thawed on ice and only used once, rather than re-freezing.\nMake substantial volumes for homogeneity. Ideally you should synthesise enough standards for all of your test plates using a single batch of standards. If you have 100 plates to run, you will need 100 * 70 µL = 7 mL per standard. You should make at least 20% extra to account for liquid handling errors and the need to occasionally repeat runs.\nStandards degrade with time and are best used within 2-3 months. You should aim to process all of your plates in the shortest time-frame possible."
  },
  {
    "objectID": "Magpix_Protocol.html#overview",
    "href": "Magpix_Protocol.html#overview",
    "title": "11  MagPix Protocol",
    "section": "11.1 Overview",
    "text": "11.1 Overview\nThis protocol will support you to set up a run on the xPONENT software. This protocol is used to test specimens with the final 12-plex assay on the MagPix machine, as well as to carry out the confirmations of bead conjugation and the cross-reactivity tests,\nPlease note that this protocol does not detail basic operations, routine maintenance and calibration of the MagPix. Please refer to the manufacturer’s guidance on this."
  },
  {
    "objectID": "Magpix_Protocol.html#setup",
    "href": "Magpix_Protocol.html#setup",
    "title": "11  MagPix Protocol",
    "section": "11.2 Setup",
    "text": "11.2 Setup\n\nIn the xPONENT software, go to ‘Protocols’ &gt; ‘Create new Protocol’.\nEnter a name for the protocol e.g. “12-plex Biomarker” and select the plate type [TM1] from the drop-down menu.\nSet the sample volume to 50uL. Click ‘Next’.\nSelect and label the required bead regions with their coupled antibodies so that the table on screen maps to the table below (double-check that the regions are in this order [numeric by bead region] before labelling [TM2] them):\n\n\n\n\nName\nAnalysis\nUnits\nCount\nRegion\n\n\n\n\nsTREM1\nNo Analysis\n\n50\n14\n\n\nAng2\nNo Analysis\n\n50\n15\n\n\nAng1\nNo Analysis\n\n50\n18\n\n\nsTNFR1\nNo Analysis\n\n50\n20\n\n\nIL6\nNo Analysis\n\n50\n21\n\n\nIL8\nNo Analysis\n\n50\n22\n\n\nTRAIL\nNo Analysis\n\n50\n25\n\n\nIL10\nNo Analysis\n\n50\n26\n\n\nAzu\nNo Analysis\n\n50\n27\n\n\nMxA\nNo Analysis\n\n50\n28\n\n\nIP10\nNo Analysis\n\n50\n29\n\n\nCHI3L1\nNo Analysis\n\n50\n30\n\n\n\n\nClick ‘Next’"
  },
  {
    "objectID": "Magpix_Protocol.html#plate-layout",
    "href": "Magpix_Protocol.html#plate-layout",
    "title": "11  MagPix Protocol",
    "section": "11.3 Plate Layout",
    "text": "11.3 Plate Layout\n\nHighlight all wells and select ‘Unknown’ so that the whole plate is yellow.\nEnsure that ‘Direction’ is the left-hand option for vertical reading order.\nAdd a ‘Post-Batch Routine’ under ‘Commands and Routines’.\nClick ‘Save’.\n\nThe protocol is ready to use and can now be found under ‘Protocols’ or ‘Batches’."
  },
  {
    "objectID": "Magpix_Protocol.html#initiating-the-run",
    "href": "Magpix_Protocol.html#initiating-the-run",
    "title": "11  MagPix Protocol",
    "section": "11.4 Initiating the run",
    "text": "11.4 Initiating the run\nAdd cal/ver info\nAdd details about how to put the plate in and start the run\nCheck what the options are & which one to use. [TM1]\nCheck whether they come up in numeric order or in the order that they are clicked on. [TM2]"
  },
  {
    "objectID": "Magpix_Protocol.html#exporting-the-data-to-csv",
    "href": "Magpix_Protocol.html#exporting-the-data-to-csv",
    "title": "11  MagPix Protocol",
    "section": "11.5 Exporting the data to CSV",
    "text": "11.5 Exporting the data to CSV\nAdd some instructions for export"
  },
  {
    "objectID": "Coefficients_of_Variation.html#overview",
    "href": "Coefficients_of_Variation.html#overview",
    "title": "12  Coefficients of Variation",
    "section": "12.1 Overview",
    "text": "12.1 Overview\nThis protocol can be used to calculate the inter- and intra-assay variation. It can be performed repeatedly on different days or by different operators to provide a measure of variation.\nThe protocol was run here using anonymous DBS samples and recombinant protein standards. 12 repeats of pooled DBS eluate were run on plate 1, 12 repeats of the protein standards on plate 2, and single wells of each of these samples on a further 6 plates.\nThis protocol was carried out when the CRP assay was still part of the multiplex. It has since been removed."
  },
  {
    "objectID": "Coefficients_of_Variation.html#reagents-consumables-equipment",
    "href": "Coefficients_of_Variation.html#reagents-consumables-equipment",
    "title": "12  Coefficients of Variation",
    "section": "12.2 Reagents, consumables & equipment",
    "text": "12.2 Reagents, consumables & equipment\n\nItems form the Shopping List and the following equipment will be needed:\nPrepare General Assay Buffers as per Buffers and Reagents protocol.\nPrepare capture and detection antibodies and recombinant protein standards as per the respective protocols.\nCouple beads and confirm coupling as per respective protocols.\n\n\nTable …. Lab worksheet to record batch dates and reagents. Supplier is bio-techne unless specified.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAntibody on bead\nBead Ab conc (ug/millionbeads)\nBead region\nDate beads coupled\nAntigen\nDetection Ab\nDetection Ab (ug/ml)\n\n\nCRP\nMAB17071\n5\n12\n\n1707-CR\nBAM17072\n1\n\n\nIL8\nM801 (Thermo)\n5\n22\n\n208-IL\nBAF208\n1.5\n\n\nsTNF-R1\nMAB225\n6\n20\n\n636-R1\nBAF225\n1.5\n\n\nIL6\nMAB206\n5\n21\n\n206-IL\nBAF206\n1\n\n\nAng2\nNB110-85467\n5\n15\n\n623-AN\nBAF623\n1\n\n\nAng1\nMAB9231\n5\n18\n\n923-AN\nBAF923\n1.5\n\n\nTRAIL\nMAB375\n6\n25\n\n375-TL\nBAF375\n1\n\n\nIL10\nMAB2172\n4\n26\n\n1064-IL\nBAF217\n1.5\n\n\nsTREM1\nH00054210-M04\n6\n14\n\n1278-TR\nBAF1278\n2\n\n\nIP-10\nMAB266\n5\n29\n\n266-IP\nBAF266\n1\n\n\nAzu\nNBP2-12045\n7\n27\n\n2200-SE\nAF2200+B\n1.5\n\n\nMxA\nMA5-24914 (Thermo)\n6\n28\n\nTP307418 (OriGene)\nAF7946+B\n1\n\n\nCHI3L1\nMAB25991\n4.5\n30\n\n2599-CH\nBAF2599\n1"
  },
  {
    "objectID": "Coefficients_of_Variation.html#protocol",
    "href": "Coefficients_of_Variation.html#protocol",
    "title": "12  Coefficients of Variation",
    "section": "12.3 Protocol",
    "text": "12.3 Protocol\n⌚ Timing: 1-2 hours on Day 1 (if eluting DBS),\n\nIf using DBS: The day before assay day, prepare elution buffer with 1 ml of 25X protease inhibitor plus 24 ml PBS-TBN. In 8 x 5 ml tubes, add 16 DBS to each tube. Add 800 ul elution buffer to each tube and incubate overnight at 4C.\nOn assay day, get coupled beads from the fridge, vortex and sonicate for 30 sec of each.\nDilute beads: add 14.183 ml of PBS-TBN to a universal. Total final volume after addition of beads, will be 14.7 ml. (14.7 ml minus 517.4 ul) (288 wells, 3 plates’ worth x 50 ul = 14.4 ml)\n     Vortex bead stocks again immediately before pipetting and add ____ ul of each bead to the tube (to get 20k beads/ml [ie 1000 beads/well] based on stock of ____x106 beads/ml). Tick as you add the beads:\n\n\n\n\n\n\n\n\nCRP\nsTNFR1\nIL6\nIL8\nAng1\nAng2\nTRAIL\nAzu\nIL10\nsTREM1\nIP-10\nCHI3L1\nMxA\n\n\n\n     Get black plates and label with date etc.\n     Add 50 ul of diluted beads to all labelled wells."
  },
  {
    "objectID": "Coefficients_of_Variation.html#analysis-interpretation-of-results",
    "href": "Coefficients_of_Variation.html#analysis-interpretation-of-results",
    "title": "12  Coefficients of Variation",
    "section": "12.4 Analysis & interpretation of results",
    "text": "12.4 Analysis & interpretation of results"
  },
  {
    "objectID": "Specimen_Testing.html",
    "href": "Specimen_Testing.html",
    "title": "13  Specimen Testing",
    "section": "",
    "text": "14 Testing DBS samples with the biomarker assay\nLab worksheet protocol\nAssay dates _____________ done by ____________________\nAim\nTo measure 12 immune markers in dried blood spot samples.\nImportant notes/Things that differ this time:\n·         Biotin Ab aliquots allow for multichannel pipetting.\n·         DBS rehydrated at 1 per 50 ul (2 in 100 ul) overnight.\n·         Samples are run in SINGLE wells at each dilution.\nAll samples, standards & detection Abs are 30 ul per well volume.\nRecord date that standards were pre-diluted and frozen on __________\nSample plate IDs: ……………………………………………………………………………\n\nDispense samples into elution plates and record sample ID electronically to correspond with plate name.\n\nAssay set-up\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAll 12 beads\n\nDBS eluted in PBS-TBN+pi & previously frozen buffer standards\n\nAll 12 detection Abs\n\nSA-PE @ 3 ug/ml\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAll reagents (bio-techne unless specified)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAntibody on bead\n\n\n\n\n\n\nBead Ab conc (ug/million)\n\n\n\n\n\n\nBead region\n\n\n\n\n\n\nDate beads coupled\n\n\n\n\n\n\nAg\n\n\n\n\n\n\nBiotin detection Ab\n\n\n\n\n\n\nBiotin Ab expiry\n\n\n\n\n\n\ndetection Ab (ug/ml)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIL8\n\n\n\n\n\n\nM801 (Thermo)\n\n\n\n\n\n\n5\n\n\n\n\n\n\n22\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n208-IL\n\n\n\n\n\n\nBAF208\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsTNF-R1\n\n\n\n\n\n\nMAB225\n\n\n\n\n\n\n6\n\n\n\n\n\n\n20\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n636-R1\n\n\n\n\n\n\nBAF225\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIL6\n\n\n\n\n\n\nMAB206\n\n\n\n\n\n\n5\n\n\n\n\n\n\n21\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n206-IL\n\n\n\n\n\n\nBAF206\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAng2\n\n\n\n\n\n\nNB110-85467\n\n\n\n\n\n\n5\n\n\n\n\n\n\n15\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n623-AN\n\n\n\n\n\n\nBAF623\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAng1\n\n\n\n\n\n\nMAB9231\n\n\n\n\n\n\n5\n\n\n\n\n\n\n18\n\n\n\n\n\n\n220729\n\n\n\n\n\n\n923-AN\n\n\n\n\n\n\nBAF923\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTRAIL\n\n\n\n\n\n\nMAB375\n\n\n\n\n\n\n6\n\n\n\n\n\n\n25\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n375-TL\n\n\n\n\n\n\nBAF375\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIL10\n\n\n\n\n\n\nMAB2172\n\n\n\n\n\n\n4\n\n\n\n\n\n\n26\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n1064-IL\n\n\n\n\n\n\nBAF217\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsTREM1\n\n\n\n\n\n\nH00054210-M04\n\n\n\n\n\n\n6\n\n\n\n\n\n\n14\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n1278-TR\n\n\n\n\n\n\nBAF1278\n\n\n\n\n\n\n \n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIP-10\n\n\n\n\n\n\nMAB266\n\n\n\n\n\n\n5\n\n\n\n\n\n\n29\n\n\n\n\n\n\n220729\n\n\n\n\n\n\n266-IP\n\n\n\n\n\n\nBAF266\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAzu\n\n\n\n\n\n\nNBP2-12045\n\n\n\n\n\n\n7\n\n\n\n\n\n\n27\n\n\n\n\n\n\n230516\n\n\n\n\n\n\n2200-SE\n\n\n\n\n\n\nAF2200+B\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMxA\n\n\n\n\n\n\nMA5-24914 (Thermo)\n\n\n\n\n\n\n6\n\n\n\n\n\n\n28\n\n\n\n\n\n\n230516\n\n\n\n\n\n\nTP307418\n\n\n(OriGene)\n\n\n\n\n\n\nAF7946+B\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nChit/CH3L1\n\n\n\n\n\n\nMAB25991\n\n\n\n\n\n\n4.5\n\n\n\n\n\n\n30\n\n\n\n\n\n\n220729\n\n\n\n\n\n\n2599-CH\n\n\n\n\n\n\nBAF2599\n\n\n\n\n\n\n \n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPreparation\n     Book MagPix on Skedda for the day after running the assay: https://app.skedda.com/account/login?returnUrl=https%3A%2F%2Flshtm.skedda.com%2Fbooking%2Fmine\n     Prepare elution buffer fresh on day of use:\no  Protease inhibitor: dissolve 1 tablet in 2 ml PBS to give 25X (Sigma, cOmplete, 04693116001)\no  PBS-TBN\n24 ml PBS-TBN + 1 ml of 25X protease inhibitor solution\n# Tablets are in fridge in 247, sonicate to get them to dissolve quicker.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNumber of plates\n\n\n\n\n\n\nPBS-TBN volume (ul)\n\n\n\n\n\n\nTotal volume (ul)\n\n\n\n\n\n\n25X Protease inhibitor (ul)\n\n\n\n\n\n\nThis many tablets\n\n\n\n\n\n\n \n\n\n\n\n\n\nNumber of plates\n\n\n\n\n\n\nPBS-TBN volume (ul)\n\n\n\n\n\n\nTotal volume (ul)\n\n\n\n\n\n\n25X Protease inhibitor (ul)\n\n\n\n\n\n\nThis many tablets\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1\n\n\n\n\n\n\n 8,448\n\n\n\n\n\n\n 8,800\n\n\n\n\n\n\n 352\n\n\n\n\n\n\n1\n\n\n\n\n\n\n \n\n\n\n\n\n\n6\n\n\n\n\n\n\n 50,688\n\n\n\n\n\n\n 52,800\n\n\n\n\n\n\n 2,112\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2\n\n\n\n\n\n\n 16,896\n\n\n\n\n\n\n 17,600\n\n\n\n\n\n\n 704\n\n\n\n\n\n\n1\n\n\n\n\n\n\n \n\n\n\n\n\n\n7\n\n\n\n\n\n\n 59,136\n\n\n\n\n\n\n 61,600\n\n\n\n\n\n\n 2,464\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3\n\n\n\n\n\n\n 25,344\n\n\n\n\n\n\n 26,400\n\n\n\n\n\n\n 1,056\n\n\n\n\n\n\n1\n\n\n\n\n\n\n \n\n\n\n\n\n\n8\n\n\n\n\n\n\n 67,584\n\n\n\n\n\n\n 70,400\n\n\n\n\n\n\n 2,816\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n4\n\n\n\n\n\n\n 33,792\n\n\n\n\n\n\n 35,200\n\n\n\n\n\n\n 1,408\n\n\n\n\n\n\n1\n\n\n\n\n\n\n \n\n\n\n\n\n\n9\n\n\n\n\n\n\n 76,032\n\n\n\n\n\n\n 79,200\n\n\n\n\n\n\n 3,168\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n5\n\n\n\n\n\n\n42,240\n\n\n\n\n\n\n 44,000\n\n\n\n\n\n\n1,760\n\n\n\n\n\n\n1\n\n\n\n\n\n\n \n\n\n\n\n\n\n10\n\n\n\n\n\n\n84,480\n\n\n\n\n\n\n88,000\n\n\n\n\n\n\n3,520\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n     Label black plate(s) with date & plate ID.\n     Add 100 ul/well of elution buffer to DBS in the low-bind plate that they are in.\n     Cover with sticky plate cover, label, and place in fridge overnight. Time put in fridge ______________\nAssay running\n     GET ICE FIRST! 2nd floor- new room 209.\n     Take the box of wet ice to get standards from -70. When thawed, put in fridge.\nPBS-TBN makes the blank, standard 8.\n#Do not re-freeze standards. Just use a new aliquot each day.\n     Bring sample plates to ambient temperature & put on a shaker until ready to use. Start time ___________\n     Prepare beads: Get coupled beads from fridge, vortex and sonicate for 30 sec of each.\n#Take care to select the correct bead batches for each bead.\n     Add the “Buffer volume” of PNS-TBN to a single tube. Allows 7% surplus.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBead volume of each bead (ul)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPlates\n\n\n\n\n\n\nBuffer volume (ul)\n\n\n\n\n\n\nTotal needed (ml)\n\n\n\n\n\n\n230516 beads\n\n\n(8.8 x 106 stock)\n\n\n\n\n\n\n220729 beads (small tubes) 12.4 x 106\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1\n\n\n\n\n\n\n\n\n\n\n5136\n\n\n\n\n\n\n \n\n\n\n\n\n\n8.3\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2\n\n\n\n\n\n\n\n\n\n\n10272\n\n\n\n\n\n\n \n\n\n\n\n\n\n16.6\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3\n\n\n\n\n\n\n\n\n\n\n15408\n\n\n\n\n\n\n \n\n\n\n\n\n\n24.9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n4\n\n\n\n\n\n\n\n\n\n\n20544\n\n\n\n\n\n\n \n\n\n\n\n\n\n33.1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n5\n\n\n\n\n\n\n\n\n\n\n25680\n\n\n\n\n\n\n \n\n\n\n\n\n\n41.4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n6\n\n\n\n\n\n\n\n\n\n\n30816\n\n\n\n\n\n\n \n\n\n\n\n\n\n49.7\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n7\n\n\n\n\n\n\n\n\n\n\n35952\n\n\n\n\n\n\n \n\n\n\n\n\n\n58.0\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n8\n\n\n\n\n\n\n\n\n\n\n41088\n\n\n\n\n\n\n \n\n\n\n\n\n\n66.3\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n9\n\n\n\n\n\n\n\n\n\n\n46224\n\n\n\n\n\n\n \n\n\n\n\n\n\n74.6\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n10\n\n\n\n\n\n\n50,060.4\n\n\n\n\n\n\n51360\n\n\n\n\n\n\n116.8\n\n\n\n\n\n\n82.8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n     Vortex bead stocks again & add volumeof each bead to the tube.\n(calculated to get 20k beads/ml [ie 1000 beads/well). Tick as you add the beads:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n        TNFR1\n\n\n        MxA\n\n\n\n\n\n\n        Ang1\n\n\n        Ang2\n\n\n\n\n\n\n        IL10\n\n\n        TREM\n\n\n\n\n\n\n        IL6\n\n\n        IL8\n\n\n\n\n\n\n        TRAIL\n\n\n        Azu\n\n\n\n\n\n\n        IP-10\n\n\n        Chit\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n     Add 50 ul of mixed beads to ALL wells with multichannel.\n     Wash the beads: put plate on magnet, 60 sec, flick out liquid, remove from magnet add 100 ul PBST to each well, on magnet 60 sec, flick out wash liquid, bang gently on tissue.\n     Vortex & spin down the standards.\n     Add 30 ul/well of all samples to the black plate with multichannel.\n     Add STANDARDS, 30 ul per well in duplicates.\n     Cover plates with black cover & incubate on shaker at room temp for 2 hours. Start _______ Ended _____\nDuring incubation, prepare biotin detection Abs…\nDetection Abs: Get aliquots of appropriate size from the freezer, depending on number of plates being run. Fill in expiry dates on table at the start of this protocol.\n     Add PBS-TBN to a tube for: ……………………………………………………………..… ↓\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNumber of plates\n\nVolume of each Ab (ul)\n\nTotal\n(allowing 3.16ml per plate which is almost 10% extra)\n\nVolume of PBS-TBN\n(ul, before adding Abs. Now 12-plex)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1\n\n14\n\n3160\n\n3,010.7\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2\n\n28\n\n6320\n\n6,021.7\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3\n\n42\n\n9480\n\n9,032.8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n4\n\n56\n\n12640\n\n12,044.0\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n5\n\n70\n\n15800\n\n15,052.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n6\n\n84\n\n18960\n\n18,063.1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n7\n\n98\n\n22120\n\n21,073.6\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n8\n\n112\n\n25280\n\n24,084.2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n9\n\n126\n\n28440\n\n27,094.7\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n10\n\n140\n\n31600\n\n30,105.2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n     Use this to recover the full volume from biotin Ab aliquot tubes. i.e. add 200 ul of buffer to the aliquot tube, vortex mix, spin down, then transfer all of it back to the main tube.\nNOTE- Azu and MxA are NOT aliquots, just take the volume needed out of the glass vial (fridge door)\nTick as you add each Ab:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n        TNFR1\n        IL6\n        IL8\n        MxA ***\n\n        Ang1\n        Ang2\n        TRAIL\n        Azu ***\n\n        IL10\n        TREM\n        IP-10\n        Chit\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n***\n\n\n\n\n\n\nNumber of plates\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1\n\n\n\n\n\n\n2\n\n\n\n\n\n\n3\n\n\n\n\n\n\n4\n\n\n\n\n\n\n5\n\n\n\n\n\n\n6\n\n\n\n\n\n\n7\n\n\n\n\n\n\n8\n\n\n\n\n\n\n9\n\n\n\n\n\n\n10\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAzu\n\n\n\n\n\n\n5.6\n\n\n\n\n\n\n11.0\n\n\n\n\n\n\n16.3\n\n\n\n\n\n\n21.6\n\n\n\n\n\n\n28.5\n\n\n\n\n\n\n34.1\n\n\n\n\n\n\n39.8\n\n\n\n\n\n\n45.5\n\n\n\n\n\n\n51.2\n\n\n\n\n\n\n56.9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMxA\n\n\n\n\n\n\n3.7\n\n\n\n\n\n\n7.3\n\n\n\n\n\n\n10.9\n\n\n\n\n\n\n14.4\n\n\n\n\n\n\n19.0\n\n\n\n\n\n\n22.8\n\n\n\n\n\n\n26.6\n\n\n\n\n\n\n30.3\n\n\n\n\n\n\n34.1\n\n\n\n\n\n\n37.9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBack to the plate when incubation is over….\n     WASHES: Prepare a wad of blue roll AND tub of Presept in sink- 2 tablets in about 1 L of tap water.\n     Putplate on magnet, wait 60 sec, still on magnet, turn plate over on tissue and bang gently. Discard tissue into autoclave bin. Remove plate from magnet & add 100 ul PBST to each well. Subsequent washes can be emptied into disinfectant in the sink.\n     Add 30 ul/well of detection antibody mixture……\nè These are new fixed volume aliquots (now with 10% added volume) so there is enough to multichannel! 😊\n     Cover plates & gentle shake for 60 mins. Start time __________ Ended ___________\n     DURING THE INCUBATION, prepare SA-PE to be 3 ug/ml. (This includes 10% extra volume to allow multichannel pipetting):\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPlates\n\nPBS-TBN volume (ml)\n\nTotal needed (ml)\n\nSA-PE volume (ul)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n1\n\n3.151\n\n3.160\n\n9.5\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2\n\n6.301\n\n6.320\n\n19.0\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n3\n\n9.452\n\n9.480\n\n28.4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n4\n\n12.602\n\n12.640\n\n37.9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n5\n\n15.753\n\n15.800\n\n47.4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n6\n\n18.903\n\n18.960\n\n56.9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n7\n\n22.054\n\n22.120\n\n66.4\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n8\n\n25.204\n\n25.280\n\n75.8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n9\n\n28.355\n\n28.440\n\n85.3\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n10\n\n31.505\n\n31.600\n\n94.8\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n     Wash plate 3 times with 100 ul PBST to each well.\n     Add 30 ul/well of the SA-PE dilution across the plate.\n     Cover & incubate 45 mins on gentle shaker. Start time ___________ Ended ___________\n     Wash 3 times with 100 ul PBST to each well.\n     Add 100 ul/well of PBS-TBN.\n     Cover plate and store plate in fridge to be read tomorrow.\n     On day of reading: MIX plate on shaker before putting in the MagPix machine."
  },
  {
    "objectID": "Analysis_01.html",
    "href": "Analysis_01.html",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "",
    "text": "15 Example Analysis 4 : Identifying clusters via Expectation Maximisation\nSometimes you will perform some measures on specimens and will want to identify clusters, or groups of specimens in a way that is driven only by the data. A simple way to do this is to use an expectation maximisation algorithm. The assumption here is that there are two or more normal distributions that overlap, and that those groups reflect some biological or real world characteristic. We often assume that there will be one tall and narrow (the ‘normal’ group) and another low and wide (disease group). This is not always the case, but does reflect the biological reality that biomarker levels are typically low and have low variance when there’s no immune response, but when an immune response happens, expression increases, but with substantial heterogeneity that leads to the wide variance.\nIn this model we run an EM algorithm from the mixtools package. We’ll set a fixed seed for each modelling process, to ensure reproducibility.\nset.seed(12341)\nOD2&lt;-normalmixEM(day0_stnfr1$Estimate.norm.adj)\n\nnumber of iterations= 505\nIt’s a fairly simple process to extract and plot the posterior probability distributions from the model and to chart them. We can also add a vertical line on the 95% centile of the ‘negative’ group. This is controlled by defining how many standard deviations away from the mean the line should be (1.96*OD1$sigma). 1.96 is the 95th centile, but this could be increased for higher specificity or decreased for lower specificity.\nReally this analysis has a lot of analogies with ROC. They are related in lots of ways. Note that here we are making an assumption about normal distributions that may not be true. It also assumes that there’s only two distributions in there.\nggplot(day0_stnfr1, aes(x = Estimate.norm.adj)) +\n  geom_histogram(binwidth = 0.007,color=\"white\",fill=\"grey\") +\n  mapply(\n    function(mean, sd, lambda, n, binwidth) {\n      stat_function(\n        fun = function(x) {\n          (dnorm(x, mean = mean, sd = sd)) * n * binwidth * lambda\n        }\n      )\n    },\n    mean = OD2[[\"mu\"]], #mean\n    sd = OD2[[\"sigma\"]], #standard deviation\n    lambda = OD2[[\"lambda\"]], #amplitude\n    n = length(day0_stnfr1$Estimate.norm.adj), #sample size\n    binwidth = 0.007 #binwidth used for histogram\n  )+\n  geom_vline(xintercept = OD2$mu[1]+(1.96*OD2$sigma[1]),lty=2,lwd=1)\nIf you thought that the data were better described by four distributions, then you could simply change the assumptions of the EM model. You may also need to increase the value of maxit to allow more iterations. More complex models take longer to converge\nset.seed(12341)\nOD3&lt;-normalmixEM(day0_stnfr1$Estimate.norm.adj, k=3,maxit = 5000)\n\nnumber of iterations= 1447\nYou may want to add multiple lines to complex models like this\nggplot(day0_stnfr1, aes(x = Estimate.norm.adj)) +\n  geom_histogram(binwidth = 0.007,color=\"white\",fill=\"grey\") +\n  mapply(\n    function(mean, sd, lambda, n, binwidth) {\n      stat_function(\n        fun = function(x) {\n          (dnorm(x, mean = mean, sd = sd)) * n * binwidth * lambda\n        }\n      )\n    },\n    mean = OD3[[\"mu\"]], #mean\n    sd = OD3[[\"sigma\"]], #standard deviation\n    lambda = OD3[[\"lambda\"]], #amplitude\n    n = length(day0_stnfr1$Estimate.norm.adj), #sample size\n    binwidth = 0.007 #binwidth used for histogram\n  )+\n  geom_vline(xintercept = OD3$mu[1]+(1.96*OD3$sigma[1]),lty=2,lwd=1,col=\"red\")+\n  geom_vline(xintercept = OD3$mu[2]+(1.96*OD3$sigma[2]),lty=2,lwd=1,col=\"blue\")\nAs with most modelling exercises, you may want to compare multiple models to see which describes your data best. Don’t forget that you have some assumptions being used here.\nLet’s test to see if a two, three, four, or five distribution model best describes the data.\nWe’ve already done two and three, so let’s add four\nset.seed(12343)\nOD4&lt;-normalmixEM(day0_stnfr1$Estimate.norm.adj, k=4,maxit = 6000)\n\nnumber of iterations= 3946\nand five\nset.seed(12341)\nOD5&lt;-normalmixEM(day0_stnfr1$Estimate.norm.adj, k=5,maxit = 6000)\n\nnumber of iterations= 3804\nand six\nset.seed(12341)\nOD6&lt;-normalmixEM(day0_stnfr1$Estimate.norm.adj, k=6,maxit = 10000)\n\nnumber of iterations= 1837\nTo find the best model, we simply look at the log likelihood values for each model.\nmod.table &lt;- tibble(\n                    models = 2:6,\n                    log.liklihood = c(OD2$loglik,OD3$loglik,OD4$loglik,OD5$loglik,OD6$loglik)\n                    )\n  \nkable(mod.table)\n\n\n\n\nmodels\nlog.liklihood\n\n\n\n\n2\n0.5111328\n\n\n3\n4.1048346\n\n\n4\n4.9392136\n\n\n5\n6.2638805\n\n\n6\n13.8913185\nYou can see that mathematically, and taking in to account the assumptions, the best model we tested (i.e. the one with the fewest components but the largest log liklihood) is a model with six components. Note in the chart below that the three minor groups are pretty spiky and pretty small. It really looks like a two component model with some noise.\nIt’s hard to imagine how a 5 component model can be useful in the contenxt of developing a dipstick test. This is a good demonstration of the fact that the maths doesn’t always match the pragmatic operational use of a test. Two component models are pretty much the only viable option for most people.\nggplot(day0_stnfr1, aes(x = Estimate.norm.adj)) +\n  geom_histogram(binwidth = 0.007,color=\"white\",fill=\"grey\") +\n  mapply(\n    function(mean, sd, lambda, n, binwidth) {\n      stat_function(\n        fun = function(x) {\n          (dnorm(x, mean = mean, sd = sd)) * n * binwidth * lambda\n        }\n      )\n    },\n    mean = OD6[[\"mu\"]], #mean\n    sd = OD6[[\"sigma\"]], #standard deviation\n    lambda = OD6[[\"lambda\"]], #amplitude\n    n = length(day0_stnfr1$Estimate.norm.adj), #sample size\n    binwidth = 0.007 #binwidth used for histogram\n  )\nPrincipal Components Analysis (PCA) is a relatively simple way to identify clusters and to visualise patterns in the profile-wide expression of cytokines. In order to perform PCA in R, we need to pivot the data in to a wide format.\nb&lt;-full_data %&gt;% \n  pivot_wider(id_cols = c(test.id,timepoint),names_from = assay, values_from = Estimate.norm) %&gt;% \n  left_join(.,select(full_data,sample,test.id,cf_5_inpatient_outcome),by=\"test.id\") %&gt;% \n  distinct()\nThe first step in PCA is to run the prcomp command on the columns of interest. This is necessarily a complete case table with numeric values, so missing values should be imputed. The mice package is good for imputation in R, but isn’t used here as the data are mostly complete. There’s just one missing value which we’ll drop to keep this tutorial focussed.\nb&lt;-filter(b,!is.na(ang_1))\nstr(b)\n\ntibble [3,198 × 16] (S3: tbl_df/tbl/data.frame)\n $ test.id               : chr [1:3198] \"SHGKD1852U\" \"ILAID4151N\" \"VGHJM4359F\" \"KOANM9309M\" ...\n $ timepoint             : Factor w/ 3 levels \"control\",\"day0\",..: 2 2 3 3 2 3 2 3 2 2 ...\n $ il_8                  : num [1:3198] -0.183 -0.0674 -0.1619 -0.0352 -0.0708 ...\n $ stnf_r1               : num [1:3198] -0.376 -0.1708 -0.3848 -0.0617 -0.1193 ...\n $ il_6                  : num [1:3198] -0.1027 -0.0358 -0.0839 -0.024 -0.0436 ...\n $ ang_2                 : num [1:3198] -0.2565 -0.117 -0.1757 -0.0263 -0.0963 ...\n $ ang_1                 : num [1:3198] -0.3442 -0.1223 -0.2816 -0.0393 -0.019 ...\n $ trail                 : num [1:3198] -0.1745 0.0304 -0.239 -0.0885 -0.1108 ...\n $ il_10                 : num [1:3198] -0.1926 -0.1084 -0.1637 -0.0413 -0.0913 ...\n $ strem1                : num [1:3198] -0.47364 -0.1528 -0.30748 -0.12789 0.00108 ...\n $ ip_10                 : num [1:3198] -0.0352 0.5973 -0.2128 -0.1713 -0.1765 ...\n $ azu                   : num [1:3198] -0.0553 -0.0437 -0.0117 0.0234 -0.0241 ...\n $ mxa                   : num [1:3198] -0.0995 0.0628 -0.1966 -0.098 -0.0689 ...\n $ chit                  : num [1:3198] -0.26251 0.09555 -0.19727 0.00249 -0.11033 ...\n $ sample                : chr [1:3198] \"LA11033\" \"LA11039\" \"LA11037\" \"LA11039\" ...\n $ cf_5_inpatient_outcome: chr [1:3198] NA NA NA NA ...\nThis now looks fine as all the variables are in the right format, so let’s run the PCA commands on the biomarker columns, scaling the data as we go.\nset.seed(888)\n\ndf.pca&lt;-prcomp(select(b,il_8:chit),scale. = T)\ndf.pca.summary&lt;-summary(df.pca)\ndf.pca.summary\n\nImportance of components:\n                          PC1    PC2    PC3     PC4    PC5    PC6     PC7\nStandard deviation     2.5868 1.2279 1.1281 0.81303 0.7707 0.6444 0.55897\nProportion of Variance 0.5576 0.1257 0.1061 0.05508 0.0495 0.0346 0.02604\nCumulative Proportion  0.5576 0.6833 0.7893 0.84443 0.8939 0.9285 0.95456\n                           PC8     PC9   PC10    PC11    PC12\nStandard deviation     0.50370 0.31430 0.2684 0.25656 0.23422\nProportion of Variance 0.02114 0.00823 0.0060 0.00549 0.00457\nCumulative Proportion  0.97571 0.98394 0.9899 0.99543 1.00000\nWhenever you work with PCA, it is useful to start by looking at the scree plots, which show (a) the proportion of all variance in the data that are explained by each principal component and (b) the cumulative proportion of variance explained by PCs 1-n.\ndf.importance&lt;-tibble(pc = 1:length(df.pca.summary$importance[1,]),\n                      standard.deviation = df.pca.summary$importance[1,],\n                      prop.of.variance = df.pca.summary$importance[2,],\n                      cumulative.variance = df.pca.summary$importance[3,]\n)\n\nggplot(df.importance,aes(pc,prop.of.variance))+geom_bar(stat=\"identity\") +\nggplot(df.importance,aes(pc,cumulative.variance))+geom_bar(stat=\"identity\")\nIt looks like most of the variance is explained by the first principal component.\nThe prcomp data outputs are not compatible with ggplot, so we’ll grab the PC values and add them to our data frame. This is possible because the prcomp data is embedded in an object x which maps to the original df on a row-by-row basis. This allows merging via the bind_cols function.\nb&lt;- bind_cols(b,as.data.frame(df.pca$x))\nJust because the first PC explains the majority of the variance, this doesn’t mean that it is the most informative PC with respect to the differences between different clinical groups.\nWe can use linear regression to explore this in terms of the day of the specimen.\nsummary(\n  glm(data = b,formula = timepoint ~ PC1+PC2+PC3+PC4+PC5+PC6+PC7+PC8+PC9+PC10+PC11+PC12,family = \"binomial\")\n)\n\n\nCall:\nglm(formula = timepoint ~ PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + \n    PC7 + PC8 + PC9 + PC10 + PC11 + PC12, family = \"binomial\", \n    data = b)\n\nCoefficients:\n            Estimate Std. Error z value Pr(&gt;|z|)    \n(Intercept)  2.72229    0.10017  27.176  &lt; 2e-16 ***\nPC1          0.16889    0.03040   5.556 2.75e-08 ***\nPC2         -1.10276    0.09943 -11.091  &lt; 2e-16 ***\nPC3          0.21629    0.06728   3.215 0.001305 ** \nPC4         -0.20417    0.09392  -2.174 0.029719 *  \nPC5         -0.57056    0.14469  -3.943 8.04e-05 ***\nPC6         -0.68866    0.11984  -5.746 9.12e-09 ***\nPC7         -0.06555    0.17248  -0.380 0.703911    \nPC8         -0.03599    0.21484  -0.168 0.866964    \nPC9         -0.17391    0.22012  -0.790 0.429471    \nPC10         0.35690    0.23733   1.504 0.132626    \nPC11         0.93674    0.26237   3.570 0.000357 ***\nPC12         0.88775    0.29217   3.039 0.002377 ** \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n(Dispersion parameter for binomial family taken to be 1)\n\n    Null deviance: 2347.8  on 3197  degrees of freedom\nResidual deviance: 1896.7  on 3185  degrees of freedom\nAIC: 1922.7\n\nNumber of Fisher Scoring iterations: 7\nHere we can see that several PCs are associated with differences between groups in terms of the timepoint.\nBiplots are used to explore PCA data visually. We’ll start by looking at PC1 and PC2. Our chart will be scaled on the x and y axes [using the aspect ratio controls within theme()]so that the dimensions of the chart don’t misrepresent the proportion of variance explained by each PC. The ellipses show the 95% confidence interval for the various groups.\nggplot(b,aes(PC1,PC2,color=timepoint,label=sample,pch=timepoint))+\n  geom_point(alpha=0.4,size=1) +\n  stat_ellipse(geom=\"polygon\", aes(fill = timepoint), alpha = 0.2, show.legend = FALSE, level = 0.95)+\n  xlab(label = str_c(\"PC1 (\",round(100*df.importance$prop.of.variance[1],2),\" %)\",sep = \"\"))+\n  ylab(label = str_c(\"PC2 (\",round(100*df.importance$prop.of.variance[2],2),\" %)\",sep = \"\"))+\n  theme(aspect.ratio=df.importance$prop.of.variance[2]/df.importance$prop.of.variance[1],\n                  legend.position = \"bottom\"\n)\nThere’s some gross effects here that are pretty easy to see. The day 0 specimens are more positive in PC1 and more negative in PC2 than the other two groups. The day 28 specimens look identical to controls. This fits with what we saw in individual marker analysis earlier.\nIt is hard to interpret this in the context of various markers without understanding which variables contributed to the observed variance in the PCA. A loadings plot is really useful for this. We can get the Loadings from the prcomp object.\ndf.pca %&gt;%\n    tidy(matrix = \"rotation\") %&gt;% \n    filter(PC==\"1\" | PC==\"2\") %&gt;% \n    ggplot(aes(column,value)) +\n  geom_bar(stat=\"identity\")+\n    facet_grid(PC~.)+\n  coord_flip()\nThe loadings plot seems to show that basically all the markers are explaining variation in PC1. A simple interpretation here is that an immune response across the whole profile is the single biggest variation between controls, day 0 and day 28 specimens. Meanwhile there’s more nuance in PC2, where Azu, IP-10 and Mxa associate with movement in the negative direction, whilst Ang-1 and Chit associate with movement in the positive direction. Notable also is that those five markers which associate most with PC2 are the least informative with respect to PC1. This is exactly what we expect with PCA, which is essentially a kind of nth dimensional spatial analysis, where movement in one direction is somewhat counter to movement in another direction.\nIn some circumstances, you might want to look at more specific questions, like “how well does PC1 diagnose bad outcomes?”. For a simple diagnostic like this, we might want to drop the control group so that we are only looking at bad vs good outcomes. We’ll create a new df which just includes these outcomes, then run the PCA.\nset.seed(888)\n\nd&lt;-full_data %&gt;% \n  pivot_wider(id_cols = c(test.id,timepoint),names_from = assay, values_from = Estimate.norm) %&gt;% \n  left_join(.,select(full_data,sample,test.id,cf_5_inpatient_outcome)) %&gt;% \n  distinct() %&gt;% \n  filter(\n         timepoint == \"day0\",\n         !is.na(ang_1),\n         !is.na(cf_5_inpatient_outcome)\n        ) %&gt;% \n  mutate(\n    outcome = as.factor(case_when(\n                                                      cf_5_inpatient_outcome == \"died\" ~ \"Bad\",\n                                                      cf_5_inpatient_outcome == \"discharged_pallative\" ~ \"Bad\",\n                                                      cf_5_inpatient_outcome == \"discharged\" ~ \"Good\"\n                                  )),\n                                    \n                                  outcome = relevel(as.factor(outcome), ref=\"Good\")\n  ) %&gt;% \n  filter(!is.na(outcome))\n         \n\ndf.pca&lt;-prcomp(select(d,il_8:chit),scale. = T)\ndf.pca.summary&lt;-summary(df.pca)\ndf.pca.summary\n\nImportance of components:\n                          PC1    PC2     PC3     PC4     PC5     PC6     PC7\nStandard deviation     2.6573 1.1812 1.04344 0.81819 0.78112 0.64480 0.53011\nProportion of Variance 0.5885 0.1163 0.09073 0.05579 0.05085 0.03465 0.02342\nCumulative Proportion  0.5885 0.7047 0.79545 0.85124 0.90208 0.93673 0.96015\n                           PC8     PC9    PC10    PC11   PC12\nStandard deviation     0.48200 0.29268 0.25389 0.22666 0.2107\nProportion of Variance 0.01936 0.00714 0.00537 0.00428 0.0037\nCumulative Proportion  0.97951 0.98665 0.99202 0.99630 1.0000\nThen save the importance data to an object and show the scree plots\ndf.importance&lt;-tibble(pc = 1:length(df.pca.summary$importance[1,]),\n                      standard.deviation = df.pca.summary$importance[1,],\n                      prop.of.variance = df.pca.summary$importance[2,],\n                      cumulative.variance = df.pca.summary$importance[3,]\n)\n\nggplot(df.importance,aes(pc,prop.of.variance))+geom_bar(stat=\"identity\") +\nggplot(df.importance,aes(pc,cumulative.variance))+geom_bar(stat=\"identity\")\nIt looks like most of the variance is explained by the first principal component.\nd&lt;- bind_cols(d,as.data.frame(df.pca$x))\nWe can use linear regression to explore this in terms of the outcomes.\nsummary(\n  glm(data = d,formula = outcome ~ PC1+PC2+PC3+PC4+PC5+PC6+PC7+PC8+PC9+PC10+PC11+PC12,family = \"binomial\")\n)\n\n\nCall:\nglm(formula = outcome ~ PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + \n    PC8 + PC9 + PC10 + PC11 + PC12, family = \"binomial\", data = d)\n\nCoefficients:\n             Estimate Std. Error z value Pr(&gt;|z|)    \n(Intercept) -2.705406   0.164177 -16.479  &lt; 2e-16 ***\nPC1          0.081339   0.053240   1.528 0.126568    \nPC2          0.120255   0.116785   1.030 0.303144    \nPC3         -0.002822   0.109005  -0.026 0.979347    \nPC4          0.286575   0.156221   1.834 0.066591 .  \nPC5         -0.627712   0.183450  -3.422 0.000622 ***\nPC6          0.026040   0.196581   0.132 0.894618    \nPC7         -0.546553   0.246166  -2.220 0.026401 *  \nPC8         -0.715481   0.247323  -2.893 0.003817 ** \nPC9         -0.309860   0.437927  -0.708 0.479219    \nPC10         1.436397   0.514159   2.794 0.005211 ** \nPC11        -0.461633   0.552861  -0.835 0.403724    \nPC12        -1.704401   0.652076  -2.614 0.008954 ** \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n(Dispersion parameter for binomial family taken to be 1)\n\n    Null deviance: 452.60  on 781  degrees of freedom\nResidual deviance: 397.57  on 769  degrees of freedom\nAIC: 423.57\n\nNumber of Fisher Scoring iterations: 6\nHere we can see that several PCs are associated with differences between groups in terms of the timepoint.\nBased on the evidence here, there’s no way to accurately prognosticate the clinical outcome on the basis of these markers, either individually or according to multi-marker expression profiles. This is not surprising given the small number of bad outcomes in the data and given the heterogeneous disease backgrounds of the samples.\nThis document provides functions and should have taught you how to\nThe Specimens used in this analysis were collected as part of the Febrile Illness Evaluation in a Broad Range of Endemicity (FIEBRE) study (https://pubmed.ncbi.nlm.nih.gov/32699131/). Clinical work and specimen collection took place at the Institute of Research and Education Development, University of Health Sciences, Ministry of Health, Vientiane, Lao People’s Democratic Republic.\nThe Febrile Illness Evaluation in a Broad Range of Endemicities study is funded by UK Aid from the UK government; the views expressed, however, do not necessarily reflect the UK government’s official policies. Biomarker analysis is funded by GHLabs (https://www.ghlabs.org/)."
  },
  {
    "objectID": "Analysis_01.html#introduction",
    "href": "Analysis_01.html#introduction",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.1 Introduction",
    "text": "14.1 Introduction\nThe first part of this analysis defines functions to read in a Luminex MagPix data file and analyse the data one assay at a time.\nThis requires a standards file to be provided (MOSDEF_Standard_Concs). It should look like the one below. Beware that the names of the assays and the names of the standards both need to match exactly to those in the data sets. Standard 8 is a background control (i.e. buffer blank). You could manually build this if you wanted to with the tibble command."
  },
  {
    "objectID": "Analysis_01.html#note",
    "href": "Analysis_01.html#note",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.2 Note",
    "text": "14.2 Note\nIn this analysis, you will note that we sometimes refer to the marker CHI3L1 as Chit. This was a local name for the marker which just made it easier for us to label tubes in the lab. The name Chit has no formal recognition and you should refer to this marker only by its correct name."
  },
  {
    "objectID": "Analysis_01.html#libraries",
    "href": "Analysis_01.html#libraries",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.3 Libraries",
    "text": "14.3 Libraries\nLoad the libraries used in this analysis and set a seed so that this is fully reproducible.\n\nstandards = read_csv(\"data/MOSDEF_Standard_Concs.csv\",show_col_types = F)\nkable(standards)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nassay\nunit\nS1\nS2\nS3\nS4\nS5\nS6\nS7\nS8\n\n\n\n\nCRP\npg_ml\n10000\n2500.0\n625.000\n156.25000\n39.0625000\n9.7656250\n2.4414062\n0\n\n\nsTREM1\npg_ml\n10000\n2500.0\n625.000\n156.25000\n39.0625000\n9.7656250\n2.4414062\n0\n\n\nAng-2\nng_ml\n100\n25.0\n6.250\n1.56250\n0.3906250\n0.0976562\n0.0244141\n0\n\n\nAng-1\nng_ml\n50\n12.5\n3.125\n0.78125\n0.1953125\n0.0488281\n0.0122070\n0\n\n\nsTNF-R1\npg_ml\n2500\n625.0\n156.250\n39.06250\n9.7656250\n2.4414062\n0.6103516\n0\n\n\nIL-6\npg_ml\n10000\n2500.0\n625.000\n156.25000\n39.0625000\n9.7656250\n2.4414062\n0\n\n\nTRAIL\npg_ml\n10000\n2500.0\n625.000\n156.25000\n39.0625000\n9.7656250\n2.4414062\n0\n\n\nIL-10\npg_ml\n4000\n1000.0\n250.000\n62.50000\n15.6250000\n3.9062500\n0.9765625\n0\n\n\nAzu\nng_ml\n200\n50.0\n12.500\n3.12500\n0.7812500\n0.1953125\n0.0488281\n0\n\n\nMxA\nng_ml\n300\n75.0\n18.750\n4.68750\n1.1718750\n0.2929688\n0.0732422\n0\n\n\nIP-10\npg_ml\n10000\n2500.0\n625.000\n156.25000\n39.0625000\n9.7656250\n2.4414062\n0\n\n\nChit\nng_ml\n100\n25.0\n6.250\n1.56250\n0.3906250\n0.0976562\n0.0244141\n0\n\n\nIL-8\npg_ml\n2500\n625.0\n156.250\n39.06250\n9.7656250\n2.4414062\n0.6103516\n0\n\n\n\n\nrm(standards)"
  },
  {
    "objectID": "Analysis_01.html#define-functions",
    "href": "Analysis_01.html#define-functions",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.4 Define Functions",
    "text": "14.4 Define Functions\n\n14.4.1 Read and analyse Luminex Plates\nNote that there’s a section in this which creates a median/range normalised value. This could be useful under some circumstances, but you should think about the underlying assumptions if you are using something like this. For the most part, we can’t imagine that it would be helpful unless you were using a very high multiplex and/or had very rare cases among a huge control data set. For the most part, calibrating using the standard curve should be sufficient and the underlying assumption is not that the median values should be normalised/homogenised. You should therefore use Estimate rather than Estimate.norm\n\nluminex.process.data&lt;-function(file,standards.file=\"data/MOSDEF_Standard_Concs.csv\"){\n\n######################################################################\n# Load in data from luminex machine\n######################################################################\n  df&lt;-read_csv(file,skip = 41,na = c(\"\",\"NA\",\"NaN\"),show_col_types = F)%&gt;%\n                setNames(tolower(gsub(\"-\",\"_\",names(.)))) %&gt;%\n                mutate(sample= fct_explicit_na(sample)) %&gt;%\n                select_if(!names(.) %in% c('...17', 'location', 'total events')) %&gt;%\n                rename_at(vars(matches(\"^ch3l1$\")), function(x) \"chit\")\n\n  if('crp' %in% names(df) == FALSE){df$crp &lt;- NA} \n\n######################################################################\n# Make function to create a unique ID for each test\n######################################################################\n  randomid &lt;- function(n = 1) {\n    a &lt;- do.call(paste0, replicate(5, sample(LETTERS, n, TRUE), FALSE))\n    paste0(a, sprintf(\"%04d\", sample(9999, n, TRUE)), sample(LETTERS, n, TRUE))\n  }\n######################################################################\n# Make data tidy and then remove when beadcount is below 15 or when sample ID is missing\n# Also assign a unique random ID to each test (deals with issues of duplicate names or replicate tests)\n######################################################################\n  MFI.medians&lt;- df[1:(which(str_detect(string = df$sample,pattern = \"Net MFI\"))[1]-1),]  %&gt;%\n                mutate(test.id=randomid(n=nrow(.))) %&gt;%\n                pivot_longer(cols=2:14, names_to = \"assay\", values_to = \"mfi\")\n\n  MFI.counts&lt;- df[((which(str_detect(string = df$sample,pattern = \"Count\")))[1]+2):(which(str_detect(string = df$sample,pattern = \"Avg Net MFI\"))[1]-1),] %&gt;%\n                pivot_longer(cols=2:14, names_to = \"assay\", values_to = \"bead.count\") %&gt;%\n                mutate(test.id=MFI.medians$test.id)\n\n\n  df&lt;- full_join(MFI.medians,MFI.counts) %&gt;%\n                mutate(\n                      mfi = as.numeric(as.character(mfi)),\n                      bead.count = as.numeric(as.character(bead.count))\n                      ) %&gt;%\n                filter(\n                      sample!=\"(Missing)\",\n                      sample!=\"NA\",\n                      sample!=\"Na\",\n                      sample!=\"NULL\",\n                      bead.count&gt;15,\n                      !is.na(mfi)\n                      )\n\n  ######################################################################\n  # Bind standards from file\n  ######################################################################\n\n   standards&lt;-read_csv(standards.file,show_col_types = F) %&gt;%\n                      pivot_longer(cols=S1:S8, names_to = \"sample\", values_to = \"conc\") %&gt;%\n                      mutate(\n                            conc = as.numeric(\n                                              case_when(\n                                                        unit=='ng_ml' ~ conc * 1000,\n                                                        TRUE ~ conc\n                                                        )\n                                              ),\n                            assay=tolower(assay),\n                            assay=gsub(x = assay,pattern = \"-\",replacement = \"_\")\n                            ) %&gt;%\n                      select(-unit) %&gt;%\n                      mutate(class=\"standard\")\n\n\n  df &lt;- left_join(df,standards)\n  df$class[which(is.na(df$class))]&lt;-\"specimen\" \n  \n  ################################################################################\n  ################################################################################\n  # Nested function to predict relative concentrations in a curve\n  ################################################################################\n  ################################################################################\n\n\n  luminex.standard.curve.estimator&lt;-function(data,test.assay){\n\n  x&lt;-filter(data,assay == test.assay)       # filter the data to the current assay (test.assay)\n  bg &lt;- filter(x,sample==\"S8\")              # get value of background from standard 8 (buffer blank)\n  x&lt;- mutate(x, bg= min(bg$mfi,na.rm = T))  # set the background value for all lines of data to the minium value of standard 8\n  tp &lt;- filter(x,sample==\"S1\")              # get highest value of the curve from standard 1\n  x &lt;- mutate(x,tp=max(tp$mfi,na.rm = T))   # set the top value for all lines of data using tp\n  mn &lt;- filter(x,sample==\"S7\")              # get lowest value of the curve from standard 7\n  x &lt;- mutate(x,mn=min(mn$mfi,na.rm = T))   # set the bottom value for all lines of data using mn\n  # DON'T subtract background from MFI - In tests it worked better this way\n  # For other data sets, it may be worth doing this\n\n  x &lt;- x %&gt;% mutate(\n                    log10.mfi = log10(mfi), # log transform mfi data\n                    conc=log10(conc)        # log transform the standard concentration data\n                    ) %&gt;%\n             filter(sample!=\"S8\")           # remove standard 8 (background, which isn't used again)   \n\n    x.standards&lt;-x %&gt;% filter(class==\"standard\",log10.mfi&gt;=0) # Get standards only, and remove any spurious values with negative mfi\n    # in practice this will only happen if subtracting background from mfi, which isn't done here. This line is to remind future users\n    # that they should probably do this, or do something bout negative values, like set them to zero.\n\n    x.samples&lt;-x %&gt;% filter(class!=\"standard\",log10.mfi&gt;=0)   # Get specimens only\n\n\n\n  # run dose response model (drm command from drc package, see helpfiles for info)\n  model1&lt;-drm(conc~log10.mfi,\n              fct=LL.4(names=c(\"Slope\", \"Lower\", \"Upper\", \"ED50\")),\n              data=x.standards)\n\n\n  # get the predicted values of concentration from the measured values of the experimental specimens\n  # also create the normalised estimate of the same. \n  # normalisation used here is (Estimate - median of all Estimates) / 95th centile of range of values\n  x&lt;-x %&gt;%\n    mutate(\n      Estimate = predict(model1,data.frame(log10.mfi=x$log10.mfi)),\n      Estimate.norm = (Estimate - median(Estimate,na.rm=T))/(quantile(Estimate,0.95) - quantile(Estimate,0.05))\n    )\n\n    return(x) # Return the estimate and normalised estimate to the parent function\n  }\n\n  ######################################################################\n  # run the standard curves for all assays\n  ######################################################################\n\n  unique.assays&lt;-unique(df$assay) # gets a list of the unique assays in the study\n  \n  #run the luminex.standard.curve.estimator function on assay 1, creating a data set called df.out\n  df.out&lt;-luminex.standard.curve.estimator(data = df,test.assay = unique.assays[1]) \n\n  #run the luminex.standard.curve.estimator function on assays 2-n, binding returned dfs to df.out\n for(i in 2:length(unique.assays)){\n                                  df.out&lt;-bind_rows(df.out,luminex.standard.curve.estimator(data = df,test.assay = unique.assays[i]))\n }\n  \n  ######################################################################\n  # get plate name from file name\n  ######################################################################\n\n  plate = str_replace(string = file,pattern =  \"data_in//\",replacement = \"\") # remove pathname\n  plate = str_replace(string = plate,pattern =  \".csv\",replacement = \"\")     # remove file extension\n  df.out$plate&lt;-plate                                                        # add plate name to the df\n  return(df.out)                                                             # return df, which has processed all assays for the plate\n}"
  },
  {
    "objectID": "Analysis_01.html#plate-setup-and-data-reading",
    "href": "Analysis_01.html#plate-setup-and-data-reading",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.5 Plate Setup and data reading",
    "text": "14.5 Plate Setup and data reading\n\n14.5.1 Setup Plate data\nList all the Luminex plate data files in a folder\n\nc.files&lt;-list.files(\"data/luminex_files/\",pattern = \".csv\",full.names = T)\nkable(unlist(c.files))\n\n\n\n\nx\n\n\n\n\ndata/luminex_files//plate_01.csv\n\n\ndata/luminex_files//plate_02.csv\n\n\ndata/luminex_files//plate_03.csv\n\n\ndata/luminex_files//plate_04.csv\n\n\ndata/luminex_files//plate_05.csv\n\n\ndata/luminex_files//plate_06.csv\n\n\ndata/luminex_files//plate_07.csv\n\n\ndata/luminex_files//plate_08.csv\n\n\ndata/luminex_files//plate_09.csv\n\n\ndata/luminex_files//plate_10.csv\n\n\ndata/luminex_files//plate_11.csv\n\n\ndata/luminex_files//plate_12.csv\n\n\ndata/luminex_files//plate_13.csv\n\n\ndata/luminex_files//plate_14.csv\n\n\ndata/luminex_files//plate_15.csv\n\n\ndata/luminex_files//plate_16.csv\n\n\ndata/luminex_files//plate_17.csv\n\n\ndata/luminex_files//plate_18.csv\n\n\ndata/luminex_files//plate_19.csv\n\n\ndata/luminex_files//plate_20.csv\n\n\ndata/luminex_files//plate_21.csv\n\n\ndata/luminex_files//plate_22.csv\n\n\ndata/luminex_files//plate_23.csv\n\n\ndata/luminex_files//plate_24.csv\n\n\ndata/luminex_files//plate_25.csv\n\n\ndata/luminex_files//plate_26.csv\n\n\ndata/luminex_files//plate_27.csv\n\n\ndata/luminex_files//plate_28.csv\n\n\ndata/luminex_files//plate_29.csv\n\n\ndata/luminex_files//plate_30.csv\n\n\ndata/luminex_files//plate_31.csv\n\n\ndata/luminex_files//plate_32.csv\n\n\ndata/luminex_files//plate_33.csv\n\n\ndata/luminex_files//plate_34.csv\n\n\ndata/luminex_files//plate_40.csv\n\n\ndata/luminex_files//plate_41.csv\n\n\ndata/luminex_files//plate_42.csv\n\n\ndata/luminex_files//plate_43.csv\n\n\ndata/luminex_files//plate_44.csv\n\n\ndata/luminex_files//plate_45.csv\n\n\n\n\n\n\n\n14.5.2 Run first plate\n\na&lt;-suppressMessages(luminex.process.data(file = c.files[1],standards.file = \"data/MOSDEF_Standard_Concs.csv\"))\nkable(tail(a,100))\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsample\ntest.id\nassay\nmfi\nbead.count\nconc\nclass\nbg\ntp\nmn\nlog10.mfi\nEstimate\nEstimate.norm\nplate\n\n\n\n\nLA13044CFP\nSWXZA6598N\nmxa\n400.0\n147\nNA\nspecimen\n130\n21363\n173\n2.602060\n2.403529\n-0.0233599\ndata/luminex_files//plate_01\n\n\nLA13047CFP\nNPDXB8563J\nmxa\n279.0\n134\nNA\nspecimen\n130\n21363\n173\n2.445604\n2.228882\n-0.0966426\ndata/luminex_files//plate_01\n\n\nLA13044FP\nPEVIK2267H\nmxa\n705.0\n212\nNA\nspecimen\n130\n21363\n173\n2.848189\n2.708080\n0.1044319\ndata/luminex_files//plate_01\n\n\nLA13046FP\nXFJNU8182S\nmxa\n1274.0\n195\nNA\nspecimen\n130\n21363\n173\n3.105169\n3.064583\n0.2540229\ndata/luminex_files//plate_01\n\n\nLA13046CFP\nOQKJI1993Q\nmxa\n433.0\n162\nNA\nspecimen\n130\n21363\n173\n2.636488\n2.443939\n-0.0064036\ndata/luminex_files//plate_01\n\n\nLA12587CFP\nDYKJQ0547B\nmxa\n332.5\n166\nNA\nspecimen\n130\n21363\n173\n2.521792\n2.312086\n-0.0617298\ndata/luminex_files//plate_01\n\n\nS1\nKUGAX1968M\nchit\n47395.0\n164\n5.00000\nstandard\n107\n47395\n124\n4.675732\n4.596514\n0.2284418\ndata/luminex_files//plate_01\n\n\nS2\nYCIPI4839P\nchit\n43295.5\n146\n4.39794\nstandard\n107\n47395\n124\n4.636443\n4.534911\n0.1997272\ndata/luminex_files//plate_01\n\n\nS3\nHXARC3921M\nchit\n24411.5\n162\n3.79588\nstandard\n107\n47395\n124\n4.387594\n4.154074\n0.0222096\ndata/luminex_files//plate_01\n\n\nS4\nRENFU0997O\nchit\n5922.0\n184\n3.19382\nstandard\n107\n47395\n124\n3.772468\n3.288581\n-0.3812183\ndata/luminex_files//plate_01\n\n\nS5\nFAPGM9685C\nchit\n957.0\n169\n2.59176\nstandard\n107\n47395\n124\n2.980912\n2.356713\n-0.8155851\ndata/luminex_files//plate_01\n\n\nS6\nHYMGE3339V\nchit\n266.0\n77\n1.98970\nstandard\n107\n47395\n124\n2.424882\n1.838670\n-1.0570577\ndata/luminex_files//plate_01\n\n\nS7\nVVBAO6795F\nchit\n126.5\n174\n1.38764\nstandard\n107\n47395\n124\n2.102091\n1.592458\n-1.1718236\ndata/luminex_files//plate_01\n\n\nS1\nLVIWY2295U\nchit\n45946.0\n127\n5.00000\nstandard\n107\n47395\n124\n4.662248\n4.575327\n0.2185661\ndata/luminex_files//plate_01\n\n\nS2\nLJANW6592I\nchit\n44417.0\n139\n4.39794\nstandard\n107\n47395\n124\n4.647549\n4.552285\n0.2078258\ndata/luminex_files//plate_01\n\n\nS3\nUKRAL2169L\nchit\n22638.0\n110\n3.79588\nstandard\n107\n47395\n124\n4.354838\n4.105187\n-0.0005778\ndata/luminex_files//plate_01\n\n\nS4\nEGSNN8900J\nchit\n5999.0\n159\n3.19382\nstandard\n107\n47395\n124\n3.778079\n3.295948\n-0.3777844\ndata/luminex_files//plate_01\n\n\nS5\nJBVKY4698E\nchit\n1022.5\n208\n2.59176\nstandard\n107\n47395\n124\n3.009663\n2.386661\n-0.8016254\ndata/luminex_files//plate_01\n\n\nS6\nKOCQE8393Q\nchit\n274.5\n210\n1.98970\nstandard\n107\n47395\n124\n2.438542\n1.849982\n-1.0517849\ndata/luminex_files//plate_01\n\n\nS7\nUGOYG8637W\nchit\n124.0\n172\n1.38764\nstandard\n107\n47395\n124\n2.093422\n1.586405\n-1.1746450\ndata/luminex_files//plate_01\n\n\nLA11033FP\nSHGKD1852U\nchit\n9166.0\n176\nNA\nspecimen\n107\n47395\n124\n3.962180\n3.543253\n-0.2625092\ndata/luminex_files//plate_01\n\n\nLA11039FP\nILAID4151N\nchit\n31025.5\n196\nNA\nspecimen\n107\n47395\n124\n4.491719\n4.311424\n0.0955542\ndata/luminex_files//plate_01\n\n\nLA11037CFP\nVGHJM4359F\nchit\n11562.0\n196\nNA\nspecimen\n107\n47395\n124\n4.063033\n3.683213\n-0.1972705\ndata/luminex_files//plate_01\n\n\nLA11039CFP\nKOANM9309M\nchit\n22870.0\n196\nNA\nspecimen\n107\n47395\n124\n4.359266\n4.111778\n0.0024946\ndata/luminex_files//plate_01\n\n\nLA11037FP\nEGPPE6968D\nchit\n15636.5\n218\nNA\nspecimen\n107\n47395\n124\n4.194140\n3.869739\n-0.1103259\ndata/luminex_files//plate_01\n\n\nLA11036CFP\nLWPQA3913Y\nchit\n35098.5\n194\nNA\nspecimen\n107\n47395\n124\n4.545289\n4.393510\n0.1338168\ndata/luminex_files//plate_01\n\n\nLA11036FP\nWIUSH3317X\nchit\n39089.0\n179\nNA\nspecimen\n107\n47395\n124\n4.592055\n4.465787\n0.1675067\ndata/luminex_files//plate_01\n\n\nLA11034CFP\nHASCA4592S\nchit\n7312.0\n192\nNA\nspecimen\n107\n47395\n124\n3.864036\n3.410079\n-0.3245851\ndata/luminex_files//plate_01\n\n\nLA11040FP\nSTYAL4876A\nchit\n33963.0\n123\nNA\nspecimen\n107\n47395\n124\n4.531006\n4.371550\n0.1235809\ndata/luminex_files//plate_01\n\n\nLA11034FP\nHLPGU1397F\nchit\n9173.0\n160\nNA\nspecimen\n107\n47395\n124\n3.962511\n3.543708\n-0.2622971\ndata/luminex_files//plate_01\n\n\nLA11033CFP\nUPJRU9129S\nchit\n14845.0\n169\nNA\nspecimen\n107\n47395\n124\n4.171580\n3.837282\n-0.1254552\ndata/luminex_files//plate_01\n\n\nLA11040CFP\nJVOSI1587O\nchit\n7597.0\n162\nNA\nspecimen\n107\n47395\n124\n3.880642\n3.432399\n-0.3141810\ndata/luminex_files//plate_01\n\n\nLA12027CFP\nFCIFG0648D\nchit\n34638.0\n157\nNA\nspecimen\n107\n47395\n124\n4.539553\n4.384685\n0.1297031\ndata/luminex_files//plate_01\n\n\nLA12027FP\nHJYDE3625F\nchit\n17165.5\n162\nNA\nspecimen\n107\n47395\n124\n4.234656\n3.928406\n-0.0829800\ndata/luminex_files//plate_01\n\n\nLA12026CFP\nVRHCL9504V\nchit\n28559.0\n171\nNA\nspecimen\n107\n47395\n124\n4.455743\n4.256726\n0.0700583\ndata/luminex_files//plate_01\n\n\nLA12026FP\nVAYHW1782L\nchit\n37131.0\n208\nNA\nspecimen\n107\n47395\n124\n4.569737\n4.431223\n0.1513959\ndata/luminex_files//plate_01\n\n\nLA12024CFP\nNPLGF7754K\nchit\n28885.0\n151\nNA\nspecimen\n107\n47395\n124\n4.460672\n4.264200\n0.0735421\ndata/luminex_files//plate_01\n\n\nLA12022CFP\nJQKTV5449U\nchit\n34388.0\n159\nNA\nspecimen\n107\n47395\n124\n4.536407\n4.379848\n0.1274486\ndata/luminex_files//plate_01\n\n\nLA12024FP\nFOLVC5757H\nchit\n33679.0\n171\nNA\nspecimen\n107\n47395\n124\n4.527359\n4.365952\n0.1209713\ndata/luminex_files//plate_01\n\n\nLA12028FP\nYDITP1935G\nchit\n13637.5\n172\nNA\nspecimen\n107\n47395\n124\n4.134735\n3.784591\n-0.1500154\ndata/luminex_files//plate_01\n\n\nLA12021CFP\nQBWQM4347F\nchit\n18157.0\n161\nNA\nspecimen\n107\n47395\n124\n4.259044\n3.963946\n-0.0664136\ndata/luminex_files//plate_01\n\n\nLA12028CFP\nZZIZF0455C\nchit\n26270.0\n181\nNA\nspecimen\n107\n47395\n124\n4.419460\n4.201915\n0.0445097\ndata/luminex_files//plate_01\n\n\nLA12022FP\nWTCZZ6985E\nchit\n27339.0\n183\nNA\nspecimen\n107\n47395\n124\n4.436783\n4.228039\n0.0566866\ndata/luminex_files//plate_01\n\n\nLA12021FP\nOIXZA0659A\nchit\n1192.5\n180\nNA\nspecimen\n107\n47395\n124\n3.076458\n2.457411\n-0.7686473\ndata/luminex_files//plate_01\n\n\nLA12023FP\nTUCFK1156H\nchit\n12064.0\n189\nNA\nspecimen\n107\n47395\n124\n4.081491\n3.709164\n-0.1851742\ndata/luminex_files//plate_01\n\n\nLA12034FP\nJFNKQ9365E\nchit\n21850.0\n116\nNA\nspecimen\n107\n47395\n124\n4.339451\n4.082326\n-0.0112336\ndata/luminex_files//plate_01\n\n\nLA12031FP\nKKTBR9167G\nchit\n10950.0\n169\nNA\nspecimen\n107\n47395\n124\n4.039414\n3.650157\n-0.2126786\ndata/luminex_files//plate_01\n\n\nLA12030FP\nZLHKQ3056W\nchit\n32480.0\n169\nNA\nspecimen\n107\n47395\n124\n4.511616\n4.341824\n0.1097246\ndata/luminex_files//plate_01\n\n\nLA12032FP\nOPEWU1360J\nchit\n44005.0\n177\nNA\nspecimen\n107\n47395\n124\n4.643502\n4.545950\n0.2048730\ndata/luminex_files//plate_01\n\n\nLA12033FP\nCUVAC1977G\nchit\n40933.0\n204\nNA\nspecimen\n107\n47395\n124\n4.612074\n4.496899\n0.1820090\ndata/luminex_files//plate_01\n\n\nLA12025FP\nQYMHD2998X\nchit\n24232.0\n179\nNA\nspecimen\n107\n47395\n124\n4.384389\n4.149277\n0.0199738\ndata/luminex_files//plate_01\n\n\nLA12029FP\nVHKUC4047G\nchit\n11726.0\n197\nNA\nspecimen\n107\n47395\n124\n4.069150\n3.691801\n-0.1932672\ndata/luminex_files//plate_01\n\n\nLA19076FP\nVFZHQ3422A\nchit\n17629.0\n129\nNA\nspecimen\n107\n47395\n124\n4.246228\n3.945247\n-0.0751296\ndata/luminex_files//plate_01\n\n\nLA19075FP\nKHUXL8867Y\nchit\n11563.0\n191\nNA\nspecimen\n107\n47395\n124\n4.063071\n3.683266\n-0.1972459\ndata/luminex_files//plate_01\n\n\nLA19074FP\nSQSNR6198H\nchit\n31448.5\n172\nNA\nspecimen\n107\n47395\n124\n4.497600\n4.320398\n0.0997375\ndata/luminex_files//plate_01\n\n\nLA19073FP\nSSWIM3847X\nchit\n33707.0\n162\nNA\nspecimen\n107\n47395\n124\n4.527720\n4.366506\n0.1212294\ndata/luminex_files//plate_01\n\n\nLA19072FP\nFOIZY7136I\nchit\n19664.0\n185\nNA\nspecimen\n107\n47395\n124\n4.293672\n4.014703\n-0.0427548\ndata/luminex_files//plate_01\n\n\nLA19071FP\nWGJOZ6938A\nchit\n26330.0\n189\nNA\nspecimen\n107\n47395\n124\n4.420451\n4.203407\n0.0452051\ndata/luminex_files//plate_01\n\n\nLA19070FP\nFCNHC5405J\nchit\n32785.0\n181\nNA\nspecimen\n107\n47395\n124\n4.515675\n4.348039\n0.1126215\ndata/luminex_files//plate_01\n\n\nLA19069FP\nBJNDC1787J\nchit\n31667.5\n184\nNA\nspecimen\n107\n47395\n124\n4.500614\n4.325001\n0.1018830\ndata/luminex_files//plate_01\n\n\nLA19068FP\nSOAWG2729N\nchit\n26859.0\n128\nNA\nspecimen\n107\n47395\n124\n4.429090\n4.216428\n0.0512742\ndata/luminex_files//plate_01\n\n\nLA19067FP\nYKYZG4464G\nchit\n24071.0\n163\nNA\nspecimen\n107\n47395\n124\n4.381494\n4.144947\n0.0179554\ndata/luminex_files//plate_01\n\n\nLA19066FP\nZABYK9626H\nchit\n29642.0\n153\nNA\nspecimen\n107\n47395\n124\n4.471908\n4.281259\n0.0814940\ndata/luminex_files//plate_01\n\n\nLA19065FP\nFCIID4951Q\nchit\n16713.5\n174\nNA\nspecimen\n107\n47395\n124\n4.223067\n3.911577\n-0.0908244\ndata/luminex_files//plate_01\n\n\nLA19064FP\nFFARN9962A\nchit\n19824.0\n151\nNA\nspecimen\n107\n47395\n124\n4.297191\n4.019881\n-0.0403413\ndata/luminex_files//plate_01\n\n\nLA19063FP\nYSPMQ7157A\nchit\n7087.0\n222\nNA\nspecimen\n107\n47395\n124\n3.850462\n3.391899\n-0.3330591\ndata/luminex_files//plate_01\n\n\nLA19062FP\nXKMHL2286R\nchit\n16094.0\n214\nNA\nspecimen\n107\n47395\n124\n4.206664\n3.887823\n-0.1018965\ndata/luminex_files//plate_01\n\n\nLA19061FP\nZJUTH0630E\nchit\n28419.0\n177\nNA\nspecimen\n107\n47395\n124\n4.453609\n4.253492\n0.0685509\ndata/luminex_files//plate_01\n\n\nLA19060FP\nPQNTB0480Q\nchit\n18365.0\n128\nNA\nspecimen\n107\n47395\n124\n4.263991\n3.971176\n-0.0630435\ndata/luminex_files//plate_01\n\n\nLA19059FP\nVFWTH5193U\nchit\n31604.5\n118\nNA\nspecimen\n107\n47395\n124\n4.499749\n4.323680\n0.1012672\ndata/luminex_files//plate_01\n\n\nLA19058FP\nZKQKJ4765K\nchit\n23945.0\n107\nNA\nspecimen\n107\n47395\n124\n4.379215\n4.141540\n0.0163671\ndata/luminex_files//plate_01\n\n\nLA19057FP\nBJLNT2569K\nchit\n16394.0\n177\nNA\nspecimen\n107\n47395\n124\n4.214685\n3.899428\n-0.0964870\ndata/luminex_files//plate_01\n\n\nLA19056FP\nWDIEJ7300D\nchit\n25363.5\n154\nNA\nspecimen\n107\n47395\n124\n4.404209\n4.178984\n0.0338207\ndata/luminex_files//plate_01\n\n\nLA19055FP\nWBEMZ8364O\nchit\n22725.0\n171\nNA\nspecimen\n107\n47395\n124\n4.356504\n4.107666\n0.0005778\ndata/luminex_files//plate_01\n\n\nLA19054FP\nGQLIG2522J\nchit\n25889.0\n179\nNA\nspecimen\n107\n47395\n124\n4.413115\n4.192367\n0.0400591\ndata/luminex_files//plate_01\n\n\nLA14029FP\nCEOMW0540K\nchit\n42000.5\n160\nNA\nspecimen\n107\n47395\n124\n4.623254\n4.514321\n0.1901295\ndata/luminex_files//plate_01\n\n\nLA14029CFP\nCGNQI1160J\nchit\n17772.0\n203\nNA\nspecimen\n107\n47395\n124\n4.249736\n3.950362\n-0.0727457\ndata/luminex_files//plate_01\n\n\nLA14028FP\nUKESF7004Q\nchit\n29761.0\n127\nNA\nspecimen\n107\n47395\n124\n4.473648\n4.283905\n0.0827269\ndata/luminex_files//plate_01\n\n\nLA14027FP\nYSQYR9458Q\nchit\n26256.0\n165\nNA\nspecimen\n107\n47395\n124\n4.419229\n4.201567\n0.0443472\ndata/luminex_files//plate_01\n\n\nLA14028CFP\nIQWRF4475A\nchit\n36194.5\n192\nNA\nspecimen\n107\n47395\n124\n4.558643\n4.414091\n0.1434098\ndata/luminex_files//plate_01\n\n\nLA14027CFP\nHDHBH5824I\nchit\n28571.0\n169\nNA\nspecimen\n107\n47395\n124\n4.455925\n4.257002\n0.0701872\ndata/luminex_files//plate_01\n\n\nLA14026CFP\nNIVWI2815C\nchit\n21558.0\n179\nNA\nspecimen\n107\n47395\n124\n4.333609\n4.073663\n-0.0152721\ndata/luminex_files//plate_01\n\n\nLA14026FP\nTWRXA5018E\nchit\n5411.0\n232\nNA\nspecimen\n107\n47395\n124\n3.733277\n3.237406\n-0.4050720\ndata/luminex_files//plate_01\n\n\nLA14025CFP\nQZAQT6173F\nchit\n16233.0\n193\nNA\nspecimen\n107\n47395\n124\n4.210399\n3.893225\n-0.0993788\ndata/luminex_files//plate_01\n\n\nLA14025FP\nKCGKZ4596G\nchit\n5400.0\n196\nNA\nspecimen\n107\n47395\n124\n3.732394\n3.236258\n-0.4056072\ndata/luminex_files//plate_01\n\n\nLA14024FP\nQHAAS3070U\nchit\n28896.0\n170\nNA\nspecimen\n107\n47395\n124\n4.460838\n4.264451\n0.0736591\ndata/luminex_files//plate_01\n\n\nLA14024CFP\nUGUGS0605Z\nchit\n39745.0\n149\nNA\nspecimen\n107\n47395\n124\n4.599283\n4.477008\n0.1727373\ndata/luminex_files//plate_01\n\n\nLA13051FP\nLPAMF2203X\nchit\n9338.0\n211\nNA\nspecimen\n107\n47395\n124\n3.970254\n3.554343\n-0.2573400\ndata/luminex_files//plate_01\n\n\nLA13050FP\nHPEUL6649T\nchit\n36107.5\n178\nNA\nspecimen\n107\n47395\n124\n4.557597\n4.412478\n0.1426583\ndata/luminex_files//plate_01\n\n\nLA13051CFP\nTOWYT4920L\nchit\n19797.0\n175\nNA\nspecimen\n107\n47395\n124\n4.296599\n4.019010\n-0.0407473\ndata/luminex_files//plate_01\n\n\nLA13050CFP\nGTKLW6867M\nchit\n16790.0\n198\nNA\nspecimen\n107\n47395\n124\n4.225051\n3.914454\n-0.0894832\ndata/luminex_files//plate_01\n\n\nLA13048FP\nTUFEH9339A\nchit\n1322.5\n192\nNA\nspecimen\n107\n47395\n124\n3.121396\n2.505926\n-0.7460332\ndata/luminex_files//plate_01\n\n\nLA13048CFP\nWSATP2009K\nchit\n24000.0\n163\nNA\nspecimen\n107\n47395\n124\n4.380211\n4.143029\n0.0170613\ndata/luminex_files//plate_01\n\n\nLA13047FP\nPIRTJ0833C\nchit\n9020.0\n151\nNA\nspecimen\n107\n47395\n124\n3.955207\n3.533691\n-0.2669661\ndata/luminex_files//plate_01\n\n\nLA13044CFP\nSWXZA6598N\nchit\n11052.0\n134\nNA\nspecimen\n107\n47395\n124\n4.043441\n3.655781\n-0.2100573\ndata/luminex_files//plate_01\n\n\nLA13047CFP\nNPDXB8563J\nchit\n10940.5\n140\nNA\nspecimen\n107\n47395\n124\n4.039037\n3.649631\n-0.2129239\ndata/luminex_files//plate_01\n\n\nLA13044FP\nPEVIK2267H\nchit\n36310.0\n185\nNA\nspecimen\n107\n47395\n124\n4.560026\n4.416226\n0.1444051\ndata/luminex_files//plate_01\n\n\nLA13046FP\nXFJNU8182S\nchit\n30445.0\n164\nNA\nspecimen\n107\n47395\n124\n4.483516\n4.298921\n0.0897267\ndata/luminex_files//plate_01\n\n\nLA13046CFP\nOQKJI1993Q\nchit\n21359.0\n167\nNA\nspecimen\n107\n47395\n124\n4.329581\n4.067696\n-0.0180531\ndata/luminex_files//plate_01\n\n\nLA12587CFP\nDYKJQ0547B\nchit\n9441.0\n205\nNA\nspecimen\n107\n47395\n124\n3.975018\n3.560896\n-0.2542855\ndata/luminex_files//plate_01\n\n\n\n\n\n\n\n14.5.3 Look at the plate 1 standards and specimens\n\n       ( \n        ggplot(filter(a,class==\"standard\"),aes(log10.mfi,Estimate.norm,color=class))+\n        facet_wrap(assay~.)+\n        geom_point(data=filter(a,class==\"specimen\"),aes(log10.mfi,Estimate.norm),size=0.2,alpha=0.3)+\n        geom_point(size=0.2)\n       )\n\n\n\n\nThe pink dots show the specimens and the blue dots (and line) show the standard curve. You can see that most specimen estimates fall inside the standard curve, which is desirable and which is essentially forced by our choice of dose-response model. Note also that CRP didn’t work on this plate. This is not unexpected. It was quite an ask to get CRP on to this multiplex as it has very high activity compared to other markers. For the most part these all look pretty good.\n\n\n14.5.4 Read in the rest of the plates\n\nsuppressMessages(for(i in 2:length(c.files)){a&lt;-bind_rows(a,luminex.process.data(file = c.files[i],standards.file = \"data/MOSDEF_Standard_Concs.csv\"))})\n\n\n\n14.5.5 Chart the results for all assays on all plates\n\n######################################################################\n# Draw charts\n######################################################################\n\n(ggplot(a,aes(log10.mfi,Estimate,color=class))+geom_point(size=0.1)+facet_wrap(.~assay,scales = \"free\"))\n\n\n\ntry(dir.create(\"output\"))#make an output folder to save hard copies\n\na$plate&lt;-str_remove(string = a$plate,\"data/luminex_files/\")\na$plate&lt;-str_remove(string = a$plate,\".csv\")\n\nAs you can see, the CRP assay didn’t really work at all, so we’ll remove it.\n\na&lt;-a %&gt;%  filter(assay!=\"crp\",\n                class==\"specimen\") %&gt;% \n          distinct()\n\nYou can also see that some plates behaved unusually in the Azu assay. We’ll investigate those further next."
  },
  {
    "objectID": "Analysis_01.html#visualisation",
    "href": "Analysis_01.html#visualisation",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.6 Visualisation",
    "text": "14.6 Visualisation\n\n14.6.1 Define a function that will draw a chart for each assay, showing effects of normalisation on a plate-by-plate basis\nThis type of chart is useful for identifying outlier plates which may have behaved differently. You should note that if you’ve got all of your clinical cases on one plate, but all your control cases on another, then you’d expect to see outliers because of this.\n\nplot.assay&lt;-function(test.assay){\n  ggplot(filter(a,assay==test.assay),aes(plate,Estimate))+\n    geom_boxplot(size=0.3)+\n    ggtitle(test.assay)+\n    facet_wrap(.~class,scales = \"free\")+\n    theme(legend.position = \"none\",axis.text.x = element_text(angle = 90,size=3))\n}\n\n\n\n14.6.2 Apply the function to all assays\nNotably, the standards were odd in these plates, which suggests that there may be some issues that could be solved by running the plates again.\n\n14.6.2.1 IL-8\n\nplot.assay(\"il_8\")\n\n\n\n\n\n\n14.6.2.2 Azu\n\nplot.assay(\"azu\");\n\n\n\n\n\n\n14.6.2.3 STNF-R1\n\nplot.assay(\"stnf_r1\")\n\n\n\n\n\n\n14.6.2.4 IL-6\n\nplot.assay(\"il_6\")\n\n\n\n\n\n\n14.6.2.5 ANG-2\n\nplot.assay(\"ang_2\")\n\n\n\n\n\n\n14.6.2.6 ANG-1\n\nplot.assay(\"ang_1\")\n\n\n\n\n\n\n14.6.2.7 TRAIL\n\nplot.assay(\"trail\")\n\n\n\n\n\n\n14.6.2.8 IL-10\n\nplot.assay(\"il_10\")\n\n\n\n\n\n\n14.6.2.9 STREM-1\n\nplot.assay(\"strem1\")\n\n\n\n\n\n\n14.6.2.10 IP-10\n\nplot.assay(\"ip_10\")\n\n\n\n\n\n\n14.6.2.11 MxA\n\nplot.assay(\"mxa\")\n\n\n\n\n\n\n14.6.2.12 CHI3L1\n\nplot.assay(\"chit\")"
  },
  {
    "objectID": "Analysis_01.html#clinical-data",
    "href": "Analysis_01.html#clinical-data",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.7 Clinical data",
    "text": "14.7 Clinical data\nThe data imported from the Luminex files do not include clinical parameters that will be used in an analysis. The ID numbers do contain some information though. Here, the last characters of the sample variable tell us whether the data relate to a specimen taken at day 0 (FP) or day 28 (CFP). We’ll make a new variable which captures this, then remove those characters from the sample variable.\n\na&lt;- a %&gt;% \n  mutate(\n    timepoint = case_when(\n                          str_detect(sample, pattern = \"CFP\") ~ \"day28\",\n                          str_detect(sample, pattern = \"FP\") ~ \"day0\"\n                          ),\n    timepoint = factor(timepoint),\n    sample = str_remove(sample,\"CFP|FP\")\n  )\n\nThe clinical data are provided in the file 0000_clinical_data.csv and include the following variables\n\nsample\n\nThe sample ID now stored in the Luminex derived df\n\ninpatient_outpatient\n\nThis is a factor indicating whether the person was\n\nA person with a clinical case of fever, who was treated as an outpatient\n\nA person with a clinical case of fever, who was treated as an inpatient\n\nA person without fever, living in the same communities as the cases\n\n\noutcome\n\ngood\n\nThe person recovered by day 28\n\nbad\n\nThe person was still ill, or was dead at day 28\n\ncontrol\n\nCommunity Control, no fever\n\nltfu\n\nLost to follow-up\n\n\nfever_days\n\nThe number of days that the person was symptomatic prior to triage at day 0\n\ntime_death\n\nThe days elapsed between day 0 and death\n\ntime_death_plus_fever_days\n\nThe days elapsed between symptom onset and death\n\nFor cases where symptom onset was unknown, this was set to the modal value (2)\n\n\n\n\nclinical.and.control.data &lt;- read_csv(\"data/0000_clinical_data.csv\",show_col_types = F)\nkable(clinical.and.control.data[1:100,])\n\n\n\n\nsample\ninpatient_outpatient\ncf_5_inpatient_outcome\n\n\n\n\nLA19485\ncontrol\nControl\n\n\nLA19484\ncontrol\nControl\n\n\nLA19483\ncontrol\nControl\n\n\nLA19482\ncontrol\nControl\n\n\nLA19481\ncontrol\nControl\n\n\nLA19480\ncontrol\nControl\n\n\nLA19479\ncontrol\nControl\n\n\nLA19478\ncontrol\nControl\n\n\nLA19477\ncontrol\nControl\n\n\nLA19476\ncontrol\nControl\n\n\nLA19475\ncontrol\nControl\n\n\nLA19474\ncontrol\nControl\n\n\nLA19473\ncontrol\nControl\n\n\nLA19472\ncontrol\nControl\n\n\nLA19471\ncontrol\nControl\n\n\nLA19470\ncontrol\nControl\n\n\nLA19469\ncontrol\nControl\n\n\nLA19468\ncontrol\nControl\n\n\nLA19467\ncontrol\nControl\n\n\nLA19466\ncontrol\nControl\n\n\nLA19465\ncontrol\nControl\n\n\nLA19464\ncontrol\nControl\n\n\nLA19463\ncontrol\nControl\n\n\nLA19462\ncontrol\nControl\n\n\nLA19461\ncontrol\nControl\n\n\nLA19460\ncontrol\nControl\n\n\nLA19459\ncontrol\nControl\n\n\nLA19458\ncontrol\nControl\n\n\nLA19457\ncontrol\nControl\n\n\nLA19456\ncontrol\nControl\n\n\nLA19455\ncontrol\nControl\n\n\nLA19454\ncontrol\nControl\n\n\nLA19453\ncontrol\nControl\n\n\nLA19452\ncontrol\nControl\n\n\nLA19451\ncontrol\nControl\n\n\nLA19450\ncontrol\nControl\n\n\nLA19449\ncontrol\nControl\n\n\nLA19448\ncontrol\nControl\n\n\nLA19447\ncontrol\nControl\n\n\nLA19446\ncontrol\nControl\n\n\nLA19445\ncontrol\nControl\n\n\nLA19444\ncontrol\nControl\n\n\nLA19443\ncontrol\nControl\n\n\nLA19442\ncontrol\nControl\n\n\nLA19441\ncontrol\nControl\n\n\nLA19440\ncontrol\nControl\n\n\nLA19439\ncontrol\nControl\n\n\nLA19438\ncontrol\nControl\n\n\nLA19437\ncontrol\nControl\n\n\nLA19436\ncontrol\nControl\n\n\nLA19435\ncontrol\nControl\n\n\nLA19434\ncontrol\nControl\n\n\nLA19433\ncontrol\nControl\n\n\nLA19432\ncontrol\nControl\n\n\nLA19431\ncontrol\nControl\n\n\nLA19430\ncontrol\nControl\n\n\nLA19429\ncontrol\nControl\n\n\nLA19428\ncontrol\nControl\n\n\nLA19427\ncontrol\nControl\n\n\nLA19426\ncontrol\nControl\n\n\nLA19425\ncontrol\nControl\n\n\nLA19424\ncontrol\nControl\n\n\nLA19423\ncontrol\nControl\n\n\nLA19422\ncontrol\nControl\n\n\nLA19421\ncontrol\nControl\n\n\nLA19420\ncontrol\nControl\n\n\nLA19419\ncontrol\nControl\n\n\nLA19418\ncontrol\nControl\n\n\nLA19417\ncontrol\nControl\n\n\nLA19416\ncontrol\nControl\n\n\nLA19415\ncontrol\nControl\n\n\nLA19414\ncontrol\nControl\n\n\nLA19413\ncontrol\nControl\n\n\nLA19412\ncontrol\nControl\n\n\nLA19411\ncontrol\nControl\n\n\nLA19410\ncontrol\nControl\n\n\nLA19409\ncontrol\nControl\n\n\nLA19408\ncontrol\nControl\n\n\nLA19407\ncontrol\nControl\n\n\nLA19406\ncontrol\nControl\n\n\nLA19405\ncontrol\nControl\n\n\nLA19404\ncontrol\nControl\n\n\nLA19403\ncontrol\nControl\n\n\nLA19402\ncontrol\nControl\n\n\nLA19401\ncontrol\nControl\n\n\nLA19400\ncontrol\nControl\n\n\nLA19399\ncontrol\nControl\n\n\nLA19398\ncontrol\nControl\n\n\nLA19397\ncontrol\nControl\n\n\nLA19396\ncontrol\nControl\n\n\nLA19395\ncontrol\nControl\n\n\nLA19394\ncontrol\nControl\n\n\nLA19393\ncontrol\nControl\n\n\nLA19392\ncontrol\nControl\n\n\nLA19391\ncontrol\nControl\n\n\nLA19390\ncontrol\nControl\n\n\nLA19389\ncontrol\nControl\n\n\nLA19388\ncontrol\nControl\n\n\nLA19387\ncontrol\nControl\n\n\nLA19386\ncontrol\nControl\n\n\n\n\n\nThe next step is to merge the clinical data with the luminex data and then to clarify that day_0 controls are separate from day 0 cases\n\nfull_data&lt;- left_join(a,clinical.and.control.data,by=\"sample\")\nfull_data$timepoint&lt;-as.character(full_data$timepoint)\nfull_data$timepoint[which(as.character(full_data$inpatient_outpatient)==\"control\")] &lt;- \"control\"\nfull_data$timepoint&lt;-as.factor(full_data$timepoint)\nkable(full_data[1:100,])\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nsample\ntest.id\nassay\nmfi\nbead.count\nconc\nclass\nbg\ntp\nmn\nlog10.mfi\nEstimate\nEstimate.norm\nplate\ntimepoint\ninpatient_outpatient\ncf_5_inpatient_outcome\n\n\n\n\nLA11033\nSHGKD1852U\nil_8\n412.0\n135\nNA\nspecimen\n311.5\n37005.0\n346\n2.614897\n0.2578131\n-0.1829545\n/plate_01\nday0\nNA\nNA\n\n\nLA11039\nILAID4151N\nil_8\n555.0\n161\nNA\nspecimen\n311.5\n37005.0\n346\n2.744293\n0.5184685\n-0.0673585\n/plate_01\nday0\nNA\nNA\n\n\nLA11037\nVGHJM4359F\nil_8\n434.5\n188\nNA\nspecimen\n311.5\n37005.0\n346\n2.637990\n0.3051793\n-0.1619484\n/plate_01\nday28\nNA\nNA\n\n\nLA11039\nKOANM9309M\nil_8\n604.5\n136\nNA\nspecimen\n311.5\n37005.0\n346\n2.781396\n0.5910819\n-0.0351557\n/plate_01\nday28\nNA\nNA\n\n\nLA11037\nEGPPE6968D\nil_8\n550.0\n163\nNA\nspecimen\n311.5\n37005.0\n346\n2.740363\n0.5107213\n-0.0707942\n/plate_01\nday0\nNA\nNA\n\n\nLA11036\nLWPQA3913Y\nil_8\n1066.5\n126\nNA\nspecimen\n311.5\n37005.0\n346\n3.027961\n1.0499422\n0.1683407\n/plate_01\nday28\nNA\nNA\n\n\nLA11036\nWIUSH3317X\nil_8\n1147.5\n174\nNA\nspecimen\n311.5\n37005.0\n346\n3.059753\n1.1061658\n0.1932748\n/plate_01\nday0\nNA\nNA\n\n\nLA11034\nHASCA4592S\nil_8\n569.0\n157\nNA\nspecimen\n311.5\n37005.0\n346\n2.755112\n0.5397400\n-0.0579249\n/plate_01\nday28\nNA\nNA\n\n\nLA11040\nSTYAL4876A\nil_8\n504.5\n106\nNA\nspecimen\n311.5\n37005.0\n346\n2.702861\n0.4362660\n-0.1038138\n/plate_01\nday0\nNA\nNA\n\n\nLA11034\nHLPGU1397F\nil_8\n642.5\n126\nNA\nspecimen\n311.5\n37005.0\n346\n2.807873\n0.6423224\n-0.0124314\n/plate_01\nday0\nNA\nNA\n\n\nLA11033\nUPJRU9129S\nil_8\n441.0\n128\nNA\nspecimen\n311.5\n37005.0\n346\n2.644439\n0.3183408\n-0.1561116\n/plate_01\nday28\nNA\nNA\n\n\nLA11040\nJVOSI1587O\nil_8\n430.0\n139\nNA\nspecimen\n311.5\n37005.0\n346\n2.633469\n0.2959345\n-0.1660483\n/plate_01\nday28\nNA\nNA\n\n\nLA12027\nFCIFG0648D\nil_8\n643.5\n138\nNA\nspecimen\n311.5\n37005.0\n346\n2.808549\n0.6436233\n-0.0118545\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12027\nHJYDE3625F\nil_8\n816.0\n139\nNA\nspecimen\n311.5\n37005.0\n346\n2.911690\n0.8386443\n0.0746338\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12026\nVRHCL9504V\nil_8\n652.0\n153\nNA\nspecimen\n311.5\n37005.0\n346\n2.814248\n0.6545875\n-0.0069921\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12026\nVAYHW1782L\nil_8\n1457.0\n153\nNA\nspecimen\n311.5\n37005.0\n346\n3.163460\n1.2850268\n0.2725965\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12024\nNPLGF7754K\nil_8\n593.0\n151\nNA\nspecimen\n311.5\n37005.0\n346\n2.773055\n0.5748391\n-0.0423591\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12022\nJQKTV5449U\nil_8\n640.0\n126\nNA\nspecimen\n311.5\n37005.0\n346\n2.806180\n0.6390600\n-0.0138783\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12024\nFOLVC5757H\nil_8\n654.0\n164\nNA\nspecimen\n311.5\n37005.0\n346\n2.815578\n0.6571433\n-0.0058587\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12028\nYDITP1935G\nil_8\n713.5\n152\nNA\nspecimen\n311.5\n37005.0\n346\n2.853394\n0.7293023\n0.0261426\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12021\nQBWQM4347F\nil_8\n625.5\n134\nNA\nspecimen\n311.5\n37005.0\n346\n2.796227\n0.6198433\n-0.0224005\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12028\nZZIZF0455C\nil_8\n520.5\n160\nNA\nspecimen\n311.5\n37005.0\n346\n2.716421\n0.4632989\n-0.0918252\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12022\nWTCZZ6985E\nil_8\n1051.0\n125\nNA\nspecimen\n311.5\n37005.0\n346\n3.021603\n1.0386186\n0.1633188\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12021\nOIXZA0659A\nil_8\n501.0\n159\nNA\nspecimen\n311.5\n37005.0\n346\n2.699838\n0.4302210\n-0.1064946\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12023\nTUCFK1156H\nil_8\n678.0\n127\nNA\nspecimen\n311.5\n37005.0\n346\n2.831230\n0.6871274\n0.0074388\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12034\nJFNKQ9365E\nil_8\n916.0\n111\nNA\nspecimen\n311.5\n37005.0\n346\n2.961895\n0.9309828\n0.1155843\n/plate_01\nday0\ninpatient\nother_health_facility\n\n\nLA12031\nKKTBR9167G\nil_8\n672.0\n149\nNA\nspecimen\n311.5\n37005.0\n346\n2.827369\n0.6797476\n0.0041659\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12030\nZLHKQ3056W\nil_8\n1376.5\n134\nNA\nspecimen\n311.5\n37005.0\n346\n3.138776\n1.2430810\n0.2539943\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12032\nOPEWU1360J\nil_8\n2434.0\n153\nNA\nspecimen\n311.5\n37005.0\n346\n3.386321\n1.6465855\n0.4329414\n/plate_01\nday0\ninpatient\nother_health_facility\n\n\nLA12033\nCUVAC1977G\nil_8\n1171.5\n176\nNA\nspecimen\n311.5\n37005.0\n346\n3.068742\n1.1219444\n0.2002724\n/plate_01\nday0\ninpatient\ndischarged_pallative\n\n\nLA12025\nQYMHD2998X\nil_8\n1262.0\n138\nNA\nspecimen\n311.5\n37005.0\n346\n3.101059\n1.1782350\n0.2252363\n/plate_01\nday0\ninpatient\ndischarged_pallative\n\n\nLA12029\nVHKUC4047G\nil_8\n431.5\n162\nNA\nspecimen\n311.5\n37005.0\n346\n2.634981\n0.2990284\n-0.1646763\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA19076\nVFZHQ3422A\nil_8\n595.0\n110\nNA\nspecimen\n311.5\n37005.0\n346\n2.774517\n0.5776899\n-0.0410948\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19075\nKHUXL8867Y\nil_8\n577.0\n178\nNA\nspecimen\n311.5\n37005.0\n346\n2.761176\n0.5516262\n-0.0526536\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19074\nSQSNR6198H\nil_8\n809.0\n156\nNA\nspecimen\n311.5\n37005.0\n346\n2.907948\n0.8316951\n0.0715520\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19073\nSSWIM3847X\nil_8\n694.0\n129\nNA\nspecimen\n311.5\n37005.0\n346\n2.841359\n0.7064440\n0.0160053\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19072\nFOIZY7136I\nil_8\n700.0\n157\nNA\nspecimen\n311.5\n37005.0\n346\n2.845098\n0.7135556\n0.0191592\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19071\nWGJOZ6938A\nil_8\n1203.0\n172\nNA\nspecimen\n311.5\n37005.0\n346\n3.080266\n1.1420935\n0.2092081\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19070\nFCNHC5405J\nil_8\n1019.0\n156\nNA\nspecimen\n311.5\n37005.0\n346\n3.008174\n1.0146156\n0.1526740\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19069\nBJNDC1787J\nil_8\n680.5\n176\nNA\nspecimen\n311.5\n37005.0\n346\n2.832828\n0.6901801\n0.0087926\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19068\nSOAWG2729N\nil_8\n944.0\n123\nNA\nspecimen\n311.5\n37005.0\n346\n2.974972\n0.9547578\n0.1261281\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19067\nYKYZG4464G\nil_8\n559.0\n123\nNA\nspecimen\n311.5\n37005.0\n346\n2.747412\n0.5246086\n-0.0646355\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19066\nZABYK9626H\nil_8\n615.0\n121\nNA\nspecimen\n311.5\n37005.0\n346\n2.788875\n0.6056042\n-0.0287153\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19065\nFCIID4951Q\nil_8\n719.0\n144\nNA\nspecimen\n311.5\n37005.0\n346\n2.856729\n0.7356192\n0.0289440\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19064\nFFARN9962A\nil_8\n743.0\n107\nNA\nspecimen\n311.5\n37005.0\n346\n2.870989\n0.7625453\n0.0408852\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19063\nYSPMQ7157A\nil_8\n547.0\n164\nNA\nspecimen\n311.5\n37005.0\n346\n2.737987\n0.5060340\n-0.0728729\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19062\nXKMHL2286R\nil_8\n880.5\n156\nNA\nspecimen\n311.5\n37005.0\n346\n2.944729\n0.8995999\n0.1016665\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19061\nZJUTH0630E\nil_8\n713.5\n172\nNA\nspecimen\n311.5\n37005.0\n346\n2.853394\n0.7293023\n0.0261426\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19060\nPQNTB0480Q\nil_8\n744.0\n105\nNA\nspecimen\n311.5\n37005.0\n346\n2.871573\n0.7636453\n0.0413731\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19059\nVFWTH5193U\nil_8\n587.0\n101\nNA\nspecimen\n311.5\n37005.0\n346\n2.768638\n0.5662198\n-0.0461816\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19058\nZKQKJ4765K\nil_8\n682.5\n108\nNA\nspecimen\n311.5\n37005.0\n346\n2.834103\n0.6926130\n0.0098715\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19057\nBJLNT2569K\nil_8\n565.0\n149\nNA\nspecimen\n311.5\n37005.0\n346\n2.752048\n0.5337245\n-0.0605927\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19056\nWDIEJ7300D\nil_8\n617.0\n133\nNA\nspecimen\n311.5\n37005.0\n346\n2.790285\n0.6083379\n-0.0275030\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19055\nWBEMZ8364O\nil_8\n735.0\n173\nNA\nspecimen\n311.5\n37005.0\n346\n2.866287\n0.7536830\n0.0369550\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA19054\nGQLIG2522J\nil_8\n728.0\n153\nNA\nspecimen\n311.5\n37005.0\n346\n2.862131\n0.7458366\n0.0334752\n/plate_01\ncontrol\ncontrol\nControl\n\n\nLA14029\nCEOMW0540K\nil_8\n14689.0\n167\nNA\nspecimen\n311.5\n37005.0\n346\n4.166992\n2.6948373\n0.8978224\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA14029\nCGNQI1160J\nil_8\n562.0\n177\nNA\nspecimen\n311.5\n37005.0\n346\n2.749736\n0.5291805\n-0.0626079\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA14028\nUKESF7004Q\nil_8\n607.0\n107\nNA\nspecimen\n311.5\n37005.0\n346\n2.783189\n0.5945658\n-0.0336107\n/plate_01\nday0\ninpatient\nother_health_facility\n\n\nLA14027\nYSQYR9458Q\nil_8\n864.0\n143\nNA\nspecimen\n311.5\n37005.0\n346\n2.936514\n0.8845106\n0.0949747\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA14028\nIQWRF4475A\nil_8\n956.0\n154\nNA\nspecimen\n311.5\n37005.0\n346\n2.980458\n0.9646982\n0.1305365\n/plate_01\nday28\ninpatient\nother_health_facility\n\n\nLA14027\nHDHBH5824I\nil_8\n600.5\n154\nNA\nspecimen\n311.5\n37005.0\n346\n2.778513\n0.5854729\n-0.0376432\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA14026\nNIVWI2815C\nil_8\n595.5\n170\nNA\nspecimen\n311.5\n37005.0\n346\n2.774882\n0.5784008\n-0.0407795\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA14026\nTWRXA5018E\nil_8\n502.0\n191\nNA\nspecimen\n311.5\n37005.0\n346\n2.700704\n0.4319531\n-0.1057265\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA14025\nQZAQT6173F\nil_8\n496.0\n154\nNA\nspecimen\n311.5\n37005.0\n346\n2.695482\n0.4215007\n-0.1103620\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA14025\nKCGKZ4596G\nil_8\n476.0\n151\nNA\nspecimen\n311.5\n37005.0\n346\n2.677607\n0.3855801\n-0.1262921\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA14024\nQHAAS3070U\nil_8\n2032.0\n123\nNA\nspecimen\n311.5\n37005.0\n346\n3.307924\n1.5228646\n0.3780734\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA14024\nUGUGS0605Z\nil_8\n861.0\n155\nNA\nspecimen\n311.5\n37005.0\n346\n2.935003\n0.8817313\n0.0937421\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA13051\nLPAMF2203X\nil_8\n1110.0\n149\nNA\nspecimen\n311.5\n37005.0\n346\n3.045323\n1.0807288\n0.1819940\n/plate_01\nday0\nNA\nNA\n\n\nLA13050\nHPEUL6649T\nil_8\n1246.0\n175\nNA\nspecimen\n311.5\n37005.0\n346\n3.095518\n1.1686310\n0.2209770\n/plate_01\nday0\nNA\nNA\n\n\nLA13051\nTOWYT4920L\nil_8\n961.0\n163\nNA\nspecimen\n311.5\n37005.0\n346\n2.982723\n0.9687974\n0.1323544\n/plate_01\nday28\nNA\nNA\n\n\nLA13050\nGTKLW6867M\nil_8\n812.0\n133\nNA\nspecimen\n311.5\n37005.0\n346\n2.909556\n0.8346818\n0.0728765\n/plate_01\nday28\nNA\nNA\n\n\nLA13048\nTUFEH9339A\nil_8\n495.5\n152\nNA\nspecimen\n311.5\n37005.0\n346\n2.695044\n0.4206231\n-0.1107512\n/plate_01\nday0\nNA\nNA\n\n\nLA13048\nWSATP2009K\nil_8\n512.0\n148\nNA\nspecimen\n311.5\n37005.0\n346\n2.709270\n0.4490586\n-0.0981405\n/plate_01\nday28\nNA\nNA\n\n\nLA13047\nPIRTJ0833C\nil_8\n638.5\n110\nNA\nspecimen\n311.5\n37005.0\n346\n2.805161\n0.6370955\n-0.0147495\n/plate_01\nday0\nNA\nNA\n\n\nLA13044\nSWXZA6598N\nil_8\n642.0\n139\nNA\nspecimen\n311.5\n37005.0\n346\n2.807535\n0.6416711\n-0.0127203\n/plate_01\nday28\nNA\nNA\n\n\nLA13047\nNPDXB8563J\nil_8\n582.0\n101\nNA\nspecimen\n311.5\n37005.0\n346\n2.764923\n0.5589591\n-0.0494016\n/plate_01\nday28\nNA\nNA\n\n\nLA13044\nPEVIK2267H\nil_8\n584.0\n165\nNA\nspecimen\n311.5\n37005.0\n346\n2.766413\n0.5618720\n-0.0481098\n/plate_01\nday0\nNA\nNA\n\n\nLA13046\nXFJNU8182S\nil_8\n877.0\n133\nNA\nspecimen\n311.5\n37005.0\n346\n2.943000\n0.8964266\n0.1002592\n/plate_01\nday0\nNA\nNA\n\n\nLA13046\nOQKJI1993Q\nil_8\n824.0\n165\nNA\nspecimen\n311.5\n37005.0\n346\n2.915927\n0.8465023\n0.0781187\n/plate_01\nday28\nNA\nNA\n\n\nLA12587\nDYKJQ0547B\nil_8\n576.0\n176\nNA\nspecimen\n311.5\n37005.0\n346\n2.760422\n0.5501509\n-0.0533079\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA11033\nSHGKD1852U\nstnf_r1\n235.0\n161\nNA\nspecimen\n208.0\n16683.5\n219\n2.371068\n0.2657945\n-0.3760046\n/plate_01\nday0\nNA\nNA\n\n\nLA11039\nILAID4151N\nstnf_r1\n291.5\n146\nNA\nspecimen\n208.0\n16683.5\n219\n2.464639\n0.6994402\n-0.1707881\n/plate_01\nday0\nNA\nNA\n\n\nLA11037\nVGHJM4359F\nstnf_r1\n233.0\n141\nNA\nspecimen\n208.0\n16683.5\n219\n2.367356\n0.2471477\n-0.3848289\n/plate_01\nday28\nNA\nNA\n\n\nLA11039\nKOANM9309M\nstnf_r1\n332.0\n149\nNA\nspecimen\n208.0\n16683.5\n219\n2.521138\n0.9299112\n-0.0617211\n/plate_01\nday28\nNA\nNA\n\n\nLA11037\nEGPPE6968D\nstnf_r1\n309.5\n146\nNA\nspecimen\n208.0\n16683.5\n219\n2.490661\n0.8083424\n-0.1192517\n/plate_01\nday0\nNA\nNA\n\n\nLA11036\nLWPQA3913Y\nstnf_r1\n697.0\n132\nNA\nspecimen\n208.0\n16683.5\n219\n2.843233\n1.8927803\n0.3939427\n/plate_01\nday28\nNA\nNA\n\n\nLA11036\nWIUSH3317X\nstnf_r1\n533.0\n174\nNA\nspecimen\n208.0\n16683.5\n219\n2.726727\n1.6036457\n0.2571139\n/plate_01\nday0\nNA\nNA\n\n\nLA11034\nHASCA4592S\nstnf_r1\n325.5\n158\nNA\nspecimen\n208.0\n16683.5\n219\n2.512551\n0.8962949\n-0.0776295\n/plate_01\nday28\nNA\nNA\n\n\nLA11040\nSTYAL4876A\nstnf_r1\n282.0\n128\nNA\nspecimen\n208.0\n16683.5\n219\n2.450249\n0.6371241\n-0.2002782\n/plate_01\nday0\nNA\nNA\n\n\nLA11034\nHLPGU1397F\nstnf_r1\n340.0\n136\nNA\nspecimen\n208.0\n16683.5\n219\n2.531479\n0.9697451\n-0.0428702\n/plate_01\nday0\nNA\nNA\n\n\nLA11033\nUPJRU9129S\nstnf_r1\n258.0\n109\nNA\nspecimen\n208.0\n16683.5\n219\n2.411620\n0.4621386\n-0.2830876\n/plate_01\nday28\nNA\nNA\n\n\nLA11040\nJVOSI1587O\nstnf_r1\n235.0\n118\nNA\nspecimen\n208.0\n16683.5\n219\n2.371068\n0.2657945\n-0.3760046\n/plate_01\nday28\nNA\nNA\n\n\nLA12027\nFCIFG0648D\nstnf_r1\n346.0\n143\nNA\nspecimen\n208.0\n16683.5\n219\n2.539076\n0.9985658\n-0.0292313\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12027\nHJYDE3625F\nstnf_r1\n519.5\n138\nNA\nspecimen\n208.0\n16683.5\n219\n2.715586\n1.5728778\n0.2425535\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12026\nVRHCL9504V\nstnf_r1\n288.0\n187\nNA\nspecimen\n208.0\n16683.5\n219\n2.459392\n0.6768970\n-0.1814563\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12026\nVAYHW1782L\nstnf_r1\n977.5\n224\nNA\nspecimen\n208.0\n16683.5\n219\n2.990117\n2.1850781\n0.5322683\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12024\nNPLGF7754K\nstnf_r1\n341.5\n152\nNA\nspecimen\n208.0\n16683.5\n219\n2.533391\n0.9770329\n-0.0394214\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12022\nJQKTV5449U\nstnf_r1\n378.0\n151\nNA\nspecimen\n208.0\n16683.5\n219\n2.577492\n1.1387097\n0.0370898\n/plate_01\nday28\ninpatient\ndischarged\n\n\nLA12024\nFOLVC5757H\nstnf_r1\n276.5\n170\nNA\nspecimen\n208.0\n16683.5\n219\n2.441695\n0.5993538\n-0.2181525\n/plate_01\nday0\ninpatient\ndischarged\n\n\nLA12028\nYDITP1935G\nstnf_r1\n432.0\n143\nNA\nspecimen\n208.0\n16683.5\n219\n2.635484\n1.3335822\n0.1293103\n/plate_01\nday0\ninpatient\ndischarged"
  },
  {
    "objectID": "Analysis_01.html#removing-bad-plates",
    "href": "Analysis_01.html#removing-bad-plates",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.8 Removing bad plates",
    "text": "14.8 Removing bad plates\nIt is really important to remember that a plate may have a very different distribution of values if it contains mostly controls/mostly cases/mostly day 0 specimens etc. or if something went wrong.\nLet’s look at what’s on each plate\n\ntmp&lt;-full_data %&gt;% \n  select(plate,sample,timepoint,cf_5_inpatient_outcome,inpatient_outpatient) %&gt;% \n  distinct() %&gt;% \n  group_by(plate,timepoint,cf_5_inpatient_outcome,inpatient_outpatient) %&gt;% \n  count() %&gt;% \n  mutate(type = str_c(inpatient_outpatient,timepoint,cf_5_inpatient_outcome,sep=\" \"))\n\nggplotly(ggplot(tmp,aes(plate,n))+geom_bar(stat=\"identity\")+\n  facet_wrap(.~type)+\n  theme(legend.position = \"none\",axis.text.x = element_text(angle = 90,size=3))\n)\n\n\n\n\nrm(tmp)\n\nIt is clear from this chart that the unusual patterns observed for plate 14 are actually likely to relate to the fact that plate 14 had lots of specimens from people who had bad outcomes. These are likely to be the most sick. Removing this plate would be a very bad idea. Similarly there are some plates to the right of plate 14 which have more ‘good’ outcomes than the other plates. You can see this in the boxplots above this chart, where those plates had slightly depressed levels of some of the cytokines compared to other plates.\nThere appears to be no reason why the Azu and a few other markers behaved differently in plates 6, 7 and 8. These may have failed for technical reasons and should be removed.\n\nfull_data&lt;- full_data %&gt;% \n        filter(\n              plate != \"plate_06\",\n              plate != \"plate_07\",\n              plate != \"plate_08\"\n              )\n\nWrite the main data frame a to an R object for future use\n\nsaveRDS(full_data,file = \"data/a.RDS\")"
  },
  {
    "objectID": "Analysis_01.html#reality-check",
    "href": "Analysis_01.html#reality-check",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.9 Reality check",
    "text": "14.9 Reality check\nThink carefully about what you’re going to use this data for. If you’re working in a lab that has routine access to a Luminex machine, then doing fancy maths (transformations, dimensionality reduction, etc) on the variables is a viable option. If you’re really just looking for a marker that you could add to a diagnostic rapid test strip, then you need something really simple. Analysis should always be led by your ultimate purpose."
  },
  {
    "objectID": "Analysis_01.html#analysis",
    "href": "Analysis_01.html#analysis",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "14.10 Analysis",
    "text": "14.10 Analysis\n\n14.10.1 Expression of markers in different clinical classes at day 0\nThis example shows how to assess variance in the markers according to clinical class or another variable such as patient admission types.\n\nggplot(filter(full_data,(timepoint==\"day0\" | timepoint==\"control\") & !is.na(inpatient_outpatient)),aes(Estimate.norm,fill=inpatient_outpatient))+\n    geom_density(alpha=0.3)+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = \"bottom\",\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )+\n    facet_wrap(.~assay,\n               ncol = 2,\n               scales=\"free_y\",\n               strip.position = 'left')\n\n\n\n\nHere we can also show the results for the “IL-8” assay on its own\n\nggplot(filter(full_data,(timepoint==\"day0\" | timepoint==\"control\") & assay==\"il_8\" & !is.na(inpatient_outpatient)),aes(Estimate.norm,fill=inpatient_outpatient))+\n  geom_density(alpha=0.3)+  \n  geom_boxplot()+\n  theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n        legend.position = c(.8, .8)\n        )+\n  ggtitle(\"IL-8\")\n\n\n\n\nIt’s pretty easy to see the difference between cases and controls. Be careful what you set out to do/prove/associate with a set of immuno-assays such as these ones because not all markers work this well. For instance, IP10 is also really good\n\nggplot(filter(full_data,(timepoint==\"day0\" | timepoint==\"control\") & assay==\"ip_10\" & !is.na(inpatient_outpatient)),aes(Estimate.norm,fill=inpatient_outpatient))+\n  geom_density(alpha=0.3)+  \n  geom_boxplot()+\n  theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n        legend.position = c(.8, .8)\n        )+\n  ggtitle(\"IP-10\")\n\n\n\n\nbut TRAIL doesn’t look very specific with respect to severity, and also has a lot of overlap between disease cases and control specimens.\n\nggplot(filter(full_data,(timepoint==\"day0\" | timepoint==\"control\") & assay==\"trail\" & !is.na(inpatient_outpatient)),aes(Estimate.norm,fill=inpatient_outpatient))+\n  geom_density(alpha=0.3)+  \n  geom_boxplot()+\n  theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n        legend.position = c(.8, .8)\n        )+\n  ggtitle(\"TRAIL\")\n\n\n\n\n\n\n14.10.2 Expression of markers at different time points\nThis is similar in most respects to the analysis above. Here we make use of the fact that for some participants, there are paired specimens from day 0 and day 28. We won’t include the people with bad outcomes here because most of them were either dead (so could not provide day 28 specimen), or just did not provide a paired day 28 specimen. To address questions about how measuring increases or decreases in biomarker levels might be prognostic of disease severity/prognosis/progression, you’d need a more granular sampling frame, for instance specimens collected in a longitudinal series.\nHere, we can look at how patterns of marker expression changed 28 days after the initial day 0 visit. Note the free y axes on these charts below.\n\nggplot(full_data,aes(Estimate.norm,fill=timepoint))+\n  geom_density(alpha=0.3)+\n  facet_wrap(assay~.,\n              scales = \"free_y\",\n              strip.position = 'left'\n             )+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = \"bottom\",\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nThis shows pretty much what we’d expect to see in the context of a diseased state at day 0 and a resolved disease state at day 28. Most of these immune response markers were higher at day 0 than at day 28. How much we choose to read in to the individual assay responses is contextual to the specific disease/condition/infection and to different population settings. In this setting, we see a very high level of IP-10 at day 0, and a clear distinction between the day 0 and day 28 groups. These specimens were collected during an outbreak of Dengue virus, and IP-10 has well described associations with Dengue infections.\nWe can’t infer from the decrease in the resolved cases by day 28 that there was a concomitant increase in biomarker levels in cases which progressed to bad outcomes. We can infer that a number of these markers are indicative of a diseased state, especially if we add back the control group.\nLooking at an individual marker can be useful. IL-8 clearly discriminates day 0 cases from controls and day 28 specimens\n\nggplot(filter(full_data,assay==\"il_8\"),aes(Estimate.norm,fill=timepoint))+\n  geom_density(alpha=0.3)+\n\n    geom_boxplot(alpha=0.3)+\n  facet_wrap(.~assay)+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = c(0.8,0.8),\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nMeanwhile IP-10 is also great\n\nggplot(filter(full_data,assay==\"ip_10\"),aes(Estimate.norm,fill=timepoint))+\n  geom_density(alpha=0.3)+\n\n    geom_boxplot(alpha=0.3)+\n  facet_wrap(.~assay)+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = c(0.8,0.8),\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nbut TRAIL is less conclusive\n\nggplot(filter(full_data,assay==\"trail\"),aes(Estimate.norm,fill=timepoint))+\n  geom_density(alpha=0.3)+\n\n    geom_boxplot(alpha=0.3)+\n  facet_wrap(.~assay)+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = c(0.8,0.8),\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nThere’s very obvious differences between the diseased state and those who are recovered for some, but not all of these markers.\n\n\n14.10.3 Towards a rapid prognostic test\nWe can take a look at day 0 and see if we can see differences in IP-10 expression between those who go on to have bad outcomes and those who don’t. Here, we are imagining that a simple rapid ‘dipstick’ type test is the ultimate goal. That limits what manipulations we can do, because tests like that are based on ‘more is worse’ type tests. While the dose response curve of a real world rapid test is not usually strictly linear, we have to find candidate markers that indicate disease/infection when they are more abundant.\n\nday0_ip10&lt;- filter(full_data,assay==\"ip_10\",timepoint==\"day0\",cf_5_inpatient_outcome!=\"other_health_facility\",!is.na(cf_5_inpatient_outcome))\nggplot(day0_ip10,aes(Estimate.norm,fill=cf_5_inpatient_outcome))+\n  geom_density(alpha=0.3)\n\n\n\n\nLet’s also go back to the data and look at day 0 for all assays\n\nday_0 &lt;- filter(full_data,timepoint==\"day0\",cf_5_inpatient_outcome!=\"other_health_facility\",!is.na(cf_5_inpatient_outcome))\nggplot(day_0,aes(Estimate.norm,fill=cf_5_inpatient_outcome))+\n  geom_density(alpha=0.3)+\n  facet_wrap(assay~.,\n              scales=\"free_y\",\n              strip.position = 'left'\n             \n             )+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = \"bottom\",\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nIl-8 looks interesting because a lot of the distribution of ‘bad’ values is to the right of the ‘good’ values. This suggests that more of this marker is prognostic of a bad outcome. Interestingly, whilst IP-10 was good at distinguishing the diseased/non-diseased states, it has less obvious use as a prognostic for outcomes. Meanwhile, sTNF-R1, which didn’t look very interesting before, looks like a decent prognostic.\nFor the following analyses, it’s a pain if any values cross zero, so to make our maths a bit easier, we’ll add a constant to the values. This has the effect of shifting everything to the right so that the minimum value is 1. Doing this also allows for log, square root and other transformations (but we won’t use those here, remembering that we are working towards a dipstick test and want linear responses. The constant is calculated by adding 1 plus the absolute value of the minimum estimated value to each value of Estimate.norm.\n\\(Estimate.adj = Estimate+(1+abs(min(Estimate)))\\)\n\nday0_stnfr1&lt;- filter(full_data,\n                     assay==\"stnf_r1\",\n                     cf_5_inpatient_outcome!=\"other_health_facility\",\n                     !is.na(cf_5_inpatient_outcome),\n                     timepoint==\"day0\"\n                     ) %&gt;%               \n              mutate(\n                    Estimate.norm.adj = Estimate.norm+(1+abs(min(Estimate.norm)))\n                    )\n\nggplot(day0_stnfr1,aes(Estimate.norm.adj,fill=cf_5_inpatient_outcome,alpha=0.3))+\n  geom_density(alpha=0.3)+\n    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust=1),\n          legend.position = c(0.8,0.8),\n          strip.background = element_blank(),\n          strip.placement='outside'\n          )\n\n\n\n\nThere’s better ways to look at how prognostic this type of measurement could be. Let’s try a ROC analysis, using the ROCit package. We’ll apply the rocit command to our sTNF-R1 data (day 0 only).\nWhen using a ROC analysis, you need to be careful to ensure that your outcome variable is a binary factor with the correct reference group. Here, we want to predict who is going to have a bad outcome, so good outcomes should be the reference point.\nWe also need to collapse the bad outcomes in to a single class “good” (discharged) or “bad” (palliative care / dead)\n\nday0_stnfr1 &lt;- day0_stnfr1 %&gt;% mutate(\n                                  outcome = as.factor(case_when(\n                                                      cf_5_inpatient_outcome == \"died\" ~ \"Bad\",\n                                                      cf_5_inpatient_outcome == \"discharged_pallative\" ~ \"Bad\",\n                                                      cf_5_inpatient_outcome == \"discharged\" ~ \"Good\"\n                                  )),\n                                    \n                                  outcome = relevel(as.factor(outcome), ref=\"Good\")\n                                  )\nsummary(day0_stnfr1$outcome)\n\nGood  Bad \n 717   66 \n\n\nNow that we have the correct reference group, we can run the ROC analysis.\n\nsummary(rocit(score=day0_stnfr1$Estimate.norm.adj,class=day0_stnfr1$outcome))\n\n                           \n Method used: empirical    \n Number of positive(s): 66 \n Number of negative(s): 717\n Area under curve: 0.5696  \n\n\nIt seems to be a reasonably good (but not great) prognostic as the area under the curve (a general indicator of overall performance across a range of threshold values) is somewhat greater than 0.5 (the toss of a coin odds of getting the class right).\n\n14.10.3.1 Function to draw ROC chart in ggplot\nROCit is a really neat package with lots of features, but doesn’t make ggplots. The following function makes a ggplot version of the ROC curves calculated with the rocit command\n\nROCit_plot&lt;-function(df){\n\n  roc.curve&lt;-tibble(\n    TPR=df$TPR,\n    FPR=df$FPR\n  )\n\n  p&lt;- ggplot(data = roc.curve,aes(FPR,TPR))+\n    geom_line()+\n    geom_abline(intercept = 0,slope = 1,lty=2)+\n    annotate(geom = \"text\", x = 0.8, y = 0.05, label = str_c(\"AUC = \", \n                                                             round(df$AUC,2),sep = \"\") \n            )\n    annotate(geom = \"text\", x = 0.8, y = 0.05, label = str_c(\"AUC = \", \n                                                             round(df$AUC,2),sep = \"\")\n             )\n  return(p)\n}\n\nLet’s now plot the ROC curve and visualise the overall performance of the test.\n\nROCit_plot(rocit(score=day0_stnfr1$Estimate.norm.adj,class=day0_stnfr1$outcome))\n\n\n\n\nTo use this data to inform the design of a rapid test, we’d need to find a cutoff value where we felt we got the best balance between sensitivity and specificity.\nLet’s get some values out of the ROC analysis, using an arbitrarily chosen threshold at 1.5 units of Estimate.norm.adj\n\nroc.stnfr1 &lt;- rocit(score=day0_stnfr1$Estimate.norm.adj,class=day0_stnfr1$outcome)\n\nIt is pretty simple to extract the sensitivity and specificity values for any threshold value.\n\ncutoff = 1.5\nstr_c(\"Cutoff = \",cutoff)\n\n[1] \"Cutoff = 1.5\"\n\nstr_c(\"Sensitivity = \",round(roc.stnfr1$TPR[max(which(roc.stnfr1$Cutoff&gt;cutoff))],3))\n\n[1] \"Sensitivity = 0.727\"\n\nstr_c(\"Specificity = \", round(1-(roc.stnfr1$FPR[max(which(roc.stnfr1$Cutoff&gt;cutoff))]),3))\n\n[1] \"Specificity = 0.324\"\n\n\nAs with basic diagnostics theory, if you increase the threshold, you get more specificity, whilst decreasing the threshold buys you more sensitivity. With different thresholds, you can see this in action\n\ncutoff = 1.1\n\n\nkable(\n  tibble(\n        Cutoff = c(1.1,1.4,1.5,1.75),\n        Sensitivity = c(round(roc.stnfr1$TPR[max(which(roc.stnfr1$Cutoff&gt;1.1))],3),\n                        round(roc.stnfr1$TPR[max(which(roc.stnfr1$Cutoff&gt;1.4))],3),\n                        round(roc.stnfr1$TPR[max(which(roc.stnfr1$Cutoff&gt;1.5))],3),\n                        round(roc.stnfr1$TPR[max(which(roc.stnfr1$Cutoff&gt;1.75))],3)),\n        Specificity = c(round(1-(roc.stnfr1$FPR[max(which(roc.stnfr1$Cutoff&gt;1.1))]),3),\n                        round(1-(roc.stnfr1$FPR[max(which(roc.stnfr1$Cutoff&gt;1.4))]),3),\n                        round(1-(roc.stnfr1$FPR[max(which(roc.stnfr1$Cutoff&gt;1.5))]),3),\n                        round(1-(roc.stnfr1$FPR[max(which(roc.stnfr1$Cutoff&gt;1.75))]),3))\n        )\n    )\n\n\n\n\nCutoff\nSensitivity\nSpecificity\n\n\n\n\n1.10\n0.985\n0.003\n\n\n1.40\n0.833\n0.187\n\n\n1.50\n0.727\n0.324\n\n\n1.75\n0.500\n0.688\n\n\n\n\n\nPicking a cutoff is not a trivial pursuit and a lot of care and thought should go in to this.\nYour primary thought should be about how you plan to use the test. If you want a really specific test, then a high classification threshold is more appropriate. If you want a more sensitive test, then place the threshold lower down. Some situations may have reasons to avoid the extremes and to go for a threshold somewhere in the middle."
  },
  {
    "objectID": "Analysis_01.html#note-on-open-licences",
    "href": "Analysis_01.html#note-on-open-licences",
    "title": "14  Data Analysis - A Tutorial based on the Mos-Def study",
    "section": "19.1 Note on open licences",
    "text": "19.1 Note on open licences\nThe EM code used here is modified from code found on https://dozenoaks.twelvetreeslab.co.uk/2019/06/mixture-models. The source code appears to have been aggregated from various open sources and we interpret a copyright notice by the author of the webpage referred to here, to actually refer only to the body text and not to the code presented and subsequently modified for use here. We believe that all of the code statically linked from https://dozenoaks.twelvetreeslab.co.uk/2019/06/mixture-models is actually open source and likely to be derived from the following sources.\nhttps://cran.r-project.org/web/packages/mixtools/index.html\nhttps://cran.r-project.org/web/packages/mixtools/vignettes/mixtools.pdf\nhttps://exploringdatablog.blogspot.com/2011/08/fitting-mixture-distributions-with-r.html\nhttp://tinyheero.github.io/2015/10/13/mixture-model.html\nhttp://tinyheero.github.io/2016/01/03/gmm-em.html#checking-for-convergence\nPlease respect the licenses of the code originators."
  },
  {
    "objectID": "appendix.html#funding",
    "href": "appendix.html#funding",
    "title": "15  Funding & Declarations",
    "section": "15.1 Funding",
    "text": "15.1 Funding\nThis work was funded by Global Health Labs and the United Kingdom Foreign, Commonwealth and Development Office (FCDO)."
  },
  {
    "objectID": "appendix.html#ethics-statement",
    "href": "appendix.html#ethics-statement",
    "title": "15  Funding & Declarations",
    "section": "15.2 Ethics statement",
    "text": "15.2 Ethics statement\nEthical approval for this study was granted by the ethics committee of the London School of Hygiene & Tropical Medicine, as well as the National Ethics Committee for Health Research of the Lao People’s Democratic Republic (Lao PDR), where sample collection took place. Informed consent or assent was given by all participants, or their carers or guardians, as appropriate."
  },
  {
    "objectID": "appendix.html#section",
    "href": "appendix.html#section",
    "title": "15  Funding & Declarations",
    "section": "15.3 ",
    "text": "15.3"
  },
  {
    "objectID": "appendix.html#mit-license",
    "href": "appendix.html#mit-license",
    "title": "15  Funding & Declarations",
    "section": "15.4 MIT License",
    "text": "15.4 MIT License\n(C) 2024, Chrissy h Roberts, Tegwen Marlais. LSHTM\nPermission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the “Software”), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions: The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.\nTHE SOFTWARE IS PROVIDED “AS IS”, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.\n\n15.4.1 Disclaimer 1\nThis project makes use of third-party R packages, which are dynamically linked. To the best of our knowledge, this project does not incorporate or statically link any third-party code. The licenses of these third-party packages are respected and their respective notices are included below. Please refer to the documentation of each package for more details about their licenses and terms of use.\n\n\n              package packrat.version                                License\n1           BiasedUrn          2.0.12                                  GPL-3\n2                 DBI           1.2.3                          LGPL (&gt;= 2.1)\n3          KernSmooth         2.23-24                              Unlimited\n4                MASS        7.3-60.2                          GPL-2 | GPL-3\n5              Matrix           1.7-0              GPL (&gt;= 2) | file LICENCE\n6        MatrixModels           0.5-3                             GPL (&gt;= 2)\n7                  R6           2.5.1                     MIT + file LICENSE\n8        RColorBrewer           1.1-3                     Apache License 2.0\n9               ROCit           2.1.2                                  GPL-3\n10               Rcpp          1.0.12                             GPL (&gt;= 2)\n11          RcppEigen       0.3.4.0.0              GPL (&gt;= 2) | file LICENSE\n12            SparseM            1.83                             GPL (&gt;= 2)\n13            TH.data           1.1-2                                  GPL-3\n14              abind           1.4-5                            LGPL (&gt;= 2)\n15            askpass           1.2.0                     MIT + file LICENSE\n16          backports           1.5.0                          GPL-2 | GPL-3\n17          base64enc           0.1-3                          GPL-2 | GPL-3\n18                bit           4.0.5                          GPL-2 | GPL-3\n19              bit64           4.0.5                          GPL-2 | GPL-3\n20               blob           1.2.4                     MIT + file LICENSE\n21               boot          1.3-30                              Unlimited\n22              broom           1.0.6                     MIT + file LICENSE\n23              bslib           0.7.0                     MIT + file LICENSE\n24             cachem           1.1.0                     MIT + file LICENSE\n25              callr           3.7.6                     MIT + file LICENSE\n26                car           3.1-2                             GPL (&gt;= 2)\n27            carData           3.0-5                             GPL (&gt;= 2)\n28         cellranger           1.1.0                     MIT + file LICENSE\n29              class          7.3-22                          GPL-2 | GPL-3\n30           classInt          0.4-10                             GPL (&gt;= 2)\n31                cli           3.6.2                     MIT + file LICENSE\n32              clipr           0.8.0                                  GPL-3\n33          codetools          0.2-20                                    GPL\n34         colorspace           2.1-0            BSD_3_clause + file LICENSE\n35         commonmark           1.9.1            BSD_2_clause + file LICENSE\n36         conflicted           1.2.0                     MIT + file LICENSE\n37              cpp11           0.4.7                     MIT + file LICENSE\n38             crayon           1.5.2                     MIT + file LICENSE\n39          crosstalk           1.2.1                     MIT + file LICENSE\n40               crul           1.4.2                     MIT + file LICENSE\n41               curl           5.2.1                     MIT + file LICENSE\n42         data.table          1.15.4                 MPL-2.0 | file LICENSE\n43             dbplyr           2.5.0                     MIT + file LICENSE\n44             digest          0.6.35                             GPL (&gt;= 2)\n45              dplyr           1.1.4                     MIT + file LICENSE\n46                drc           3.0-1                   GPL-2 | file LICENCE\n47             dtplyr           1.3.1                     MIT + file LICENSE\n48              e1071          1.7-14                          GPL-2 | GPL-3\n49               epiR          2.0.75                             GPL (&gt;= 2)\n50           evaluate          0.24.0                     MIT + file LICENSE\n51              fansi           1.0.6                          GPL-2 | GPL-3\n52             farver           2.1.2                     MIT + file LICENSE\n53            fastmap           1.2.0                     MIT + file LICENSE\n54          flextable           0.9.6                                  GPL-3\n55  fontBitstreamVera           0.1.1                           file LICENCE\n56     fontLiberation           0.1.0                           file LICENSE\n57        fontawesome           0.5.2                     MIT + file LICENSE\n58         fontquiver           0.2.1                   GPL-3 | file LICENSE\n59            forcats           1.0.0                     MIT + file LICENSE\n60                 fs           1.6.4                     MIT + file LICENSE\n61             gargle           1.5.2                     MIT + file LICENSE\n62            gdtools           0.3.7                   GPL-3 | file LICENSE\n63           generics           0.1.3                     MIT + file LICENSE\n64             gfonts           0.2.0                                  GPL-3\n65            ggplot2           3.5.1                     MIT + file LICENSE\n66               glue           1.7.0                     MIT + file LICENSE\n67        googledrive           2.1.1                     MIT + file LICENSE\n68      googlesheets4           1.1.1                     MIT + file LICENSE\n69             gtable           0.3.5                     MIT + file LICENSE\n70             gtools           3.9.5                                  GPL-2\n71              haven           2.5.4                     MIT + file LICENSE\n72              highr            0.11                                    GPL\n73                hms           1.1.3                     MIT + file LICENSE\n74          htmltools         0.5.8.1                             GPL (&gt;= 2)\n75        htmlwidgets           1.6.4                     MIT + file LICENSE\n76           httpcode           0.3.0                     MIT + file LICENSE\n77             httpuv          1.6.15              GPL (&gt;= 2) | file LICENSE\n78               httr           1.4.7                     MIT + file LICENSE\n79                ids           1.0.1                     MIT + file LICENSE\n80            isoband           0.2.7                     MIT + file LICENSE\n81          jquerylib           0.1.4                     MIT + file LICENSE\n82           jsonlite           1.8.8                     MIT + file LICENSE\n83            kernlab          0.9-32                                  GPL-2\n84              knitr            1.47                                    GPL\n85           labeling           0.4.3         MIT + file LICENSE | Unlimited\n86              later           1.3.2                     MIT + file LICENSE\n87            lattice          0.22-6                             GPL (&gt;= 2)\n88           lazyeval           0.2.2                                  GPL-3\n89          lifecycle           1.0.4                     MIT + file LICENSE\n90               lme4        1.1-35.4                             GPL (&gt;= 2)\n91          lubridate           1.9.3                             GPL (&gt;= 2)\n92           magrittr           2.0.3                     MIT + file LICENSE\n93            memoise           2.0.1                     MIT + file LICENSE\n94               mgcv           1.9-1                             GPL (&gt;= 2)\n95               mime            0.12                                    GPL\n96              minqa           1.2.7                                  GPL-2\n97           mixtools           2.0.0                             GPL (&gt;= 2)\n98             mnormt           2.1.1                          GPL-2 | GPL-3\n99             modelr          0.1.11                                  GPL-3\n100          multcomp          1.4-25                                  GPL-2\n101           munsell           0.5.1                     MIT + file LICENSE\n102           mvtnorm           1.2-5                                  GPL-2\n103              nlme         3.1-165                             GPL (&gt;= 2)\n104            nloptr           2.1.0                            LGPL (&gt;= 3)\n105              nnet          7.3-19                          GPL-2 | GPL-3\n106          numDeriv      2016.8-1.1                                  GPL-2\n107           officer           0.6.6                     MIT + file LICENSE\n108           openssl           2.2.0                     MIT + file LICENSE\n109           packrat           0.9.2                                  GPL-2\n110            pander           0.6.5                  AGPL-3 | file LICENSE\n111         patchwork           1.2.0                     MIT + file LICENSE\n112          pbkrtest           0.5.2                             GPL (&gt;= 2)\n113            pillar           1.9.0                     MIT + file LICENSE\n114         pkgconfig           2.0.3                     MIT + file LICENSE\n115            plotly          4.10.4                     MIT + file LICENSE\n116           plotrix           3.8-4                             GPL (&gt;= 2)\n117       prettyunits           1.2.0                     MIT + file LICENSE\n118          processx           3.8.4                     MIT + file LICENSE\n119          progress           1.2.3                     MIT + file LICENSE\n120          promises           1.3.0                     MIT + file LICENSE\n121             proxy          0.4-27                                  GPL-2\n122                ps           1.7.6                     MIT + file LICENSE\n123             psych           2.4.3                             GPL (&gt;= 2)\n124             purrr           1.0.2                     MIT + file LICENSE\n125          quantreg            5.98                             GPL (&gt;= 2)\n126              ragg           1.3.2                     MIT + file LICENSE\n127          rappdirs           0.3.3                     MIT + file LICENSE\n128             readr           2.1.5                     MIT + file LICENSE\n129            readxl           1.4.3                     MIT + file LICENSE\n130           rematch           2.0.0                     MIT + file LICENSE\n131          rematch2           2.1.2                     MIT + file LICENSE\n132            reprex           2.1.0                     MIT + file LICENSE\n133             rlang           1.1.4                     MIT + file LICENSE\n134         rmarkdown            2.27                                  GPL-3\n135        rstudioapi          0.16.0                     MIT + file LICENSE\n136             rvest           1.0.4                     MIT + file LICENSE\n137                s2           1.1.6                Apache License (== 2.0)\n138          sandwich           3.1-0                          GPL-2 | GPL-3\n139              sass           0.4.9                     MIT + file LICENSE\n140            scales           1.3.0                     MIT + file LICENSE\n141         segmented           2.1-0                                    GPL\n142           selectr           0.4-2            BSD_3_clause + file LICENCE\n143                sf          1.0-16             GPL-2 | MIT + file LICENSE\n144             shiny         1.8.1.1                   GPL-3 | file LICENSE\n145       sourcetools         0.1.7-1                     MIT + file LICENSE\n146           stringi           1.8.4                           file LICENSE\n147           stringr           1.5.1                     MIT + file LICENSE\n148          survival           3.6-4                            LGPL (&gt;= 2)\n149               sys           3.4.2                     MIT + file LICENSE\n150       systemfonts           1.1.0                     MIT + file LICENSE\n151       textshaping           0.4.0                     MIT + file LICENSE\n152            tibble           3.2.1                     MIT + file LICENSE\n153             tidyr           1.3.1                     MIT + file LICENSE\n154        tidyselect           1.2.1                     MIT + file LICENSE\n155         tidyverse           2.0.0                     MIT + file LICENSE\n156        timechange           0.3.0                             GPL (&gt;= 3)\n157           tinytex            0.51                     MIT + file LICENSE\n158         triebeard           0.4.1                     MIT + file LICENSE\n159              tzdb           0.4.0                     MIT + file LICENSE\n160             units           0.8-5                                  GPL-2\n161          urltools           1.7.3                     MIT + file LICENSE\n162              utf8           1.2.4 Apache License (== 2.0) | file LICENSE\n163              uuid           1.2-0                     MIT + file LICENSE\n164             vctrs           0.6.5                     MIT + file LICENSE\n165       viridisLite           0.4.2                     MIT + file LICENSE\n166             vroom           1.6.5                     MIT + file LICENSE\n167             withr           3.0.0                     MIT + file LICENSE\n168                wk           0.9.1                     MIT + file LICENSE\n169              xfun            0.45                     MIT + file LICENSE\n170              xml2           1.3.6                     MIT + file LICENSE\n171            xtable           1.8-4                             GPL (&gt;= 2)\n172              yaml           2.3.8            BSD_3_clause + file LICENSE\n173               zip           2.3.1                     MIT + file LICENSE\n174               zoo          1.8-12                          GPL-2 | GPL-3\n\n\n\n\n15.4.2 Disclaimer 2\nThe EM code used in the chapter which presents ways to analyse the data is partially modified from code found on https://dozenoaks.twelvetreeslab.co.uk/2019/06/mixture-models. The source code appears to have been aggregated from various open sources and we interpret a copyright notice by the author of the webpage referred to here, to actually refer only to the body text and not to the code presented and subsequently modified for use here. We believe that all of the code statically linked from https://dozenoaks.twelvetreeslab.co.uk/2019/06/mixture-models is actually open source and likely to be derived from the following sources.\nhttps://cran.r-project.org/web/packages/mixtools/index.html\nhttps://cran.r-project.org/web/packages/mixtools/vignettes/mixtools.pdf\nhttps://exploringdatablog.blogspot.com/2011/08/fitting-mixture-distributions-with-r.html\nhttp://tinyheero.github.io/2015/10/13/mixture-model.html\nhttp://tinyheero.github.io/2016/01/03/gmm-em.html#checking-for-convergence\nPlease respect the licenses of the code originators."
  },
  {
    "objectID": "CRediT.html#conceptualization",
    "href": "CRediT.html#conceptualization",
    "title": "16  CRediT Framework",
    "section": "16.1 Conceptualization",
    "text": "16.1 Conceptualization\nIdeas; formulation or evolution of overarching research goals and aims\nChrissy h Roberts, Tegwen Marlais, Heidi Hopkins, David Mabey, Chris Drakeley - add others quique etc."
  },
  {
    "objectID": "CRediT.html#methodology",
    "href": "CRediT.html#methodology",
    "title": "16  CRediT Framework",
    "section": "16.2 Methodology",
    "text": "16.2 Methodology\nDevelopment or design of methodology; creation of models\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#software",
    "href": "CRediT.html#software",
    "title": "16  CRediT Framework",
    "section": "16.3 Software",
    "text": "16.3 Software\nProgramming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#validation",
    "href": "CRediT.html#validation",
    "title": "16  CRediT Framework",
    "section": "16.4 Validation",
    "text": "16.4 Validation\nVerification, whether as a part of the activity or separate, of the overall replication/ reproducibility of results/experiments and other research outputs\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#formal-analysis",
    "href": "CRediT.html#formal-analysis",
    "title": "16  CRediT Framework",
    "section": "16.5 Formal Analysis",
    "text": "16.5 Formal Analysis\nApplication of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#investigation",
    "href": "CRediT.html#investigation",
    "title": "16  CRediT Framework",
    "section": "16.6 Investigation",
    "text": "16.6 Investigation\nConducting a research and investigation process, specifically performing the experiments, or data/evidence collection\nTegwen Marlais, Becca Handley, Hira Tanvir"
  },
  {
    "objectID": "CRediT.html#resources",
    "href": "CRediT.html#resources",
    "title": "16  CRediT Framework",
    "section": "16.7 Resources",
    "text": "16.7 Resources\nProvision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools\nChrissy h Roberts, [Lao Clinical team names here]"
  },
  {
    "objectID": "CRediT.html#data-curation",
    "href": "CRediT.html#data-curation",
    "title": "16  CRediT Framework",
    "section": "16.8 Data curation",
    "text": "16.8 Data curation\nManagement activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse\nSham Lal, Chrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#writing-original-draft",
    "href": "CRediT.html#writing-original-draft",
    "title": "16  CRediT Framework",
    "section": "16.9 Writing – Original Draft",
    "text": "16.9 Writing – Original Draft\nPreparation, creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation)\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#writing-review-editing",
    "href": "CRediT.html#writing-review-editing",
    "title": "16  CRediT Framework",
    "section": "16.10 Writing – Review & Editing",
    "text": "16.10 Writing – Review & Editing\nPreparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision – including pre- or postpublication stages\nChrissy h Roberts, Tegwen Marlais, add team"
  },
  {
    "objectID": "CRediT.html#visualization",
    "href": "CRediT.html#visualization",
    "title": "16  CRediT Framework",
    "section": "16.11 Visualization",
    "text": "16.11 Visualization\nPreparation, creation and/or presentation of the published work, specifically visualization/ data presentation\nChrissy h Roberts, Tegwen Marlais"
  },
  {
    "objectID": "CRediT.html#supervision",
    "href": "CRediT.html#supervision",
    "title": "16  CRediT Framework",
    "section": "16.12 Supervision",
    "text": "16.12 Supervision\nOversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team\nChrissy h Roberts, David Mabey, Chris Drakeley"
  },
  {
    "objectID": "CRediT.html#project-administration",
    "href": "CRediT.html#project-administration",
    "title": "16  CRediT Framework",
    "section": "16.13 Project Administration",
    "text": "16.13 Project Administration\nManagement and coordination responsibility for the research activity planning and execution\nChrissy h Roberts, David Mabey, Heidi Hopkins, Becca Handley"
  },
  {
    "objectID": "CRediT.html#funding-acquisition",
    "href": "CRediT.html#funding-acquisition",
    "title": "16  CRediT Framework",
    "section": "16.14 Funding acquisition",
    "text": "16.14 Funding acquisition\nAcquisition of the financial support for the project leading to this publication.\nChrissy h Roberts, Heidi Hopkins, David Mabey, Chris Drakeley\n\n\n\n\nBrand, Amy, Liz Allen, Micah Altman, Marjorie Hlava, and Jo Scott. 2015. “Beyond Authorship: Attribution, Contribution, Collaboration, and Credit.” Learned Publishing 28 (2): 151–55. https://doi.org/10.1087/20150211."
  },
  {
    "objectID": "references.html",
    "href": "references.html",
    "title": "References",
    "section": "",
    "text": "Brand, Amy, Liz Allen, Micah Altman, Marjorie Hlava, and Jo Scott. 2015.\n“Beyond Authorship: Attribution, Contribution, Collaboration, and\nCredit.” Learned Publishing 28 (2): 151–55. https://doi.org/10.1087/20150211.\n\n\nBrouwers, Judith, Rintis Noviyanti, Rob Fijnheer, Philip G. de Groot,\nLeily Trianty, Siti Mudaliana, Mark Roest, Din Syafruddin, Andre van der\nVen, and Quirijn de Mast. 2013. “Platelet Activation Determines\nAngiopoietin-1 and VEGF Levels in Malaria: Implications for Their Use as\nBiomarkers.” Edited by Ana Paula Arez. PLoS ONE 8 (6):\ne64850. https://doi.org/10.1371/journal.pone.0064850.\n\n\nFisher, J., and A. Linder. 2017. “Heparin-Binding\nProtein: A Key Player in the Pathophysiology of Organ Dysfunction in\nSepsis.” Journal of Internal Medicine 281 (6): 562–74.\nhttps://doi.org/10.1111/joim.12604.\n\n\nHayney, Mary S., Kelsey M. Henriquez, Jodi H. Barnet, Tola Ewers,\nHeather M. Champion, Sean Flannery, and Bruce Barrett. 2017.\n“Serum IFN-γ-Induced Protein 10 (IP-10) as a Biomarker for\nSeverity of Acute Respiratory Infection in Healthy Adults.”\nJournal of Clinical Virology 90 (May): 32–37. https://doi.org/10.1016/j.jcv.2017.03.003.\n\n\nKim, Minah, Breanna Allen, Emilia A. Korhonen, Maximilian Nitschké, Hee\nWon Yang, Peter Baluk, Pipsa Saharinen, et al. 2016. “Opposing\nActions of Angiopoietin-2 on Tie2 Signaling and FOXO1\nActivation.” Journal of Clinical Investigation 126 (9):\n3511–25. https://doi.org/10.1172/jci84871.\n\n\nLei, Jie, Xiaowan Yin, Hong Shang, and Yongjun Jiang. 2019. “IP-10\nIs Highly Involved in HIV Infection.” Cytokine 115\n(March): 97–103. https://doi.org/10.1016/j.cyto.2018.11.018.\n\n\nLeligdowicz, Aleksandra, Melissa Richard-Greenblatt, Julie Wright,\nValerie M. Crowley, and Kevin C. Kain. 2018. “Endothelial\nActivation: The Ang/Tie Axis in Sepsis.” Frontiers in\nImmunology 9 (April). https://doi.org/10.3389/fimmu.2018.00838.\n\n\nMatsushima, Kouji, De Yang, and Joost J. Oppenheim. 2022.\n“Interleukin-8: An Evolving Chemokine.” Cytokine\n153 (May): 155828. https://doi.org/10.1016/j.cyto.2022.155828.\n\n\nZhao, Ting, Zhongping Su, Yingchang Li, Xiaoren Zhang, and Qiang You.\n2020. “Chitinase-3 Like-Protein-1 Function and Its Role in\nDiseases.” Signal Transduction and Targeted Therapy 5\n(1). https://doi.org/10.1038/s41392-020-00303-7."
  }
]